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Abstract
Streptococcus pneumoniae is the primary cause of community acquired
pneumonia and represents a substantial disease burden worldwide. The
PatAB ABC transporter is a multidrug eﬄux pump in this organism, en-
coded by the patA and patB genes, and over-expression of PatAB confers
resistance to fluoroquinolone antibiotics.
This thesis investigates the clinical relevance and the regulation of PatAB
expression. A strong association was found between cross-resistance to flu-
oroquinolones and dyes and over-expression of patAB in pneumococcal clin-
ical isolates, supporting previous assertions that PatAB is the main fluo-
roquinolone eﬄux pump in S. pneumoniae. Two mechanisms that caused
increased expression of patA and patB were identified by whole genome
sequencing of multidrug resistant mutants of S. pneumoniae R6. Firstly,
a novel duplication of a nine kilobase genomic region, including patA and
patB, was identified in one mutant. Further investigation suggested that
duplication caused high expression of the second copy of patAB by bringing
these genes under the control of a tRNA gene promoter. Secondly, mutations
were identified in the terminator stem-loop of a predicted transcriptional at-
tenuator upstream of patA in three other mutants. Transcriptional fusion
of mutated attenuator sequences with a GFP reporter gene suggested that
these mutations increased transcription from the patA promoter.
To Andy
Acknowledgements
I am extremely grateful to my supervisor Professor Laura Piddock for giving me this
opportunity, for always believing in me, and pushing me to be more confident in myself
and my abilities. I would also like to thank all members of the ARG, old and new, for
making the group such a lovely place to work. Particular thanks go to Dr Mark Webber,
Dr Jessica Blair and Dr Vito Ricci for their help and advice and for answering all my silly
questions so patiently! Thanks also go to Helen, Amelia, Grace, Steffi and Jen for their
help and support during various crises and for generally making the lab a fun place to
be. Also, thanks (again) to Jess and Helen for their excellent proof reading skills.
I would also like to thank Professor Tim Mitchell for useful feedback and advice on
working with pneumococci, and Dr Andrea Mitchell for giving me access to equipment.
A big thank you to Al Ivens and Nick Loman for giving me advice on handling genome
sequencing data.
I am also very grateful to my wonderful friends Lia, Jess and Maria for generally being
amazing, and for always being there no matter how busy we all are and how long it’s
been.
I would like to say a massive thank you to my parents, and my brother Chris, who have
always encouraged me to do my best and have supported me in everything I’ve done. I
am also extremely grateful for the last minute proof-reading!
And finally a special thank you to Andy for his continual love, support and seemingly
endless patience, and for keeping me going in the last few months with inspiring pep
talks and wonderful dinners. I couldn’t have done this without you...
Clarification of Contribution to Collaborative Work
The sections detailed below were the result of collaborative work. The contribution of
both parties to each section of work is clarified here.
Chapter 3:
Experiments and data collection, apart from measurement of grwoth rates of isolates,
were carried out by Mark Garvey and Kim Long Ryan Wong (under the supervision of
Mark Garvey). Alison Baylay carried out all data analysis, measured growth rates of
isolates and generated all figures.
Genome sequencing: sections 4.3 and 4.7.1
Genomic DNA for sequencing was extracted by Alison Baylay. The GenePool (Edinburgh)
prepared Illumina sequencing libraries, carried out Illumina sequencing, performed image
analysis to generate sequence reads, and performed preliminary filtering and quality con-
trol. All subsequent analysis of Illumina sequencing data (alignment against a reference,
de novo assembly, etc) was carried out by Alison Baylay.
Figure 5.5
Under the supervision of Alison Baylay, undergraduate student Adna Farah (University
of Birmingham) transformed R6 cells with PCR amplimers of varying sizes from patAB
over-expressing mutants to determine the genomic region containing mutations causing
patAB upregulation. All figures in the present thesis were generated by Alison Baylay.
Contents
List of Figures ix
List of Tables xi
List of Abbreviations xii
1 Introduction 1
1.1 Streptococcus pneumoniae . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Biology, phylogeny, culture and identification of the pneumococcus 1
1.2 Pneumococcal transformation . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.1 Competence . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2.2 DNA uptake and recombination . . . . . . . . . . . . . . . . . . 6
1.2.3 Evolutionary implications of transformation . . . . . . . . . . . . 8
1.3 Pneumococcal carriage, disease and treatment . . . . . . . . . . . . . . 10
1.3.1 Colonisation . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.3.1.1 Epidemiology . . . . . . . . . . . . . . . . . . . . . . 10
1.3.1.2 Mechanisms of colonisation . . . . . . . . . . . . . . . 11
1.3.2 Pneumococcal disease . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.3 Prevention and treatment of pneumococcal infections . . . . . . 14
1.3.3.1 Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . 14
1.3.3.2 Antibiotic treatment . . . . . . . . . . . . . . . . . . . 15
1.4 Antibiotic Resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
1.4.1 Mechanisms of antibiotic resistance. . . . . . . . . . . . . . . . . 16
1.4.2 Evolution of antibiotic resistance . . . . . . . . . . . . . . . . . 18
1.4.2.1 Intrinsic resistance . . . . . . . . . . . . . . . . . . . . 18
1.4.2.2 Acquired resistance . . . . . . . . . . . . . . . . . . . 19
1.4.2.3 Role of gene amplification in bacterial adaptation, in-
cluding antibiotic resistance . . . . . . . . . . . . . . . 20
1.5 Eﬄux as a mechanism of multidrug resistance . . . . . . . . . . . . . . 22
1.5.1 Secondary transporters . . . . . . . . . . . . . . . . . . . . . . . 23
1.5.2 ABC transporters . . . . . . . . . . . . . . . . . . . . . . . . . 25
1.5.2.1 Structure and function . . . . . . . . . . . . . . . . . 25
1.5.2.2 Role in multidrug resistance . . . . . . . . . . . . . . . 26
1.5.3 Role of multidrug eﬄux pumps beyond resistance . . . . . . . . . 28
1.5.4 Eﬄux pump inhibitors . . . . . . . . . . . . . . . . . . . . . . . 30
iv
1.6 Antibiotic resistance in S. pneumoniae . . . . . . . . . . . . . . . . . . 31
1.6.1 β-lactams and macrolides . . . . . . . . . . . . . . . . . . . . . 32
1.6.2 Fluoroquinolone resistance . . . . . . . . . . . . . . . . . . . . . 34
1.7 Eﬄux mediated fluoroquinolone resistance in S. pneumoniae and back-
ground to this project . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
1.7.1 PmrA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
1.7.2 PatA and PatB . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
1.7.2.1 Discovery and role in eﬄux mediated fluoroquinolone
resistance . . . . . . . . . . . . . . . . . . . . . . . . 42
1.7.2.2 patA and patB expression as a response to stress . . . . 46
1.7.2.3 Role of patA and patB in linezolid resistance, and con-
tribution to virulence . . . . . . . . . . . . . . . . . . 49
1.7.2.4 Structure of PatAB . . . . . . . . . . . . . . . . . . . 50
1.7.2.5 Homologues of patA and patB in S. suis . . . . . . . . 51
1.8 Hypotheses tested in this project . . . . . . . . . . . . . . . . . . . . . 52
1.9 Aims and objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
2 Materials and Methods 54
2.1 Bacterial strains and growth . . . . . . . . . . . . . . . . . . . . . . . . 54
2.1.1 Growth conditions and media . . . . . . . . . . . . . . . . . . . 54
2.1.2 Storage of bacterial strains . . . . . . . . . . . . . . . . . . . . 56
2.2 DNA extraction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 56
2.2.1 Extraction of genomic DNA . . . . . . . . . . . . . . . . . . . . 56
2.2.2 Extraction of plasmid DNA . . . . . . . . . . . . . . . . . . . . 57
2.2.3 Agarose gel electrophoresis . . . . . . . . . . . . . . . . . . . . 58
2.3 Transformation of whole genomic DNA from patAB over-expressing strains
into R6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.3.1 Transformation . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.3.2 Confirmation of patAB over-expression phenotype of transformants 59
2.3.2.1 Antibiotics and determination of minimum inhibitory
concentrations . . . . . . . . . . . . . . . . . . . . . . 59
2.3.2.2 Measurement of intracellular accumulation of ethidium
bromide . . . . . . . . . . . . . . . . . . . . . . . . . 60
2.3.2.3 Measurement of growth kinetics . . . . . . . . . . . . 61
2.4 Measuring gene expression by quantitative real-time PCR . . . . . . . . 62
2.4.1 Extraction of total RNA . . . . . . . . . . . . . . . . . . . . . . 62
2.4.2 cDNA synthesis . . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.4.3 Primer design . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
2.4.4 Quantitative real-time PCR . . . . . . . . . . . . . . . . . . . . 64
2.5 Whole-genome sequencing and data analysis . . . . . . . . . . . . . . . 68
2.5.1 Illumina sequencing and quality control . . . . . . . . . . . . . . 68
2.5.2 Mapping reads against reference genome . . . . . . . . . . . . . 68
2.5.3 Local and global de novo assembly . . . . . . . . . . . . . . . . 70
2.6 Further characterisation of mutations identified by genome sequencing . . 71
2.6.1 Primer design and PCR . . . . . . . . . . . . . . . . . . . . . . 71
v
2.6.2 PCR purification and sequencing . . . . . . . . . . . . . . . . . 74
2.6.3 Protein structure prediction using SWISS-MODEL . . . . . . . . 74
2.6.4 Prediction of promoters and terminators . . . . . . . . . . . . . 75
2.6.5 PCR and sequencing of short interspersed repeats . . . . . . . . 75
2.7 Measuring segregation rate of patA-spr1880 duplication . . . . . . . . . 76
2.8 Inactivation of patA in M184 . . . . . . . . . . . . . . . . . . . . . . . 77
2.9 Measuring fluorescence from wild-type and mutated patA promoters by
transcriptional fusion with promoterless gfp. . . . . . . . . . . . . . . . 78
2.9.1 Construction of plasmid pBAV1K-gfp82 . . . . . . . . . . . . . . 78
2.9.2 Construction and cloning of promoter fragments . . . . . . . . . 79
2.9.3 Fluorescence assays . . . . . . . . . . . . . . . . . . . . . . . . 81
3 Over-expression of patA and patB is observed in clinical isolates 82
3.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
3.2 Aims and Hypotheses . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
3.3 Grouping of isolates based on antibiotic resistance profile . . . . . . . . . 85
3.4 Analysis of patA and patB expression levels for each group . . . . . . . . 86
3.5 Effect of chemical and genetic inactivation of patA and patB . . . . . . 86
3.6 Hoechst 33342 accumulation and relation to patA and patB expression
level . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90
3.7 Mutations in topoisomerase genes . . . . . . . . . . . . . . . . . . . . . 92
3.8 Growth kinetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.9 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 97
3.9.1 Further work . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
3.10 Key findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 104
4 Using whole genome sequencing to identify mutations causing upreg-
ulation of patA and patB in M184 105
4.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
4.2 Aims and Hypothesis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106
4.3 Detection of mutations in M184 by whole genome resequencing . . . . . 107
4.3.1 Alignment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
4.3.2 Mutation detection . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.3.2.1 Comparison of the R6 sequence to the published R6
reference genome . . . . . . . . . . . . . . . . . . . . 108
4.3.2.2 Identification of mutations in M184 . . . . . . . . . . . 111
4.4 Investigating truncation of hrcA . . . . . . . . . . . . . . . . . . . . . . 111
4.4.1 Sequencing of hrcA gene from other patAB over-expressors . . . 113
4.4.2 Transformation of R6 with mutated hrcA . . . . . . . . . . . . . 113
4.5 Identifying mutations linked to the patAB over-expression phenotype . . 115
4.5.1 Transformation with PCR amplimers . . . . . . . . . . . . . . . 117
4.5.2 Transformation of M184 phenotype into R6 background using
whole genomic DNA . . . . . . . . . . . . . . . . . . . . . . . . 118
4.5.3 Confirmation of successful transfer of patAB overexpression . . . 119
4.5.4 Resequencing of known M184 mutations in R6M184 transformants 121
vi
4.6 Further analysis of genome sequencing data . . . . . . . . . . . . . . . . 125
4.6.1 Recalling SNPs using different software . . . . . . . . . . . . . . 125
4.6.2 Assembly of unaligned reads . . . . . . . . . . . . . . . . . . . . 126
4.6.3 Sequencing of short repetitive regions . . . . . . . . . . . . . . . 130
4.7 Identification of mutations in R6M184 transformants by new whole genome
sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
4.7.1 Genome sequencing . . . . . . . . . . . . . . . . . . . . . . . . 132
4.7.2 Reanalysis of M184 and R6 mutations using new sequencing data 132
4.7.3 Mutations detected in R6M184 transformants . . . . . . . . . . . 133
4.8 Detection of a novel gene duplication by analysis of improperly mapped
read pairs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 133
4.8.1 Investigation of putative rearrangement in the patA region of
M184 and its transformants . . . . . . . . . . . . . . . . . . . . 138
4.8.1.1 De novo assembly of R6 and M184 genomes . . . . . . 138
4.8.1.2 Realignment and local assembly of improperly mapped
read pairs . . . . . . . . . . . . . . . . . . . . . . . . 140
4.8.1.3 Comparative read depth analysis to determine extent of
putative duplication . . . . . . . . . . . . . . . . . . . 144
4.8.1.4 PCR analysis of putative duplication . . . . . . . . . . 144
4.8.2 Measuring segregation rate of duplication . . . . . . . . . . . . . 147
4.9 Effect of gene duplication on expression of patA and patB . . . . . . . . 152
4.9.1 Measuring expression of genes contained within the duplication . 153
4.9.2 Inactivation of individual copies of patA . . . . . . . . . . . . . . 155
4.9.3 Measuring readthrough from the promoter of a tRNA gene lo-
cated upstream of patA copy 2 . . . . . . . . . . . . . . . . . . 157
4.10 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 160
4.11 Further work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
4.12 Key Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
5 Identification of mutations causing over-expression of patAB in differ-
ent genetic backgrounds 177
5.1 Background . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
5.2 Aims and hypotheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
5.3 Transformation of patAB over-expression phenotype from M168 and
three clinical isolates into R6 . . . . . . . . . . . . . . . . . . . . . . . 178
5.3.1 Confirmation of patAB over-expression in transformants . . . . . 179
5.4 Whole-genome sequencing of R6 transformants of clinical isolates . . . . 184
5.4.1 Determination of the extent of primary recombination events . . 185
5.5 The region upstream of patA contains genetic changes responsible for
patAB over-expression . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
5.6 Construction of a promoter probe plasmid . . . . . . . . . . . . . . . . . 192
5.7 Measuring GFP expression from patA promoter regions containing mu-
tated and complemented transcriptional attenuators . . . . . . . . . . . 195
5.8 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
5.9 Further Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 211
vii
5.10 Key Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
6 Overall Discussion 215
References 224
viii
List of Figures
1.1 The quorum sensing system controlling development of the competent
state in S. pneumoniae (adapted from Johnsborg and Håvarstein, 2009) . 5
3.1 Expression of patA and patB in clinical isolates grouped by resistance
profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
3.2 Effect of eﬄux inhibitors on resistance of clinical isolates. . . . . . . . . 89
3.3 Effect of inactivation of patA or patB on resistance of clinical isolates. . 91
3.4 Fluorescence due to intracellular accumulation of Hoechst 33342 for iso-
lates grouped by patA expression level . . . . . . . . . . . . . . . . . . . 93
3.5 Generation times of 18 clinical isolates and the laboratory strains R6 and
M4, plotted agains patA expression level. . . . . . . . . . . . . . . . . . 98
4.1 Comparison of M184 and R6 read depth distributions . . . . . . . . . . 109
4.2 Read depth coverage of the pbpX region in R6 . . . . . . . . . . . . . . 110
4.3 Model of Sp_HrcA produced by SwissModel . . . . . . . . . . . . . . . 114
4.4 Expression of patA and patB in R6, M499 and M184, determined by
qRT-PCR . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
4.5 Ethidium bromide accumulation in M184 and four R6M184 transformants
compared to R6 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 122
4.6 Expression of patA and patB from M184 and the four R6M184 transfor-
mants compared to R6 determined by qRT-PCR. . . . . . . . . . . . . . 123
4.7 Growth of M184 and four R6M184 transformants in BHI compared to R6 . 124
4.8 Comparison of numbers of mutations detected in M184 and R6 from
alignments of Illumina sequencing reads made by Maq and Bowtie2 . . . 127
4.9 Comparison of mutations found in the new and old sequences of R6 and
M184, and three R6M184 transformants . . . . . . . . . . . . . . . . . . 135
4.10 Possible mappings of Illumina read pairs to a reference genome . . . . . 137
4.11 Alignment of improperly paired reads against the published R6 genome . 139
4.12 Comparison of contig assembled from M184 improperly mapped read
pairs against the R6 genome . . . . . . . . . . . . . . . . . . . . . . . . 142
4.13 Investigation of a putative rearrangement in M184. . . . . . . . . . . . . 143
4.14 Comparisons of per gene RPKMs of M184 against R6 . . . . . . . . . . 145
4.15 Comparisons of per gene RPKMs of M500, M501 and M503 against R6 . 146
4.16 Investigation of putative patA-spr1880 tandem duplication by PCR. . . . 148
ix
4.17 Dependence of the precision of measurement of the percentage retention
of norfloxacin resistance in populations (Pret) on sample size . . . . . . . 151
4.18 Expression of genes within the duplicated region in M184 and four R6M184
transformants, determined by qRT-PCR. . . . . . . . . . . . . . . . . . 154
4.19 Measurement of transcriptional read-through from tRNAGlu using a ppatA-
gfp transcriptional fusion . . . . . . . . . . . . . . . . . . . . . . . . . 161
4.20 Representation of the genetic change causing patAB over-expression in
M184. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
5.1 Fluorescence of R6 clinical isolate transformants due to intracellular ac-
cumulation of ethidium bromide 14 minutes after exogenous addition of
25 µM ethidium bromide. . . . . . . . . . . . . . . . . . . . . . . . . . 182
5.2 Expression of hexA, patA, spr1886, patB and guaA in R6 transformants
of M168 and three clinical isolates, determined by qRT-PCR. . . . . . . 183
5.3 Positions of putative recombination events in genome sequences of R6M168,
R6M101, R6M87 and R6M74 . . . . . . . . . . . . . . . . . . . . . . . . . 186
5.4 Extent of recombinant sequence segments in the patAB region of R6M74,
R6M101, R6M87 and R6M168 . . . . . . . . . . . . . . . . . . . . . . . . . 187
5.5 Determination of the location of polymorphisms causing patAB over-
expression in R6M74, R6M101, R6M87 and R6M168. . . . . . . . . . . . . . 190
5.6 Prediction of structure of the Rho-independent terminator upstream of
patA using RNAfold. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
5.7 Variation in endpoint fluorecence measurements from 1 ml R6 cells con-
taining pBAV1K-gfp2-ppatA constructs resuspended in 200 µl PBS . . . . 197
5.8 Fluorescence from pBAV1K-gfp-v101 and pBAV1K-gfp-v101c transcrip-
tional fusions during growth in BHI broth. . . . . . . . . . . . . . . . . 198
5.9 Fluorescence from pBAV1K-gfp-v87 and pBAV1K-gfp-v87c transcriptional
fusions during growth in BHI broth. . . . . . . . . . . . . . . . . . . . . 199
5.10 Fluorescence from pBAV1K-gfp-v168 and pBAV1K-gfp-v168c transcrip-
tional fusions during growth in BHI broth. . . . . . . . . . . . . . . . . 200
5.11 Fluorescence per OD660 unit from ppatA-gfp transcriptional fusions during
three phases of growth . . . . . . . . . . . . . . . . . . . . . . . . . . . 202
6.1 Gene organisation surrounding patAB homologues in several Streptococ-
cus species and Lactococcus lactis. . . . . . . . . . . . . . . . . . . . . 221
x
List of Tables
2.1 S. pneumoniae strains and isolates used in this study . . . . . . . . . . . 55
2.2 Primers used to measure gene expression by qRT-PCR . . . . . . . . . . 65
2.3 PCR primers used in this study for confirmation of mutations in M184 . . 72
2.4 Remaining primers used in this study . . . . . . . . . . . . . . . . . . . 73
3.1 Mutations in topoisomerase genes detected in FQDR and FQR clinical
isolates. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 95
4.1 Mutations detected by Maq in M184 but not R6 . . . . . . . . . . . . . 112
4.2 MICs of ciprofloxacin, ethidium bromide and reserpine for R6, M184 and
M499 in the presence or absence of 20 µg/ml reserpine . . . . . . . . . . 116
4.3 MIC profile of four R6M184 transformants . . . . . . . . . . . . . . . . . 120
4.4 Putative origins of contigs assembled from M184 reads that did not align
to the published R6 genome. . . . . . . . . . . . . . . . . . . . . . . . 129
4.5 Mutations detected in three sequenced R6M184 transformants . . . . . . 134
4.6 Retention of norfloxacin resistance by M184 and M502 in the absence of
antibiotic selection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.7 MIC profile of four R6M184 transformants . . . . . . . . . . . . . . . . . 158
5.1 MIC profiles of selected R6 transformants of M168, M101, M87 and M74 180
xi
List of Abbreviations
ABC ATP-binding cassette
BSA Bovine Serum Albumin
cfu colony forming units
CSF Cerebrospinal fluid
GFP Green Fluorescent Protein
kb kilobase
MATE Multidrug and toxic compound extrusion
MFS Major Facilitator Superfamily
MIC Minimum inhibitory concentration
NBD Nucleotide Binding Domain
OD Optical Density
PBS Phosphate buffered saline
PCV Pneumococcal Conjugate Vaccine
PPP Prokaryotic Promoter Prediction
QRDR quinolone resistance determining region
qRT-PCR quantitative real-time PCR
RND Resistance Nodulation Division
SDW Sterile Distilled Water
SMR Small Multidrug Resistance
SNP Single nucleotide polymorphism
spc spectinomycin
TBE Tris borate EDTA buffer
TE Tris EDTA buffer
xii
1 Introduction
1.1 Streptococcus pneumoniae
Streptococcus pneumoniae, also known as pneumococcus, is a Gram positive, coccoid
bacterium that colonises the human nasopharynx. Primarily, it exists as a harmless
commensal organism, carried asymptomatically by varying percentages of the population
(Bogaert et al., 2004), but becomes an important human pathogen when it evades host
defensive mechanisms and spreads to normally sterile areas of the body (Musher, 2004).
It is the most common bacterial cause of community-acquired pneumonia (Butler, 2004)
and bacterial meningitis (Mook-Kanamori et al., 2011).
1.1.1 Biology, phylogeny, culture and identification of the
pneumococcus
The streptococci belong to the Lactobacillales order of the phylum Firmicutes, which are
Gram positive bacteria with a low-GC content (Slonczewski and Foster, 2009). Mem-
bers of the Lactobacillales are facultative anaerobes, and derive energy for growth by
fermentation of glucose to lactic acid. The order contains Enterococcus, Lactobacil-
lus, Lactococcus and Streptococcus (Slonczewski and Foster, 2009). Streptococci are
coccoid, and divide along a single axis, so appear as characteristic Gram positive diplo-
coccoid pairs or chains when Gram stained. All streptococci are non-motile and non-
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spore-forming. They are do not produce catalase, allowing them to be distinguished
from catalase-positive bacteria such as staphylococci by a lack of reaction when exposed
to hydrogen peroxide. This also means that streptococci must be cultured on a medium
containing a source of catalase, such as blood, to neutralise hydrogen peroxide produced
as a by-product of aerobic metabolism.
Streptococci can be broadly separated into groups based on haemolytic activity when
grown on blood agar. Pyogenic streptococci, including the important human pathogens
S. agalactiae and S. pyogenes, are β-haemolytic (Facklam, 2002). When β-haemolytic
species are grown on blood agar a clear halo forms around the colony due to complete
lysis of red blood cells (Slonczewski and Foster, 2009). The majority of the remaining
streptococci are α-haemolytic, which is the incomplete breakdown of haemoglobin to
methaemoglobin, resulting in formation of a green halo around a colony growing on
blood agar (Slonczewski and Foster, 2009). The α-haemolytic streptococci have histor-
ically been difficult to classify due to minimal phenotypic differences between species,
and many were classified into a large polyphyletic group known as the viridans strep-
tococci (Kawamura et al., 1995). Later analysis of 16S rRNA sequences showed that
the viridans group could be split into five clusters: mitis, bovis, anginosus, sanguis and
parasanguis (Kawamura et al., 1995). S. pneumoniae is α-haemolytic, but was classified
separately from the viridans streptococci due to its unique phenotypic characteristics of
sensitivity to the antibiotic optochin and solubility in bile (Facklam, 2002). However,
16S rRNA sequencing showed that S. pneumoniae clusters within the mitis group of the
viridans streptococci, and is very closely related to S. mitis and S. oralis (Facklam, 2002;
Kawamura et al., 1995).
Most pneumococcal strains are aerotolerant, although there are some strains that require
totally anaerobic conditions for growth (Slonczewski and Foster, 2009). Pneumococci
produce H2O2 as a byproduct of metabolism, which is not neutralised as streptococci
are catalase-negative. Production of H2O2 is oxygen-dependent, meaning that a CO2-
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enriched atmosphere is required for optimal growth even for aerotolerant pneumococci,
as well as a source of catalase such as blood.
Pneumococci are Gram positive, which means their cell wall consists of a single plasma
membrane, surrounded by a thick layer of peptidoglycan. S. pneumoniae incorporates
choline into its cell wall (Brundish and Baddiley, 1968; Tomasz, 1967), which is a trait
shared by several other bacteria found in the nasopharynx. Uniquely, pneumococci have
an auxotrophic requirement for choline in the growth medium (Rane and Subbarow,
1940). Incorporation of choline has been suggested to be important for maintaining cell
shape (Horne and Tomasz, 1993). More importantly, pneumococci express proteins that
specifically bind to phosphorylchloline moieties as a method of attachment to the cell
surface, some of which are involved in pathogenesis (Swiatlo et al., 2004). Pneumococci
undergo autolysis in stationary phase (Lewis, 2000). Autolysis is a programmed cell
death response mediated by the major autolysin LytA. LytA is a murein hydrolase, which
breaks down peptidoglycan causing cell lysis (Mosser and Tomasz, 1970).
S. pneumoniae produces a polysaccharide capsule, which is attached to the cell wall.
Over 90 different capsule types have been observed to date, which differ in the sugar
moieties that make up the polysaccharide subunits (Bentley et al., 2006). Some consist
of only one or two sugars, while others have complex subunit structures (Bentley et al.,
2006). The presence of a capsule is essential for invasive pneumococcal disease, although
unencapsulated isolates have been observed in nasopharyngeal carriage studies (Marsh
et al., 2010; Salter et al., 2012). The type of capsule expressed by a strain determines its
ability to cause disease (Briles et al., 1992; Brueggemann et al., 2004; Sjöström et al.,
2006). Expression of the pneumococcal capsule is tightly regulated, and is increased
or decreased during different stages of infection. Low capsular expression promotes
adherence to epithelial tissues (Talbot et al., 1996), while increased production of capsule
protects the cell from opsonisation and therefore complement-mediated clearance by the
innate immune system (Abeyta et al., 2003).
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1.2 Pneumococcal transformation
Streptococcus pneumoniae is naturally transformable, meaning that it is able to take up
DNA from its external environment by entering a competent state. Naturally competent
cells can take up approximately 106 times more DNA than can be introduced by artificial
methods such as electroporation or ionic shock (Lacks, 2004). S. pneumoniae is able
to take up the equivalent of 10% of its cellular DNA content by natural transformation
(Hotchkiss, 1954).
1.2.1 Competence
In cultured cells, transformation takes place only at certain cell densities or stage of
growth, showing that competence is under regulatory control (Hotchkiss, 1954). In S.
pneumoniae, and other closely related streptococcal species, competence is regulated by
a two-stage system.
The first is a quorum sensing system that recognises when a streptococcal population
has reached a sufficient cell density for release and uptake of DNA to be advantageous
(Figure 1.1; Novak et al., 1999). This is controlled by two operons, comAB and comCDE.
ComC encodes a peptide precursor that is processed to a 17 amino acid competence-
stimulating peptide (CSP) (Håvarstein et al., 1995). CSP is exported from the cell by the
ComAB ABC transporter (Håvarstein et al., 1995; Hui and Morrison, 1991). Extracellular
CSP is sensed by a two-component system formed from ComD and ComE (Håvarstein
et al., 1996; Pestova et al., 1996). Phosphorylated ComE up-regulates expression of both
the comAB and comCDE operons, thereby promoting increased production, excretion
and detection of CSP.
ComE also up-regulates the expression of an alternative sigma factor, ComX, which
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controls the second stage of competence activation (Lee and Morrison, 1999). ComX
promotes transcription from promoters containing a combox sequence, TACGAATA,
which is found upstream of about 60 genes (Campbell et al., 1998). Over 180 genes
have been identified that have altered expression during competence development, but
only 23 of these are directly involved in DNA uptake and recombination (Johnsborg and
Håvarstein, 2009). Other competence regulated genes include stress response genes such
as chaperonins, heat shock proteins, membrane transporters, the major autolysin lytA
and several genes of unknown function (Bartilson et al., 2001; Peterson et al., 2004;
Rimini et al., 2000). The diversity of function of competence-induced genes has led
to the suggestion that competence is a pneumococcal stress response analogous to the
SOS response found in many other bacteria (Claverys et al., 2006). Some authors have
suggested that the competent state should be referred to as X-state to reflect the fact
that it is involved in more than just DNA uptake (Claverys et al., 2006).
Release of DNA into the extracellular medium occurs during competence (Steinmoen
et al., 2002). It was originally thought that a subpopulation of cells underwent spon-
taneous autolysis during competence as an evolutionary strategy to promote genetic
diversity within the species. However, it has since been shown that pneumococci in the
competent state actively lyse non-competent pneumococci colonising the same niche
(Guiral et al., 2005). This lysis is a form of predation that has been termed fratricide,
sobrinicide or allolysis (Johnsborg and Håvarstein, 2009). Fratricide is mediated by a
two-peptide bacteriocin, CibAB, produced during competence (Guiral et al., 2005).
1.2.2 DNA uptake and recombination
Exogenous DNA is internalised by pneumococci using a dedicated uptake system, com-
ponents of which are upregulated during competence. Double-stranded DNA binds to a
pseudopilus on the pneumococcal surface, then one strand of the bound DNA is cleaved
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into fragments and taken up into the cell, while the other is degraded (Claverys et al.,
2009). In the cytoplasm, single-stranded DNA binding proteins associate with the DNA
to form a nucleoprotein filament (Morrison et al., 2007). The internalised DNA then re-
combines with the pneumococcal chromosome at regions of similar sequence in a process
mediated by the RecA recombinase (Bergé et al., 2003; Mortier-Barrière et al., 1998).
During recombination, the Hex mismatch repair system functions to resolve polymor-
phisms between the new DNA and the pneumococcal chromosome (Claverys et al.,
1983). The Hex system, encoded by hexA and hexB, recognises and corrects purine-
purine or pyrimidine-pyrimidine transition mutations (AT to GC) with greater efficiency
than transversion mutations (AT to CG, AT to TA, or CG to GC), which means that
transversion mutations are transformed with a higher efficiency than transitions (Claverys
et al., 1983). However, the Hex system becomes saturated as the number of mismatches
between the donor and recipient DNA increases, meaning that mismatch repair plays less
of a role in acquisition of DNA from more divergent sources (Humbert et al., 1995).
The sizes of internalised and recombined DNA fragments have been estimated by several
methods. In the 1960s, recombination sizes were estimated to be about two kb by
measuring genetic linkage between selectable markers (Lacks, 1966). Other studies
suggested sizes of three to six kb using donor DNA labelled with deuterium and nitrogen-
15 (Fox and Allen, 1964; Gurney Jr. and Fox, 1968). Recent studies identified putative
recombination events by comparing the genomes of closely related pneumococcal isolates.
Examination of recombinations in the phylogeny of one particular pneumococcal lineage
estimated a mean recombination size of 6.3 kb (Croucher et al., 2011a), while comparison
of co-colonising strains from a paediatric infection identified recombination events of
between six and 28 kb (Hiller et al., 2011).
Croucher et al (2012) investigated the recombination process at high resolution us-
ing whole genome sequencing of 124 pneumococcal isolates generated through in vitro
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transformation experiments. In this study, the capsule biosynthesis operon in a serotype
23F PMEN1 strain was replaced with a kanamycin cassette by transformation with ge-
nomic DNA from a TIGR4 derivative. Analysis of recombinations at this selected locus
by defining regions of donor and recipient alleles showed that multiple non-contiguous
recombinations occurred from the same donor DNA molecule. The average combined
length of these non-contiguous recombinations was 5.9 kb, which is close to the average
length of DNA fragments imported during competence, estimated at 6.6 kb by Mor-
rison and Guild (1972). Croucher and co-workers also identified numerous secondary,
unselected recombinations distributed randomly in the genome sequences of the 124
transformants. The sizes of these secondary recombination events were typically less
than 5kb and followed an exponentially decaying distribution with an average length of
2.3 kb. The frequency of secondary recombinations increased with DNA concentration,
implying that recombinations can occur simultaneously in the pneumococcal cell from
different DNA molecules.
1.2.3 Evolutionary implications of transformation
Natural transformation is advantageous for S. pneumoniae for three main reasons.
Firstly, natural transformation allows maintenance of genetic diversity among pneumo-
coccal species. Analysis of homologous gene clusters from 17 pneumococcal genomes
by Hiller et al (2007) showed that the total set of genes existing among pneumococcal
species, all of which can be accessed by individual S. pneumoniae strains by natural
transformation, is much larger than the genome of any individual bacterium. This is
known as the distributed genome hypothesis. Of 3170 homologous gene clusters found
in the 17 pneumococcal genomes studied by Hiller and co-workers, only 46% were found
in all 17 genomes, thereby forming the core pneumococcal genome. The rest of the
gene clusters were spread among one or more genomes, with each individual genome
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consisting of 21-32% non-core genes.
Secondly, natural transformation allows the maintenance of diversity in certain key traits
among pneumococcal populations by allelic substitution. The most clinically relevant ex-
ample of this is the switching of capsular types. The genes encoding capsule biosynthetic
enzymes are encoded by the same genetic locus in all pneumococcal strains (Bentley
et al., 2006), meaning that a recipient cell can change its capsule type by uptake of
donor DNA from a strain expressing a different serotype. This allows S. pneumoniae
strains to evade the host adaptive immune response directed against a particular capsu-
lar polysaccharide. This has become particularly relevant since the introduction of the
PCV7 vaccine. Evidence of capsular switching has been observed in some pneumococ-
cal lineages associated with disease or antibiotic resistance allowing them to evade the
vaccine (Croucher et al., 2011a; Jefferies and Smith, 2004).
Finally, the human nasopharynx is host to a heterogenous population of bacterial species,
which can include more than one strain of S. pneumoniae, closely related species of oral
Streptococcus, and more diverse organisms such as Haemophilus influenzae (Bogaert
et al., 2004). Natural transformation allows the spread of advantageous gene variants
throughout the population of the nasopharynx. For example, mosaic genes formed by
repeated gene transfers between closely related Streptococcus species have been shown
to be involved in pneumococcal resistance to penicillin (Dowson et al., 1993, discussed
further in section 1.7.1).
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1.3 Pneumococcal carriage, disease and treatment
1.3.1 Colonisation
Colonisation is the key step in pneumococcal infection, as development pneumococcal
disease requires the establishment of the carrier state (Bogaert et al., 2004). A coloni-
sation event consists of three stages: acquisition, carriage and termination of carriage
(Crook et al., 2004). During acquisition, pneumococci enter the nasopharynx via respira-
tory droplets and become established by adhesion to mucosal epithelia (Musher, 2003).
Carriage then persists for a period of weeks or months, before the organism is finally
cleared by the immune system (Ekdahl et al., 1997; Högberg et al., 2007). Duration of
carriage varies according to the serotype of the colonising isolate (Högberg et al., 2007).
1.3.1.1 Epidemiology
Rates of pneumococcal carriage vary widely according to age, geographical area and
socioeconomic and genetic background, but are highest in children (Bogaert et al., 2004).
Estimation of true carriage rates is difficult due to variation in methods of nasopharyngeal
swabbing between studies (Crook et al., 2004). For example, recorded rates of carriage
measured in studies of healthy children by transnasal swabbing reviewed by Bogaert et
al (2004) ranged from 8% to 70%. However, it is clear that pneumococcal carriage
in children is highly dependent on age. Several long-term studies that have measured
colonisation of children over time have shown that pneumococcal colonisation increases
markedly during the first year of life, then declines steadily from about four years of age
due to maturation of the immune system (Aniansson et al., 1992; Bogaert et al., 2003;
Daw et al., 1997; Leino et al., 2001; Mühlemann et al., 2003).
Risk factors for pneumococcal colonisation in healthy children include number of older
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siblings, socioeconomic status and ethnicity (Bogaert et al., 2004). Time spent in
institutions with other children has also been identified as an important risk factor.
Several studies have associated time spent in day care centres with increased colonisation
(Bogaert et al., 2001; Ciftçi et al., 2001; Dunais et al., 2011, 2003; Rodrigues et al., 2009;
Sá-Leão et al., 2008). One particular study found a colonisation rate of 82% among
infants in a French orphanage (Raymond et al., 2000). Colonisation with antibiotic
resistant strains of S. pneumoniae has been linked to recent antibiotic use (Dagan et al.,
1998).
The rate of carriage among adults is typically less than 10%, and duration of carriage of
a particular serotype is reduced (Bogaert et al., 2004; Högberg et al., 2007). However,
adult carriage rates increase in crowded conditions, such as hospitals, long-term care and
prisons, and in adults taking care of small children (Crook et al., 2004; de Galan et al.,
1999; Hendley et al., 1975; Hoge et al., 1994; Millar et al., 1994).
1.3.1.2 Mechanisms of colonisation
To successfully colonise the nasopharynx pneumococci need to avoid clearance by the
host immune systems or entrapment in mucus, and then adhere to respiratory epithelia.
In addition, pneumococci must be able to withstand interspecies competition from other
bacteria that colonise the same niche. They possess numerous characteristic features
that allow them to do this.
The capsule is essential for colonisation and has been described as the most important
virulence factor in S. pneumoniae (Bogaert et al., 2004; Magee and Yother, 2001). Ex-
pression of capsule in the early stages of colonisation prevents recognition of underlying
cell wall components by antibodies or complement components, which prevents phago-
cytosis (Abeyta et al., 2003). The overall negative charge of capsular polysaccharides
also reduces entrapment of the pneumococcus in nasal mucus (Nelson et al., 2007).
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However, capsule is downregulated in later stages of colonisation as it inhibits adhesion
to epithelial cells (Magee and Yother, 2001; Weiser et al., 1994).
Adhesion of pneumococci to mucosal epithelia is mediated by several cell surface compo-
nents. Firstly, the pneumococcal cell wall contains phosphorylcholine, which binds to the
platelet activating factor receptor (Cundell and Tuomanen, 1994; Fischer et al., 1993).
Two pneumococcal cell surface proteins, CbpA and PsaA, are also involved in pneumo-
coccal adhesion. CbpA is part of a family of choline binding proteins which attach to
the pneumococcal cell wall by non-covalent interactions with phosphorylcholine (Swiatlo
et al., 2004). CbpA promotes adhesion by directly binding to the polymeric immunoglob-
ulin receptor found on mucosal surfaces (Hammerschmidt et al., 1997; Zhang et al.,
2000). PsaA is a pneumococcal surface lipoprotein that binds to N-acetyl-glucosamine,
which is a cell-surface carbohydrate found on non-inflamed epithelium (Berry and Paton,
1996; Bogaert et al., 2004; Marra et al., 2002). Finally, the LPXTG-anchored cell sur-
face protein neuraminidase A (NanA) cleaves host cell surface oligosaccharides, exposing
further N-acetyl-glucosamine for binding (Cámara et al., 1994; Tong et al., 2000).
NanA is also involved in interspecies competition. Haemophilus influenzae protects itself
from the host immune system by decorating its glycoproteins with terminal sialic acid
residues so that they resemble host polysaccharides (Harvey et al., 2001). Removal of
these residues by pneumococcal NanA reverses this molecular mimicry, causing the host
immune system to attack H. influenzae (Shakhnovich et al., 2002).
1.3.2 Pneumococcal disease
In healthy individuals, pneumococcal colonisation is contained within the nasopharynx
by the active clearance of cells from the lower respiratory tract and the action of the
immune system (Butler, 2004). However, under certain circumstances, these clearance
mechanisms fail, for example if the respiratory tract is damaged by trauma or viral in-
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fection, or if the individual is immunocompromised (Butler, 2004). Pneumococci are
then able to spread passively to normally sterile areas of the respiratory tract and cause
mucosal infections. S. pneumoniae is the most common bacterial cause of community
acquired pneumonia, which occurs when bacteria spread to the alveoli. Pneumococci
proliferate in the alveolar spaces, causing an inflammatory response. Fluid and white
blood cells then accumulate in the alveoli, causing coughing, fatigue and shortness of
breath (Musher, 2004). This inflammatory response is mediated by the pneumococcal
toxin, pneumolysin, which lyses eukaryotic cells by forming pores in the membrane (Mor-
gan et al., 1995). S. pneumoniae may also spread to the middle ear, causing acute otitis
media, which is a common disease in children. S. pneumoniae is the most common
bacterial agent isolated in otitis media cases (Dowell et al., 1999).
Pneumococci can also cross epithelia and cause invasive diseases. Invasive diseases are
rare but are associated with high mortality. Bacteraemia is caused by entry of pneumo-
cocci to the circulatory system. Invasion can occur from the lungs as a complication
of pneumonia (secondary bacteraemia) or directly from the nasopharynx resulting in a
primary bacteraemia with no obvious focus of infection (known as occult bacteraemia)
(Musher, 2004). Pneumococci can also cross the blood-brain barrier and cause menin-
gitis. S. pneumoniae is the most common cause of bacterial meningitis in adults, since
the introduction of vaccines against H. influenzae (Quagliarello and Scheld, 1997).
Pneumococcal infections are frequently associated with the extremes of age. Children
under the age of five are at risk of infection due to their high levels of nasopharyngeal
colonisation, while the elderly are susceptible due to low immune function (Dockrell
et al., 2012; Mook-Kanamori et al., 2011).
Incidence of pneumococcal disease follows a seasonal pattern that peaks in the win-
ter months and correlates with the frequency of influenza virus infections (Kim et al.,
1996). Synergy has been demonstrated between influenza infection and pneumococcal
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pneumonia, and many deaths during influenza epidemics have been retrospectively as-
cribed to secondary infection with S. pneumoniae (Chien et al., 2009; Geddes, 2009).
The influenza virus produces a neuraminidase protein similar in structure to the protein
produced by pneumococci (Peltola and McCullers, 2004). Cleavage of sialic acid residues
from host cell surface polysaccharides by the viral enzyme exposes receptors to which
pneumococci can adhere, which promotes development of pneumonia and accounts for
the synergy between the two infections (McCullers and Bartmess, 2003).
1.3.3 Prevention and treatment of pneumococcal infections
1.3.3.1 Vaccines
Pneumococcal disease can be reduced by immunisation of children under five years old
with polysaccharide conjugate vaccines (PCV). These vaccines consist of pneumococcal
capsular polysaccharides conjugated to a non-toxic version of the diptheria toxin (Weil-
Olivier et al., 2012). PCVs cannot cover all 90 pneumococcal serotypes, so are targeted
to the serotypes most commonly associated with invasive pneumococcal disease and
antibiotic resistance (Hausdorff et al., 2000; Tyrrell et al., 2009). PCV7 was introduced
in the US in 2000, and was adopted into national immunisation programs in Europe
between 2006 and 2008 (Pelton et al., 2004; Weil-Olivier et al., 2012). This vaccine
covers serotypes 4, 6B, 9V, 14, 18C, 19F and 23F (Hausdorff et al., 2000). In general,
since the introduction of PCV7, incidence of community acquired pneumonia and invasive
pneumococcal disease has decreased, and the proportions of isolates with PCV7 serotypes
has declined among invasive pneumococcal disease isolates (Gladstone et al., 2011; Weil-
Olivier et al., 2012). However, there has been an increase in relative prevalence of isolates
with serotypes not included in PCV7, particularly serotypes 1, 7F and 19A (SáâĂŘLeão
and Nunes, 2009; Tyrrell et al., 2009). To counteract this problem, PCV13, an extended
version of the vaccine which contains six additional serotypes (1, 3, 5, 6A, 7F and 19A),
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has been developed and replaced PCV7 in the US and UK in 2010 (Jefferies et al., 2011).
1.3.3.2 Antibiotic treatment
A variety of bacterial agents can cause pneumonia and invasive infections, and diagnostic
tests to rapidly identify the causative organism are not yet available. As a result, these
diseases are usually treated empirically with broad spectrum antibiotics (Jones et al.,
2010).
The recommended antibiotic treatment for community acquired pneumonia depends
on the severity of the disease, the previous health of the patient and whether they
are treated in hospital or as an outpatient. The joint guidelines from the Infectious
Diseases Society of America and the American Thoracic Society (Mandell et al., 2007)
state that outpatients who were previously healthy and have no risk factors for carrying
antibiotic resistant S. pneumoniae should be treated with a macrolide antibiotic, such
as azithromycin, clindamycin or erythromycin. Outpatients with co-morbidities, such
as influenza infection, chronic obstructive pulmonary disease, diabetes or renal failure,
should be treated with a respiratory fluoroquinolone such as moxifloxacin, gemifloxacin or
levofloxacin, or with a combination of high dose amoxicillin (a β-lactam antibiotic) and
a macrolide. This is also recommended for patients who have received antibiotic therapy
within the previous three months, which is a risk factor for carriage of antibiotic resistant
S. pneumoniae. Hospitalised patients are treated with either a respiratory fluoroquinolone
or a combination of a β-lactam (cefotaxime, ceftriaxone or ampicillin-sulbactam) and a
macrolide.
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1.4 Antibiotic Resistance
1.4.1 Mechanisms of antibiotic resistance.
Antibiotics inhibit growth of bacteria by specifically binding to bacterial cellular targets
and inhibiting their function. Antibiotics block essential cellular pathways such as protein
synthesis or cell wall biosynthesis, which may kill the bacterium (bacteriocidal antibiotic)
or prevent further growth (bacteriostatic antibiotic). Bacteria have evolved a multitude of
mechanisms to circumvent this molecular inhibition, and these can be roughly categorised
into four general mechanisms of resistance.
Antibiotic inactivation. Bacteria may produce enzymes that either degrade the an-
tibiotic molecule or modify it by addition of chemical groups such that it can no longer
bind to its cellular target. The primary mechanism of resistance to β-lactam antibi-
otics in many bacteria is production of a β-lactamase enzyme that hydrolyses the vital
β-lactam ring structure (Ambler, 1980; Bush et al., 1995). These enzymes are usually
secreted extracellularly so can destroy antibiotic molecules before they reach the cell.
A large family of enzymes that modify aminoglycoside antibiotics by addition of acetyl,
phosphate or nucleotidyl groups has been characterised (Ramirez and Tolmasky, 2010).
Other families of group transfer enzymes that confer antibiotic resistance include the
macrolide kinases and the chloramphenicol acetyltransferases (Matsuoka et al., 1998;
Nakamura et al., 2000; Noguchi et al., 1995; Schwarz et al., 2004).
Alteration or protection of antibiotic target. The molecular target of an antibiotic
may be modified, either by mutation or post-translationally, such that the antibiotic can
no longer bind but the function of the target is maintained. For example, resistance
to fluoroquinolone antibiotics is typically conferred by mutations in the topoisomerase
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genes that prevent antibiotic binding (Ruiz, 2003). Resistance to ribosome-targeting
antibiotics such as aminoglycosides and macrolides is often conferred by acquisition of
genes encoding methylase enzymes, which methylate key ribosomal nucleotides and block
antibiotic binding (Weisblum, 1995a). There are also examples of dedicated proteins that
protect intracellular targets from antibiotic binding. Tet(M) and Tet(O) proteins are
analogues of the ribosomal elongation factors EF-G and EF-Tu, which cause resistance
to tetracyline by dislodging tetracyline molecules from the ribosome (Thaker et al.,
2010). Similarly, Qnr proteins have been discovered that protect topoisomerase enzymes
from inhibition by quinolones (Martínez-Martínez et al., 1998; Tran and Jacoby, 2002).
Metabolic bypass. Bacteria may also circumvent the antibiotic inhibition of a par-
ticular metabolic pathway by expressing a modified enzyme that allows the pathway to
function by an alternative route. The most clinically relevant example of this is the
acquisition of a methicillin-insensitive penicillin binding protein, PBP2x, by methicillin-
resistant Staphylococcus aureus which allows cell wall synthesis to continue when the
native PBP enzyme is inhibited (Fuda et al., 2004; Pinho et al., 2001). Another ex-
ample is resistance to sulfonamides and trimethoprim, which inhibit the dihydropteroate
synthase and dihydrofolate reductase enzymes of the folate synthesis pathway, respec-
tively. Acquisition of genes encoding antibiotic insensitive versions of these enzymes
allows continuation of folate synthesis in the presence of antibiotic (Huovinen, 2001).
Reduced intracellular accumulation of antibiotic. Finally, decreased susceptibil-
ity to a variety of antibiotics may be conferred by reducing the amount of antibiotic that
accumulates within the cell. This means that a higher external concentration of antibi-
otic is required to achieve the intracellular concentration required for inhibition, which
may not be feasible clinically. Reduced intracellular accumulation of antibiotic can be
achieved in two ways. Antibiotic molecules may be actively exported from the cell by
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eﬄux pumps, and this mechanism is discussed in detail in section 1.5. Alternatively, the
permeability of the cell may be reduced, preventing the entry of antibiotic molecules.
Intracellular accumulation of antibiotic is typically lower in Gram negative bacteria than
in Gram positive bacteria due to the presence of the outer membrane which acts as a
permeability barrier (Piddock, 2006a). The permeability of the outer membrane can be
futher reduced by altered expression of porin proteins (Livermore, 2001; Nikaido, 2003).
1.4.2 Evolution of antibiotic resistance
1.4.2.1 Intrinsic resistance
Intrinsic or innate resistance is defined as a relatively high tolerance to an antibiotic
due to a feature that is shared by all members of a particular bacterial species. For
example, Pseudomonas aeruginosa is naturally resistant to several antibiotics due to its
low permeability. This is mediated by production of highly selective porin proteins and
expression of several multidrug eﬄux pumps (Livermore, 2001; Ochs et al., 1999; Sug-
awara et al., 2006). Intrinsic resistance to some β-lactams is found in several species
of Enterobacter and Citrobacter due to their expression of a chromosomally-encoded
cephalosporinase enzyme, AmpC (Kaye et al., 2001; Lindberg et al., 1987; Woodford
et al., 2007). Similarly, some species of Enterococcus possess an operon that encodes
vancomycin resistance genes (Leclercq et al., 1992; Navarro and Courvalin, 1994). Intrin-
sic antibiotic resistance is evolutionarily ancient and is common in soil-dwelling bacteria,
which regularly come into contact with antibiotic-producing organisms such as fungi
(Dantas et al., 2008; D’Costa et al., 2006).
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1.4.2.2 Acquired resistance
Acquired resistance refers to antibiotic resistance emerging in bacterial species that do
not possess innate resistance to the antibacterial agent being used. Resistance may be
acquired by spontaneous mutation, for example in the antibiotic binding site of the target
protein, or by horizontal transfer of a resistance determinant from a resistant strain.
Mutational resistance. Development of antibiotic resistance by mutation has been
observed for every class of antibiotics in current clinical use (Woodford and Ellington,
2007), although it is not always the predominant mechanism of resistance. Mutational
resistance is particularly important in bacterial species that do not commonly participate
in horizontal gene transfer, such as Mycobacterium tuberculosis (Gillespie, 2002), and
for resistance to synthetic antibiotics, such as fluroquinolones, for which there is not a
reservoir of ancient resistance genes in the environment (Ruiz, 2003).
Horizontal gene transfer Bacteria can acquire resistance genes that are dissemi-
nated on mobile genetic elements such as plasmids, transposons and integrons (Carat-
toli, 2001; Salyers et al., 1995), or from DNA acquired from other members of the same
species by natural transformation (Johnsborg et al., 2007). Transfer of resistance genes
by bacteriophage transduction also has a clinically relevant role in antibiotic resistance
development in bacteria (Colomer-Lluch et al., 2011; Modi et al., 2013; Parsley et al.,
2010). A wide variety of resistance determinants are associated with mobile genetic ele-
ments. The most clinically relevant example is the widespread dissemination of extended
spectrum β-lactamases and carbapenemases among the Enterobacteriaceae which are
mobilised on conjugative plasmids (Hossain et al., 2004; Nordmann et al., 2011; Yong
et al., 2009).
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1.4.2.3 Role of gene amplification in bacterial adaptation, including antibi-
otic resistance
Gene duplication and amplification is the transient increase in copy number of a chro-
mosomal region. The role of gene duplication events in eukaryotic evolution has been
extensively studied, but the role of gene amplification in bacterial adaptation has been
somewhat overlooked. It has been suggested that gene duplication and amplification in
bacteria has a role in adaptation to stressful conditions, including antibiotic exposure
(Andersson and Hughes, 2009).
In bacteria, duplications of chromosomal regions can occur spontaneously at a high
frequency compared to the emergence of point mutations. Analysis of transient dupli-
cations of 38 metabolic genes carried out by Anderson and Roth (1981) in unselected
cultures of Salmonella Typhimurium suggested that duplications occured spontaneously
at frequencies of between 10-2 and 10-4 per cell, depending on the chromosomal site
investigated. The authors estimated that, in an unselected bacterial culture, approxi-
mately 10% of cells will possess a duplication somewhere in their genome. Duplications
therefore arise with higher frequency than point mutations, suggesting that gene dupli-
cation, not point mutation, provides the majority of the initial genetic diversity required
for bacterial populations to survive external stresses (Andersson and Hughes, 2009).
Gene duplications can be formed by both RecA-dependent and RecA-independent mech-
anisms (Andersson and Hughes, 2009; Whoriskey et al., 1987). RecA-dependent mech-
anisms involve recombination between repeat regions of at least 40 nucleotides (Shen
and Huang, 1986). In particular, recombination between copies of the ribosomal RNA
genes has been observed as a common mechanism of duplication formation (Anderson
and Roth, 1981; Lehner and Hill, 1980). Other repeat sequences that can mediate dupli-
cation formation by RecA-dependent recombination are IS elements and REP sequences
(Haack and Roth, 1995; Jessop and Clugston, 1985; Lin et al., 1984). RecA-independent
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duplications do not require long repeat regions at the duplication boundaries, and exam-
ples have been observed where there was no sequence homology at the duplication join
point at all (Reams and Neidle, 2004; Seoane et al., 2003). Suggested mechanisms for
RecA-independent duplication formation are strand slippage during rolling-circle replica-
tion, and illegitimate end joining by DNA gyrase (Ikeda et al., 2004; Lovett et al., 1993;
Seoane et al., 2003; Trinh and Sinden, 1993).
Once formed, duplications can be amplified to form tandem arrays of direct repeats
(Edlund et al., 1979; Jessop and Clugston, 1985; Reams and Neidle, 2004; Tlsty et al.,
1984; Whoriskey et al., 1987). Two mechanisms have been proposed to mediate this.
The first is RecA-dependent homologous recombination between copies of the repeats,
and the second is rolling circle replication (Andersson and Hughes, 2009). The number
of copies of a chromosomal region that can be generated by amplification varies widely
and is limited by the effects of increasing gene dosage and the energetic requirements
of replicating the extra DNA. Gene amplications of up to 40 copies have been reported
(Sandegren and Andersson, 2009).
A few examples of antibiotic resistance mediated by chromosomal gene amplification
have been reported in the past three decades. The first observation was amplification
of a β-lactamase, ampC, in E. coli following in vitro selection for increased ampicillin
resistance (Normark et al., 1977). A 9-18 kb region of the genome, including the
ampC gene, was amplified between 2 and 40 times, mediated by short, 12-13bp direct
repeat sequences. Increased β-lactam resistance was observed in a strain of Yersinia
enterocolitica following growth in ampicillin, due to five-fold amplification of a 28 kb
region containing the blaA gene (Seoane et al., 2003). Growth of a methicillin-resistant
S. aureus in a high concentration of methicillin led to further increases in resistance,
due to two- to three-fold amplification of the SCCmec element (Matthews and Stewart,
1988). Transient resistance to multiple antibiotic agents was observed in E. coli strains
with decreased genomic stability caused by mutations in the lon protease, due to very
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large (149-300 kb), unstable chromosomal duplications including the genes encoding the
AcrAB-TolC eﬄux pump (Nicoloff et al., 2006, 2007). The only report to date of a large
(>1 kb) gene amplification associated with resistance in a clinical isolate was that of a
clinical isolate of Streptococcus agalactiae in which a four-fold amplification of the fol
operon was observed (Brochet et al., 2008). This caused an increase in resistance to
sulfonamide antibiotics and trimethoprim, due to overproduction of enzymes involved in
the folate synthesis pathway.
Gene duplications and amplifications are usually transient and are readily lost in the
absence of selective pressure due to recombination between copies of the repeats (An-
dersson and Hughes, 2009). This instability may explain why the involvement of gene
amplification in antibiotic resistance in clinical isolates is not well characterised.
1.5 Eﬄux as a mechanism of multidrug resistance
Eﬄux pumps are membrane-spanning transporter proteins that actively export com-
pounds from the cell. Eﬄux pumps are evolutionarily ancient and in many cases their
physiological role in the cell is unclear. One function is thought to be to protect the
bacterium from toxic substances found in the natural environment (Piddock, 2006b).
For example, some enteric pathogens express eﬄux pumps that confer resistance to bile
salts, which improves survival of the bacterium in the gut (Lin et al., 2003). However,
eﬄux pumps can also transport antibiotic compounds and resistance occurs when pumps
are over-expressed (Poole, 2005).
Some eﬄux pumps are specific for particular antibiotics, while others have much wider
substrate specificities and are known as multidrug eﬄux pumps (Lewis, 1994). Multiple
specificity means that over-expression of an eﬄux pump selected with one agent could
indirectly lead to resistance to multiple clinically relevant antibiotics.
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Multidrug eﬄux pumps can be classified as primary or secondary transporters based on
the mechanism used to power substrate eﬄux. The ATP-Binding Cassette transporters
are primary transporters as they couple transport of substrates with hydrolysis of ATP
(discussed further in section 1.5.2). Secondary transporters couple transport of sub-
strates to the proton motive force or sodium ion gradients. The balance between the use
of primary and secondary transporters varies depending on the metabolism of the bac-
terial species. Fermentative bacteria tend to rely to a greater extent on primary trans-
porters whereas aerobic bacteria contain more secondary transporters (Paulsen et al.,
1998, 2000).
1.5.1 Secondary transporters
Secondary transporters can be divided into four superfamilies based on structure (Pid-
dock, 2006a). These are the major facilitator superfamily (MFS), the resistance-nodulation-
division (RND) family, the multidrug and toxic compound extrusion (MATE) family and
the small multidrug resistance (SMR) family.
MFS eﬄux pumps are the largest family of secondary transporters involved in multidrug
eﬄux (Pao et al., 1998). MFS transporters are monomeric transporters with 12 or
14 membrane-spanning domains, which power substrate eﬄux using the proton motive
force (Paulsen et al., 1996). Bmr from Bacillus subtilis (Neyfakh et al., 1991), and NorA
from Staphylococcus aureus (Neyfakh et al., 1993) are examples of 12 transmembrane
domain transporters. The QacA and LmrS pumps from S. aureus, which export cationic
lipophilic drugs and linezolid, respectively, are examples of 14 transmembrane domain
MFS transporters (Floyd et al., 2010; Littlejohn et al., 1992).
RND eﬄux pumps are exclusively found in Gram negative bacteria (Poole, 2005). They
are tripartite eﬄux pumps consisting of an inner membrane transporter protein, and a
porin located in the outer membrane, which are joined by a periplasmic adapter protein
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(Piddock, 2006b). RND pumps export substrates by coupling transport to the proton
motive force by functional rotation of the three subunits of the inner membrane pump
(Piddock, 2006a). The best characterised system is the AcrAB-TolC eﬄux pump of
E. coli and Salmonella species, which confers resistance to various structurally diverse
antibiotics, such as β-lactams, fluoroquinolones and aminoglycosides (Piddock, 2006a).
MATE eﬄux pumps are the most recently identified group of secondary transporters
involved in multidrug resistance. The first example to be characterised was NorM from
Vibrio parahaemolyticus, which was identified in 1998 (Morita et al., 1998). There
are 20 characterised members of the family, but genomic analyses suggest that they
are widespread and found in bacteria, archaea and eukaryotes (Kuroda and Tsuchiya,
2009). MATE transporters consist of a single transporter protein with 12 transmembrane
domains (Brown et al., 1999). Unlike MFS transporters, many MATE transporters use
sodium ion gradients to power substrate transport instead of the proton motive force
(Kuroda and Tsuchiya, 2009). Examples include MepA in S. aureus, which confers
decreased susceptibility to tigecycline (McAleese et al., 2005), and NorM in Neisseria
species, which increases resistance to cationic antimicrobial compounds (Rouquette-
Loughlin et al., 2003).
The SMR family consists of small, 100-140 amino acid proteins with four membrane
spanning domains, which form functional transporters by dimerisation in the membrane.
The first protein of this family to be identified was the Smr transporter of S. aureus, which
is carried on plasmids and confers resistance to various compounds, including organic
cations and dyes (Grinius et al., 1992; Littlejohn et al., 1992). There are now more than
250 members of the family, most of which confer resistance to cationic compounts such
as quarternary ammonium compounds and ethidium bromide (Bay et al., 2008). Smr
from S. aureus and EmrE from E. coli transport clinically relevant antibiotics such as
ampicillin, erythromycin and tetracycline (Bay et al., 2008; Yerushalmi et al., 1995).
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1.5.2 ABC transporters
The ABC transporter superfamily is the largest known paralogous protein family and
examples are found in all three kingdoms of life (Bouige et al., 2002; Higgins, 2001).
The superfamily can be divided into three groups based on function: uptake transporters,
eﬄux transporters, and ATPases not involved in membrane transport (Dassa and Bouige,
2001).
1.5.2.1 Structure and function
ABC transporters consist of two transmembrane domains, each formed from six trans-
membrane helices, and two nucleotide binding domains (NBDs) (Higgins et al., 1986).
The way these domains are coded in the genome differs between subfamilies. For bacte-
rial uptake transporters, the transmembrane and nucleotide binding domains are encoded
by separate genes, and the transporter is a tetramer of four separate proteins (Higgins,
2001). In eukaryotes the four domains of the ABC transporter are usually fused and
are encoded by a single gene (Lubelski et al., 2007). ABC transporters involved in
substrate eﬄux in bacteria are often formed from homo- or heterodimerisation of two
half-transporters, each consisting of one nucleotide binding domain fused to one trans-
membrane domain (Lubelski et al., 2007).
The nucleotide binding domains of ABC transporters are highly conserved, while the
transmembrane domains are more variable allowing transport of a variety of substrates
(Cuthbertson et al., 2010). There are several important conserved motifs in the nu-
cleotide binding domain. The C-loop is a highly conserved motif (LSGGQ) which is
required to classification of a protein as a member of the ABC superfamily (Seeger and
van Veen, 2009). The Walker A and B motifs are found in all P-loop ATPase enzymes,
and form the ATP-binding site. To be fuctionally active, a dimer of NBDs is required
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where the C-loop of one monomer complements the ATP binding site of the other (Daw-
son and Locher, 2006; Hopfner et al., 2000). Other conserved sequences involved in ATP
binding and hydrolysis have also been identified, such as a conserved histidine residue
(H-loop) and a conserved glutamine residue (Q-loop) (Lubelski et al., 2007; Seeger and
van Veen, 2009).
Crystal structures of the MsbA lipid A transporter from E. coli and the Sav1866 mul-
tidrug transporter from S. aureus have been used to elucidate the mechanism of substrate
transport by ABC eﬄux pumps (Dawson and Locher, 2006; Dawson et al., 2007). Nu-
cleotide binding and hydrolysis confers conformational changes in the transmembrane
domains, switching them from a cytoplasmic-facing conformation to an outward-facing
conformation, which transports bound substrates from the cytoplasm to the outside of
the cell (Chang, 2003).
1.5.2.2 Role in multidrug resistance
The first multidrug ABC transporter to be described was the LmrA transporter found in
Lactococcus lactis in 1996 (van Veen et al., 1996). Lactococcus lactis is an important
bacterium used in the dairy industry, but has also proved to be a useful model organism
for studying ABC transporter-mediated multidrug resistance. Heterologous expression
of LmrA in E. coli conferred decreased susceptibility to a variety of structurally diverse
compounds, including aminoglycosides, macrolides, quinolones, tetracyclines, chloram-
phenicol, ethidium bromide and rhodamine 6G (van Veen et al., 1996). This transporter
may also be involved in protection against salt stress and exposure to cadmium, sodium
laureate and ethanol (Achard-Joris et al., 2005; Bourdineaud et al., 2004).
LmrA homologues have been found in several other industrially important bacteria.
Oenococcus oeni is involved in wine production and expresses the LmrA homologue
OmrA, which confers resistance to ethanol, sodium laureate and other wine compounds
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(Bourdineaud et al., 2004). Lactobacillus brevis causes beer spoilage and produces an
LmrA homologue HorA, which confers resistance to hop compounds (Sakamoto et al.,
2001). Both of these transporters confer a classic multidrug resistance phenotype when
heterologously expressed (Bourdineaud et al., 2004; Sakamoto et al., 2001).
Sav1866 is a homodimeric ABC transporter from S. aureus that is homologous to LmrA.
The role of this transporter in multidrug resistance in S. aureus has not been con-
firmed, but crystal structures of this transporter have been instrumental in determining
the molecular mechanism of substrate transport in bacterial ABC multidrug eﬄux trans-
porters (Dawson and Locher, 2006; Dawson et al., 2007).
The characterisation of the role of LmrA in multidrug resistance was mostly carried out
by heterologous expression in E. coli. Subsequent studies have suggested that multidrug
eﬄux in Lactococcus lactis itself is mainly mediated by another ABC transporter Lm-
rCD, with LmrA playing a relatively minor role (Lubelski et al., 2006). LmrCD is a het-
erodimeric transporter formed from two half-transporters encoded by lmrC and lmrD,
which are transcriptionally linked in a small operon regulated by LmrR (Agustiandari
et al., 2008). Over-expression of LmrCD confers decreased susceptibility to several toxic
compounds including ethidium, daunomycin, rhodamine 6G, Hoescht 33342 and cholate
(Lubelski et al., 2004), while inactivation of lmrC or lmrD confers hypersusceptibility to
these agents (Lubelski et al., 2006).
Homologues of LmrCD have been identified in some pathogenic Gram positive bacteria.
Enterococcus faecalis has a high intrinsic resistance to many antibiotics and is an oppor-
tunistic, nosocomial human pathogen, causing diseases such as endocarditis and urinary
tract infections (Lee et al., 2003). The LmrCD homologue EfrAB has been linked to
ciprofloxacin and doxycycline resistance in E. faecalis (Lee et al., 2003). The PatAB
transporter in S. pneumoniae, which is the focus of this study and is discussed further
in section 1.7.2, is also a LmrCD homologue, as is the related SatAB transporter in S.
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suis (section 1.7.2.5).
A few ABC transporters have been implicated in antibiotic resistance in Gram negative
bacteria. The MacAB transporter in E. coli confers decreased susceptibility to some
classes of macrolide antibiotics. Over-expression of macAB in an E. coli mutant lacking
the major RND transporter AcrAB resulted in increased resistance to macrolides with
14 and 15-membered ring structures, such as erythromycin and azithromycin, but not
to macrolides with 16-membered rings such as leucomycin (Kobayashi et al., 2001).
Unlike LmrCD, MacAB is not a heterodimeric ABC transporter formed from two different
half transporters. Instead, MacB forms a homodimeric transporter, while MacA is a
periplasmic adapter protein which stimulates ATPase activity of MacB and provides a link
between MacB and the outer membrane porin TolC (Lin et al., 2009). A similar system
has been characterised in Neisseria gonorrhoeae (Rouquette-Loughlin et al., 2005). In
addition, a classic homodimeric ABC transporter VcaM from Vibrio cholerae has been
shown to transport tetracycline, ciprofloxacin and norfloxacin, which are drugs used to
treat cholera, as well as doxorubicin and daunomycin (Huda et al., 2003).
1.5.3 Role of multidrug eﬄux pumps beyond resistance
Many multidrug eﬄux pumps have been shown to have physiological roles beyond their
contribution to antibiotic resistance, including pathogenicity, stress responses and biofilm
formation (Nishino et al., 2009). In some cases, physiological roles of eﬄux pumps can
be directly related to their multidrug transport function. For example, the AcrAB-TolC
RND eﬄux pump, and its homologue CmeAB in Campylobacter jejuni, export bile salts
(Lin et al., 2003; Thanassi et al.). This increases the resistance of the bacteria to toxic
compounds in bile, allowing them to better colonise the gut. Strains of Salmonella
lacking AcrB or TolC are attenuated in their ability to colonise chickens (Buckley et al.,
2006) Requirement of TolC for bile resistance has also been shown in V. cholerae (Bina
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and Mekalanos, 2001).
A role in virulence of Salmonella has also been observed for MacAB, which was shown
to be the multidrug eﬄux pump with the greatest contribution towards ability to cause
disease in a mouse model of infection (Nishino et al., 2006). MacAB is regulated by
PhoPQ, a two-component regulatory system that controls expression of several genes
linked to invasion of epithelial cells and which has previously been linked to bile resistance
(Behlau and Miller, 1993; Nishino et al., 2006; van Velkinburgh and Gunn, 1999).
In other cases, the link between observed physiological roles of eﬄux pumps and substrate
transport is less clear. Lack of a functional AcrAB-TolC eﬄux pump in Salmonella Ty-
phimurium substantially decreases the ability of the bacterium to invade human macrophages
and intestinal cells in vitro (Buckley et al., 2006). Inactivation of components of the
AcrAB-TolC eﬄux pump has also been shown to alter expression of genes encoded in
the Salmonella pathogenicity island 1, and of operons involved in chemotaxis and motil-
ity (Webber et al., 2009). Increased expression of eﬄux pumps, including AcrAB-TolC,
has also been observed in bacteria residing inside macrophages, suggesting that eﬄux
pumps are important for intracellular survival (Nishino et al., 2009). P. aeruginosa lack-
ing components of the MexAB-OprM RND eﬄux pump also show reduced invasion.
Attentuation of invasion in mutants lacking MexAB-OprM was alleviated by exogenous
addition of sterilised media previously used to grow wild type cultures, which suggests
that MexAB-OprM exports an unknown factor required for virulence (Hirakata et al.,
2002).
Multidrug eﬄux pumps have also been linked to bacterial responses to other cellular
stresses. In P. aeruginosa, the MexXY-OprM RND eﬄux pump is upregulated in response
to oxidative stress, and the MexCD-OprJ system is upregulated by membrane-damaging
agents (Fraud et al., 2008). AcrAB-TolC is over-expressed in E. coli in response to
ethanol exposure and high salt concentration (Ma et al., 1995).
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The regulatory pathways controlling the expression of AcrAB-TolC and MexAB-OprM
have been well studied (Fraud and Poole, 2011; Morita et al., 2006; Nishino et al., 2009).
These regulatory mechanisms are complex and involve both local and global regulators,
which is consistent with the fundamental roles of these pumps in the response of the
organism to various environmental conditions. Expression of acrAB is controlled by
the local repressor AcrR, but is also regulated by the global regulators MarR, MarA,
SoxS and Rob in E. coli, and additionally by RamR and RamA in Salmonella. These
global regulators also control expression of many other genes involved in response to
changing environmental conditions, bacterial virulence and biofilm formation. Via this
global regulatory network, expression of eﬄux pumps can be induced by exposure to a
diverse array of compounds (Lawler et al., 2013; Nikaido et al., 2008; Pomposiello et al.,
2001; Semchyshyn et al., 2005).
1.5.4 Eﬄux pump inhibitors
Due to the role of eﬄux pumps in bacterial resistance to various antimicrobial agents,
and the lack of development of new antibiotics in recent decades, there has been much
interest in developing eﬄux pump inhibitors. Specific inhibition of eﬄux pumps would
act synergistically with existing antibiotics and help circumvent resistance. Eﬄux pump
inhibitors are defined as small molecules that specifically inhibit eﬄux transporters, ei-
ther competitively or non-competitively, and this distinguishes them from compounds
that inhibit eﬄux non-specifically by dissipating the proton motive force, such as CCCP
(Lomovskaya and Watkins, 2001).
The plant alkaloid reserpine, originally extracted from the roots of Rauwolfia vomitoria
(Poisson et al., 1954), was used as an antihypertensive drug due to its ability to inhibit
the vesicular monoamine transporter that controls the transport of biogenic amines into
storage organelles in mammalian cells (Ahmed et al., 1993). Reserpine also inhibits
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bacterial eﬄux pumps such as Bmr in B. subtilis, which are similar in structure to the
monoamine transporter (Ahmed et al., 1993). Reserpine cannot be used therapeutically
as an eﬄux inhibitor as the concentrations required for this are neurotoxic, but it remains
a useful research tool for investigating eﬄux-mediated resistance (Ahmed et al., 1993).
Many compounds that inhibit bacterial eﬄux activity have been identified from a variety
of different sources. Some are modified versions of drugs known to have activity against
transporters in human cells, for example, P-glycoprotein inhibitors used as anticancer
agents (Leitner et al., 2011) and antipsychotic drugs such as phenothiazines (Kaatz
et al., 2003). Other eﬄux pump inhibitors have been identified in plant extracts and
from other natural sources (Stavri et al., 2007). However, none of these potential eﬄux
inhibitors is yet licensed for clinical use.
1.6 Antibiotic resistance in S. pneumoniae
Pneumococcal infections are usually treated with antibiotics from the β-lactam, macrolide
and fluoroquinolone classes, either alone or in combination (section 1.3.3.2). Resistance
to these agents has increased in recent decades, although there is considerable varia-
tion in reports from different geographical areas. Incidence of pneumococcal disease
caused by antibiotic resistance has recently stabilised, and in some regions decreased,
with the introduction of the PCV7 vaccine, as the serotypes most commonly associated
with antibiotic resistance were included in the vaccine. However, the prevalence of non-
vaccine serotypes has since increased, and antibiotic resistance is increasing within this
group, particularly in serotype 19A isolates (Croucher et al., 2011b; Kyaw et al., 2006).
This trend may be reversed by introduction of the PCV13 vaccine, which includes 19A
among other serotypes, but surveillance data detailing the effects of this new vaccine on
antibiotic resistance is not yet available.
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1.6.1 β-lactams and macrolides
The main mechanism of resistance to β-lactams in S. pneumoniae is through the acqui-
sition of penicillin-binding proteins (PBPs) which have a reduced affinity for β-lactam
antibiotics (Dowson et al., 1993; Laible and Hakenbeck, 1987; Laible et al., 1991). This
is thought to have arisen through recombination of pbp genes with those from other
species of Streptococcus, in particular S. mitis (Dowson et al., 1993), resulting in the
formation of mosaic genes. The first case of penicillin resistance in S. pneumoniae was
reported in 1965 (Kislak et al., 1965), about 20 years after the introduction of β-lactam
antibiotics, but the prevalence of resistant strains remained low throughout the 1960s
with less than 1% of isolates showing resistance (Swartz, 2002).
Rates of penicillin resistance are difficult to monitor as clinical breakpoints differ between
disease presentation and method of antibiotic administration. However, data from global
surveillance studies suggests that the proportion of isolates globally that were not suscep-
tible to penicillin rose from 10.4% in 1996 (Felmingham and Grüneberg, 2000) to 22.3%
in 2002 (Felmingham et al., 2002). Following this, global data suggest that penicillin
resistance remained stable at 21.8% between 2002 and 2005 (Schito and Felmingham,
2005).
Global increases in penicillin resistance have been caused primarily due to the worldwide
spread of highly successful international clones which carry penicillin resistance deter-
minants (McGee et al., 2001). This has occurred due to acquisition of recombinant
pbp genes by strains that are also highly transmissible. The first example to be dis-
covered was the Spain23F-1 clone (designated PMEN1 by the Pneumococcal Molecular
epidemiology Network), which in 1998 accounted for nearly 40% of all penicillin resistant
isolates in the USA (Corso et al., 1998; McGee et al., 2001). Incidence of disease caused
by this clone has diminished due to inclusion of serotype 23F in PCV7, but a shift in
the population towards serotype 19A capsular switch variants of the lineage has been
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observed in the USA since about 2005 (Croucher et al., 2011b). A more recent example
is that of the Spain9V-3 clonal cluster (ST156, PMEN3) which represented about 50%
of penicillin non-susceptible isolates in Sweden in 2003 (Sjöström et al., 2007) and 48%
in Poland in 2005 (Sadowy et al., 2010). This clonal type possesses the rlrA genetic
islet which encodes a pilus (Hava and Camilli, 2002; Sjöström et al., 2007). Piliated iso-
lates were shown to outcompete non-piliated isolates, suggesting that piliation promotes
nasopharyngeal colonisation (Sjöström et al., 2007). It was shown that, in Sweden,
penicillin non-susceptibility was over-represented in piliated isolates compared to the
general population, and the combination of the two features was suggested to result in
penicillin-nonsusceptible strains particularly capable of global dissemination (Sjöström
et al., 2007).
Macrolide antibiotics bind to the 50S subunit of the bacterial ribosome, blocking the
elongation step of protein synthesis (Weisblum, 1995b). In S. pneumoniae, resistance can
be conferred by two mechanisms. The first is methylation of 23S rRNA by a methylase
encoded by the erm gene, which prevents macrolide binding (Weisblum, 1995a). The
second mechanism of pneumococcal macrolide resistance is over-expression of the Mef
eﬄux pumps, which are 44 kDa MFS transporter proteins (Clancy et al., 1996). Two
variants have been observed in S. pneumoniae: MefA and MefE (Gay et al., 2000;
Santagati et al., 2000).
Both the erm and mef genes are located on mobile genetic elements. The ermB gene
is found on the conjugative transposon Tn1545, which may also carry other resistance
determinants such as tetM (Trieu-Cuot et al., 1990). The mefA gene has been found
on the defective transposon Tn1207.1 (Santagati et al., 2000), while mefE is carried by
the macrolide eﬄux genetic assembly (mega) element (Gay and Stephens, 2001),
Macrolide resistance spreads by a combination of clonal expansion and horizontal gene
transfer. For example, carriage of macrolide resistance elements was associated with
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the internationally successful PMEN1 lineage, but acquisition and switching of these
elements has occured multiple times throughout the phylogeny (Croucher et al., 2011b).
Global prevalance of macrolide resistance has increased from 16.5% in 1996 (Felmingham
and Grüneberg, 2000) to 31.8% in 2002 (Felmingham et al., 2002). From 2002 to 2005
macrolide resistance continued to rise to 36.3% despite the level of penicillin resistance
remaining stable (Schito and Felmingham, 2005).
Worryingly, high levels of multidrug resistance in S. pneumoniae isolates have been ob-
served worldwide. Multidrug resistance, defined as resistance to two or more of the an-
timicrobials penicillin, second-generation cephalosporins, macrolides, tetracyclines, and
co-trimoxazole, was observed in 38.6% of isolates in the PROTEKT study (Schito and
Felmingham, 2005). A particularly high level of co-resistance was observed between peni-
cillin and macrolides, with 73.8% of penicillin resistant isolates also showing resistance
to azithromycin (Schito and Felmingham, 2005).
1.6.2 Fluoroquinolone resistance
The quinolones are a class of synthetic antibiotics with a broad spectrum of activity.
Naladixic acid was the first quinolone to be used clinically (Lesher et al., 1962). The
second generation of quinolones, the fluoroquinolones, were developed by fluoridation of
a particular carbon atom in the quinolone structure, which improved the antimicrobial
and pharmacodynamic properties of the drug (Ball, 2000). Norfloxacin was introduced
into clinical practice in 1986, followed by ciprofloxacin in 1987 (Paton and Reeves, 1988).
Third and fourth generation quinolones have been developed by further modification of
fluoroquinolone structures to improve potency and spectrum of activity. Third generation
quinolones include levofloxacin, gatifloxacin and moxifloxacin (Barrett, 2000; Perry et al.,
1999), and gemifloxacin is a clinically important fourth generation quinolone (Blondeau
and Missaghi, 2004).
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Quinolone antibiotics inhibit the action of the type II topoisomerases, topoisomerase IV
and DNA gyrase. DNA gyrase is a tetrameric enzyme formed from two GyrA and two
GyrB subunits, which catalyses formation of negative supercoils in DNA, aiding DNA
replication (Gellert et al., 1976). Topoisomerase IV is also tetrameric and is formed from
two ParC and two ParE subunits, and its main cellular role is to decatenate replicated
chromosomes (Adams et al., 1992; Kato et al., 1990). Both enzymes create and religate
double-stranded breaks in the DNA (Drlica and Zhao, 1997). Quinolone antibiotics bind
to the enzyme DNA complex and prevent religation of double stranded DNA breaks,
which leads to cell death (Drlica et al., 2008).
In S. pneumoniae, as in other bacteria, fluoroquinolone resistance is mediated by mu-
tations in the quinolone resistance determining regions (QRDRs) of the topoisomerase
IV subunit ParC and the DNA gyrase subunit GyrA, which prevent binding of fluoro-
quinolone antibiotics (Janoir et al., 1996; Pan et al., 1996).
Initial studies on development of fluoroquinolone resistance in S. pneumoniae showed
that high level ciprofloxacin resistance was caused by mutations in the QRDR regions of
both ParC and GyrA (Schmitz et al., 2002). The mutations most commonly associated
with this phenotype were changes of serine 79 of ParC and serine 81 of GyrA to tyrosine
or phenylalanine respectively (de la Campa et al., 2004; Janoir et al., 1996). Mutation
of ParC alone caused a modest increase in ciprofloxacin resistance (Janoir et al., 1996).
In in vitro selection experiments, mutations in parC emerged before mutations in gyrA,
which supported the proposal that ParC is the primary target of ciprofloxacin in Gram
positive bacteria (Janoir et al., 1996; Muñoz and De La Campa, 1996; Pan et al., 1996).
This situation contrasts with that in Gram negative bacteria where GyrA is the primary
fluoroquinolone target (Yoshida et al., 1990).
This picture has since become more complicated with the introduction of new fluoro-
quinolone antibiotics and the characterisation of more fluoroquinolone resistant clinical
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isolates. Alternative mutations in ParC (A63T) and GyrA (E85K) have been found, as
well as mutations in GyrB and ParE that have been shown to contribute to resistance
(Weigel et al., 2001). There are also reports of fluoroquinolone resistance conferred by
recombinant parC alleles formed by recombination with other mitis group streptococci
(Balsalobre et al., 2003; Stanhope et al., 2005). These recombinant alleles are rare (less
than 11% of ciprofloxacin resistant isolates tested), and the reason for this is unclear.
Previous studies suggest that recombination events are more frequent than mutational
events, other viridans streptococcal species are present in the nasopharynx and posses-
sion of recombinant parC does not seem to impose a fitness cost (Balsalobre and De La
Campa, 2008).
Although topoisomerase mutations cause cross-resistance to several fluoroquinolone an-
tibiotics, the impact varies by agent and the number of mutations present. For example,
in a set of fluoroquinolone resistant isolates characterised by Weigel and co-workers,
a previously uncharacterised mutation in GyrB increased resistance to gatifloxacin but
had no effect on moxifloxacin resistance. Conversely, in the same study a GyrA muta-
tion had a particularly strong association with moxifloxacin resistance but less so with
gatifloxacin. This latter observation was linked to other studies that suggested that
moxifloxacin preferentially targets GyrA instead of ParC in S. pneumoniae. The im-
pact of particular topoisomerase mutations on fluoroquinolone resistance was further
complicated by observation of a putative eﬄux mechanism for fluoroquinolones in S.
pneumoniae, discussed further in section 1.7 below. However, mutations in ParC are
most frequently isolated, consistently reduce susceptibility to all agents, and predispose
isolates to further selection of high level antibiotic resistance (Muñoz and De La Campa,
1996).
Global prevalence of fluoroquinolone resistance remains low (<1%) (Canton et al., 2003),
although there have been reports of high incidences in some locations such as Spain
and Hong Kong (García-Rey et al., 2000; Ho et al., 2001). A long-term surveillance
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study carried out in Canada showed a steady increase in the prevalence of ciprofloxacin
resistant isolates from 1% in 1997 to 4.2% in 2005 (Adam et al., 2007). Similar in-
creases were seen in levels of resistance to levofloxacin, gatifloxacin, gemifloxacin and
moxifloxacin. However, subsequent study extended the analysis to 2009 and showed
that fluoroquinolone resistance stabilised due to changes in prescribing practices from
ciprofloxacin to the newer fluoroquinolones (Patel et al., 2011). The PneumoWorld
surveillance study measured antimicrobial susceptibility of S. pneumoniae in eight Eu-
ropean countries and showed that, although fluoroquinolone resistance rates were low
(<2%), they varied between countries with the highest rates found in Spain and Italy
(1.2-1.3%) (Reinert et al., 2005). Resistance rates correlated with the level of fluoro-
quinolone use in each country. Several surveillance studies have found that the risk of
being infected with a fluoroquinolone resistant isolate is highest in hospitals and nursing
homes, and if a patient has been treated with fluoroquinolones in the previous three
months (Ho et al., 2001; Vanderkooi et al., 2005).
Association of fluoroquinolone resistance with particular clonal lineages is controversial.
A study of levofloxacin resistant clinical isolates from the Active Bacterial Core Surveil-
lance program (CDC, USA) between 1998 and 2002 found that over half of the isolates
were related to five international clones, with the Spain23F-1 clone particularly highly
represented (Pletz et al., 2004). However, several other analyses, including the global
PROTEKT surveillance program, have shown that the clonal types of sets of fluoro-
quinolone resistant clinical isolates are heterogenous (Adam et al., 2007; Canton et al.,
2003). In a phylogenetic analysis of the PMEN1 lineage Croucher et al (2011b) observed
that multiple topoisomerase mutations had emerged independently. Mutations causing
fluoroquinolone resistance can emerge spontaneously during therapy and have been as-
sociated with treatment failures when levofloxacin or ciprofloxacin was used (Fuller and
Low, 2005).
Several studies have shown that some topoisomerase mutations confer a fitness defect
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compared to fluoroquinolone susceptible strains (Balsalobre and De La Campa, 2008;
Gillespie et al., 2003; Johnson et al., 2005; Rozen et al., 2007). The extent of the growth
defect varies depending on the mutation. Mutation of serine 79 of ParC to phenylalanine
conferred a reduction in fitness of approximately 8% compared to R6, while mutation of
the same residue to tyrosine did not affect growth (Rozen et al., 2007). The opposite
effect was observed when serine 81 of GyrA was mutated to tyrosine or phenylalanine,
and a growth defect was also observed for GyrA E85K.
However, fitness costs conferred by one topoisomerase mutation can be partially or fully
alleviated by acquisition of a second mutation (Balsalobre et al., 2011; Rozen et al.,
2007). Balsalobre and co-workers (2011) linked this to DNA supercoiling. In this study,
the fitness defect conferred by a high-cost GyrA mutation (E85K) was compensated by
acquisition of a recombinant parC allele. The authors measured global DNA supercoiling
in the single and double mutants and showed that it was disrupted in the gyrA mutant
but restored when the recombinant parC gene was added. As topoisomerase IV and
DNA gyrase have opposing effects on DNA supercoiling, it seems that expression of one
non-optimal enzyme disrupts the overall supercoiling state, but when the activity of the
opposing enzyme is also reduced the supercoiling state is restored.
1.7 Eﬄux mediated fluoroquinolone resistance in
S. pneumoniae and background to this project
The existence of an eﬄux pump in S. pneumoniae that confers resistance to fluoro-
quinolones was originally inferred from several reports of pneumococcal isolates that
showed resistance to ciprofloxacin and norfloxacin that was either reversed by addition
of eﬄux inhibitors or could be attributed to lower accumulation of drug.
A study by Piddock and co-workers (1997) showed that three ciprofloxacin resistant
38
mutants of S. pneumoniae accumulated lower levels of ciprofloxacin than their respective
parental strains. No mutations were found in the topoisomerase genes, suggesting that
there was another mechanism for ciprofloxacin resistance.
Baranova and Neyfakh (1997) observed that exposure of a pneumococcal strain to a
subinhibitory concentration of reserpine resulted in a 2.25 to 3.5-fold decrease in sus-
ceptibility to ciprofloxacin, norfloxacin, and ethidium bromide. A mutant selected for
increased resistance to ethidium bromide showed cross-resistance to ciprofloxacin and
norfloxacin that could be reversed by addition of reserpine. Ethidium bromide resistance
in the mutant was due to increased eﬄux, leading the authors to hypothesise that S.
pneumoniae possesses a multidrug transporter that can transport both ethidium bromide
and fluoroquinolones.
Brenwald and co-workers also selected S. pneumoniae mutants with decreased suscep-
tibility to ciprofloxacin and norfloxacin (Brenwald et al., 1997). Addition of reserpine
reversed fluoroquinolone resistance in three mutants selected on norfloxacin, and these
mutants were found to be cross-resistant to ciprofloxacin, ethidium bromide and acri-
flavine. A further five mutants with reserpine-sensitive norfloxacin resistance were se-
lected in a subsequent study, and a representative mutant, 1N27, was again shown to
have cross-resistance to ethidium bromide (Brenwald et al., 1998). Using this observed
phenotype as a marker for strains with increased eﬄux, the authors screened 1,037 clin-
ical isolates of S. pneumoniae for susceptibility to norfloxacin, ciprofloxacin, ethidium
bromide and acriflavine, using an agar dilution method. Of 273 isolates that showed
reduced susceptibility to the fluoroquinolone antibiotics (MIC of norfloxacin > 8 µg/ml
and MIC of ciprofloxacin > 1 µg/ml), 98 isolates showed a four-fold or greater reduction
in norfloxacin resistance in the presence of reserpine, combined with elevated resistance
to ethidium bromide and acriflavine.
The results from these three studies suggest that a multidrug eﬄux transporter that
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can transport fluoroquinolones exists in S. pneumoniae, and is a potential mechanism of
resistance in clinical isolates.
1.7.1 PmrA
Subsequent work on R6N, an R6 transformant of the 1N27 eﬄux mutant selected by
Brenwald et al (1998), identified over-expression of pmrA, a gene encoding an eﬄux
pump of the major facilitator superfamily (Gill et al., 1999). The PmrA protein showed
24% amino acid identity to the known NorA and Bmr multidrug eﬄux pumps of Staphy-
lococcus aureus and Bacillus subtilis. Gill and co-workers inactivated pmrA in R6N by
insertion of a chloramphenicol resistance cassette. This reduced MICs of norfloxacin,
ciprofloxacin, ethidium bromide and acriflavine to the levels observed in R6, leading the
authors to suggest PmrA as a candidate for the pneumococcal multidrug eﬄux pump
that confers fluoroquinolone resistance (Gill et al., 1999). However, later studies pro-
vided evidence suggesting that PmrA is not the main fluoroquinolone eﬄux pump in S.
pneumoniae.
Piddock and co-workers (2002) measured expression of pmrA in a set of clinical isolates
of which 34 were ciprofloxacin resistant and 12 were ciprofloxacin susceptible. Thirty-
eight of these isolates were norfloxacin resistant and, for eighteen of these, norfloxacin
resistance was reduced four-fold or more in the presence of reserpine. Expression of
pmrA in the isolates varied widely, and there was no correlation between high expression
of pmrA and reserpine-sensitive norfloxacin resistance.
Brenwald et al (2003) investigated two mutants, LEV1 and GEM11, which had a pheno-
type consistent with increased eﬄux. The mutants had been selected in a previous study
by exposure to levofloxacin and gemifloxacin (Davies et al., 1999). To investigate resis-
tance in these isolates due to eﬄux, without the confounding influence of topoisomerase
mutations, R6 was transformed with genomic DNA from each isolate and transformants
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were selected using ethidium bromide, a known substrate of eﬄux pumps. The pmrA
gene was not expressed at a level significantly higher than wild-type R6 in the R6LEV1
and R6GEM11 transformants, as determined by Northern blotting.
Another piece of evidence for a second fluoroquinolone eﬄux transporter in S. pneu-
moniae came from a study by Pestova and co-workers (2002), which looked at two
strains where pmrA had been inactivated by insertion of a chloramphenicol resistance
gene. Inactivation of pmrA in a wild type strain did not affect ethidium bromide or
fluoroquinolone resistance, while in a mutant with increased eﬄux pmrA inactivation
restored susceptibility to ethidium bromide, ciprofloxacin and norfloxacin to wild type
levels. However, the authors observed that an effect of reserpine on ciprofloxacin and
ethidium bromide susceptibility was not completely eliminated in either of the strains
lacking PmrA, suggesting that another reserpine-sensitive transporter is present.
Futhermore, both Pestova et al (2002) and Brenwald et al (2003) found that mutants
with increased resistance to ethidium bromide could be selected from strains lacking
functional PmrA. In both cases, the selected mutants showed cross-resistance to flu-
oroquinolones and the phenotype was reversed in the presence of reserpine, which is
suggestive of increased eﬄux.
There was considerable variation observed in the contribution of PmrA to eﬄux-mediated
fluoroquinolone resistance between different strains and studies, and several lines of evi-
dence suggested that at least two fluoroquinolone eﬄux systems exist in S. pneumoniae.
Similar evidence for the existence of more than one multidrug transporter with overlap-
ping substrate specificities had been previously observed in B. subtilis (Ahmed et al.,
1995) and S. aureus (Kaatz et al., 2000).
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1.7.2 PatA and PatB
1.7.2.1 Discovery and role in eﬄux mediated fluoroquinolone resistance
Two independent studies showed that the ABC transporter genes patA and patB were
involved in eﬄux of fluoroquinolones.
Robertson et al (2005) systematically inactivated thirteen putative eﬄux pump genes in
S. pneumoniae strain TIGR4. Inactivation of the genes encoding PatA and PatB resulted
in significant increases in susceptibiliy to ethidium bromide, acriflavine, ciprofloxacin
and norfloxacin, as well as the non-quinolone GyrB inhibitor novobiocin, a quarternary
ammonium compound berberine, and the macrolide antibiotic erythromycin (Robertson
et al., 2005). Robertson et al also constructed a double mutant where both patA and
patB were inactivated, but this did not result in any further decreases in susceptibility
to any of the tested agents. These results were later confirmed by Tocci et al (2013).
A different approach to identifying transporters involved in fluoroquinolone resistance
was taken by Marrer et al (2006a). The transcriptome of M22, a ciprofloxacin resistant
mutant selected from strain M4 (NCTC 7465) that had a phenotype suggestive of eﬄux
(Piddock and Johnson, 2002), was determined using a microarray. Gene expression
in M22 was compared to its parental strain M4 at three different growth phases and
after exposure to three different concentrations of ciprofloxacin. A set of 22 genes were
expressed at a higher level in M22 than in M4 under all conditions tested, and this
included patA and patB. Increased expression of these genes was also observed in M4
following exposure to ciprofloxacin, suggesting that ciprofloxacin induces expression of
patA and patB. Modest inductions were also seen in M22 when this strain was exposed
to ciprofloxacin. As well as patA and patB, several other genes showed altered expression
in M22 compared to M4, including genes involved in DNA repair and replication, some
other transporters, genes involved in isoleucine and valine biosynthesis and several genes
42
encoding hypothetical proteins. This pleiotropic phenotype of M22 prompted the authors
to suggest that the over-expression of patA and patB was mediated by a mutation in
a global regulator, analagous to mutations found in MarR in E. coli which leads to
altered expression of more than 60 genes, some of which are involved in antibiotic eﬄux
(Barbosa and Levy, 2000).
A follow-up study by the same authors focused more specifically on the role of patA and
patB in ciprofloxacin resistance in M22 and M4 (Marrer et al., 2006b). The patA and
patB genes were disrupted in R6 by insertion of an erythromycin resistance gene. In
M22, patB was disrupted by the same method, but mutants with an insertion in patA
could not be obtained. Growth of the R6 patA disruptant was impaired, suggesting
that patA plays an important role in the cell and may be essential in the M22 genetic
background. Disruption of either gene in R6 caused a fourfold reduction in resistance to
ciprofloxacin, and disruption of patB in M22 partially reduced resistance to ciprofloxacin
and norfloxacin, although MICs did not revert to the levels observed in M4. The M22
patB disruptant strain was shown to accumulate double the amount of ciprofloxacin
accumulated by M22.
Additionally, Marrer et al (2006b) found that expression of pmrA was undetectable in
both M4 and M22 by Northern blotting or quantative competitive reverse transcriptase
PCR, and subsequent sequencing of the gene revealed that it contains an internal deletion
of 84 nucleotides (28 amino acids) in these strains compared to R6. Based on a structural
model of the protein (Gill et al., 1999), this deletion was predicted to remove most of
the sixth transmembrane helix of the transporter, which would presumably render it
non-functional.
The involvement of patAB over-expression in ciprofloxacin resistance was further em-
phasised by Avrain and co-workers (2007). In this study, mutants were selected using
four different fluoroquinolones from two parental strains, ATCC 49619, which is a fluo-
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roquinolone susceptible type strain, and SP32, a clinical isolate known to over-express
pmrA. When each strain was exposed to half its MIC of ciprofloxacin for 13 days, the
resulting mutants showed increased resistance to ciprofloxacin, and also modest de-
creases in susceptibility to levofloxacin and gemifloxacin. Resistance to ciprofloxacin and
levofloxacin could be partially reversed by addition of reserpine. Mutants derived from
both parental strains were shown by quantitative real-time PCR to over-express patA and
patB. In mutants of SP32, which originally expressed pmrA at a level 11-fold higher than
ATCC49619, pmrA expression had decreased while expression of patA and patB was sig-
nificantly increased. In contrast to ciprofloxacin, exposure to moxifloxacin, levofloxacin
and garenoxacin selected for mutations in QRDRs of ParC, ParE and GyrA instead of
changes in expression of patA and patB. This resulted in larger increases in MIC of all
fluoroquinolones tested, and these MICs were unchanged by addition of reserpine. The
authors concluded that the mechanism of fluoroquinolone resistance depended on the
selecting antibiotic, rather than the initial strain. Ciprofloxacin selected for increased
eﬄux instead of topoisomerase mutations, and this was mediated by patAB, not pmrA.
Over-expression of patA and patB could also be selected by exposure to the eﬄux in-
hibitor reserpine (Garvey and Piddock, 2008). Garvey and Piddock characterised two
mutants with reduced susceptibility to reserpine, M169 selected from R6 and M168 se-
lected from M4. As well as reduced susceptibility to reserpine, these mutants also showed
cross-resistance to the fluoroquinolones ciprofloxacin, norfloxacin and levofloxacin, the
dyes ethidium bromide and acriflavine and the biocide cetrimide. Both mutants were
shown to over-express patA and patB. Both mutants were selected by a single round of
exposure to 100 µg/ml reserpine, which suggested that the phenotype was conferred by
a single genetic change. The mutation frequencies, defined as the number of reserpine-
resistanct mutants isolated divided by the total number of viable cells per millilitre, were
7.3×106 and 3.6×105 for R6 and M4, respectively. These mutation frequencies led the
authors to conclude that patA and patB over-expression was mediated by a mutation
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in a single gene, hypothesised to be in a regulatory gene. However, as will be described
in this thesis, the mutation causing reserpine resistance in a selected mutant of R6 was
in fact a duplication instead of a point mutation, which may explain the differences
in mutation frequencies observed between the two strains. When genomic DNA from
M168 and M169 was transformed into R6, reserpine resistant transformants with the
same phenotype as M168 and M169 could be recovered after a single round of transfor-
mation, giving strains M186 and M184, respectively. This supports the hypothesis that
patAB over-expression is conferred by a single genetic change in these strains.
Garvey and Piddock (2008) also investigated the effect of inactivation of patA or patB in
R6, M169, M184 and M186. This was carried out by insertion of a magellan2 minitrans-
poson into each gene. Inactivation of either patA or patB reversed multidrug resistance
in the strains over-expressing these genes. In the case of ciprofloxacin, ethidium bromide
and acriflavine, the resulting mutants were more susceptible to these agents than wild
type R6. A similar hypersusceptible phenotype was observed when patA or patB was
inactivated in R6. In strains over-expressing patA and patB, only inactivation of patA
was able to restore reserpine resistance to wild type levels.
A double mutant where both patA and patB were inactivated by replacement with
chloramphenicol and kanamycin resistance genes, respectively, was later constructed and
analysed by Boncoeur and co-workers (2012). Reduction in growth rate of the double
mutant compared to wild type R6 in the presence of 0.025, 0.05 and 0.1 µg/ml ethidium
bromide was not significantly different from either of the single mutants. In contrast,
when mutants were exposed to 100 ng/ml ciprofloxacin or 400 ng/ml norfloxacin, the
growth of the double mutant was inhibited to a greater degree than either of the single
mutants, particularly in the presence of ciprofloxacin.
A growth defect was observed when patA (but not patB) was inactivated in R6 in Gar-
vey’s study, but this was not observed in the Boncoeur 2012 study. Deletion of patA in
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TIGR4 also did not affect growth (Robertson et al., 2005). On the other hand, deletion
of patA could not be successfully accomplished in M22 leading to suggestions of essen-
tiality in this genetic background (Marrer et al., 2006b). These observed differences in
phenotype could be explained by differences in growth conditions; for example, Boncoeur
et al grew strains in Todd-Hewitt broth whereas Garvey and Piddock used Brain Heart
Infusion. Alternatively, the differences in the gene inactivation methods used could have
an effect on growth. Garvey and Piddock used in vitro Mariner mutagenesis, while
Boncoeur et al replaced patA and patB with chloramphenicol and kanamycin resis-
tance genes, respectively, by overlap extension PCR. Robertson et al also used overlap
extension PCR to replace patA with a spectinomycin resistance gene and patB with a
chloramphenicol resistance gene. Another possibility is that there could be strain-specific
differences in the essentiality of patA. Although Boncouer et al and Garvey and Piddock
both used R6 as the wild type strain, there may still be small differences in genomes of
the R6 parental strains used by the two different laboratories.
1.7.2.2 patA and patB expression as a response to stress
Previous studies have shown that expression of patA and patB is induced in the presence
of sub-inhibitory concentrations of ciprofloxacin and norfloxacin (Marrer et al., 2006a).
A recent study by El Garch et al (2010) extended these observations by showing that
over-expression of patA and patB may be part of a general stress response in S. pneu-
moniae. Firstly, they demonstrated that, not only can expression of patA and patB
be induced by ciprofloxacin and norfloxacin, which are good substrates for the PatAB
eﬄux pump (Avrain et al., 2007), but this expression can also be induced by three other
fluoroquinolones: levofloxacin, moxifloxacin and gemifloxacin. These fluoroquinolones
are more hydrophobic than ciprofloxacin and norfloxacin and are not considered good
substrates for eﬄux (Avrain et al., 2007). This suggests that transient induction of patA
and patB is a reaction to cell stress caused by challenge with fluoroquinolone antibiotics,
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rather than an example of an eﬄux pump being upregulated in the presence of its sub-
strate. In addition, it was shown that mitomycin C, a DNA damaging agent that is a
known stimulator of the competence pathway in S. pneumoniae, also induced expression
of patA and patB. Increases in expression of patA and patB by mitomycin C correlated
strongly with the up-regulation of two late competence genes, ssbB and recA. Induction
of the competence pathway has been suggested to be a general response to cell stress in
S. pneumoniae, analogous to the SOS response characterised in E. coli (Claverys et al.,
2006; Little and Mount, 1982). Taken together, these results suggest that induction of
patA and patB may be part of a general stress response to DNA damage, and that this
could be linked to the competence pathway.
In the study by El Garch et al induction of patA and patB over-expression was observed
in two laboratory mutants and two clinical isolates that over-expressed patA and patB,
showing that patA and patB expression can be induced by fluoroquinolones in a variety of
genetic backgrounds, and in mutants where the basal level of expression is already high.
This observation contradicts that of Marrer et al (2006a) who did not observe further
induction of patA and patB expression in the ciprofloxacin-selected M4 mutant, M22,
in the presence of ciprofloxacin or norfloxacin. However, M22 had a highly pleiotropic
phenotype so this discrepancy could be explained by the mutation causing patA and
patB upregulation in M22 occurring in a global regulator higher up in the pathway
controlling the expression of these genes. The mutants studied by El Garch et al may
be mutated in local regulators, allowing global stress response mechanisms to further
affect the expression of the genes. Alternatively, the mutants studied by El Garch et al
may be mutated such that expression of patA and patB is partially de-repressed, while
expression in M22 may be fully constitutive.
Van Opijnen and Camilli (2012) recently used Tn-seq to link pneumococcal genes to
phenotypes. The technique involves high-throughput sequencing of transposon insertion
libraries before and after application of a test condition. Changes in the frequency of
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transposon insertions in each gene in the output library compared to the input library
provides information regarding the importance of that gene for survival of the bacterium
in that test condition (van Opijnen et al., 2009). Van Opijnen and Camilli generated
transposon insertion libraries in pneumococcal strain TIGR4 and exposed them to a
variety of conditions including growth on different carbon sources, antibiotic exposure,
and other cell stresses such as altered pH and temperature. Survival of transposon
mutants in the nasopharynx and lung was also tested using a murine model of infection.
As would be expected based on the results of previous studies, mutants with a transposon
insertion in patA or patB were found to be significantly depleted in libraries exposed to
norfloxacin. However, the Tn-seq analysis also suggested a role for patA and patB in
tolerance of alkaline pH. The role of patAB in alkaline tolerance seemed to be separate
from the role in norfloxacin tolerance, and led the authors to suggest that this is the
first example of a dual-function ABC transporter.
Regulons have been determined for several pneumococcal global transcriptional regula-
tors such as CiaRH, ComX, StkP, PsaR and SczA (Halfmann et al., 2007; Kloosterman
et al., 2007, 2008; Peterson et al., 2000; Saskova et al., 2007). The patA and patB
genes have not been identified among these regulons. One possible global regulatory
mechanism that could control patAB expression is DNA supercoiling. Ferrándiz et al
(2010) investigated differences in gene expression across the whole S. pneumoniae R6
genome in the presence or absence of novobiocin, a drug that causes relaxation of su-
percoiled DNA by inhibiting DNA gyrase. This analysis revealed that the R6 genome
contains 15 distinct gene clusters, representing 13% of the genome, which show a co-
ordinated regulatory response to the level of DNA supercoiling, independent of operon
organisation. The patA and patB genes are located within topology-reacting cluster 15,
a cluster that is upregulated in response to DNA relaxation.
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1.7.2.3 Role of patA and patB in linezolid resistance, and contribution to
virulence
Over-expression of patA and patB was subsequently observed in three out of four inde-
pendent S. pneumoniae mutants selected for resistance to the oxazolidinone antibiotic
linezolid (Feng et al., 2009). Two linezolid resistant mutants were selected from parental
strains R6 and CCRI 1974 by exposure to progressively increasing concentrations of line-
zolid from one to 32 µg/ml. All four mutants were found to have acquired point
mutations in all four copies of the 23S rRNA, which was a previously known mechanism
of resistance (Prystowsky et al., 2001). However, one of the two R6 mutants and both of
the CCRI 1974 mutants also possessed a mutation upstream of patA. In the R6 mutant
and one of the CCRI 1974 mutants this was 46 bp upstream of the patA start codon,
while in the remaining CCRI 1974 mutant the mutation was located 32 bp upstream.
Both of these mutations were associated with higher expression of patA and patB, as
shown by qRT-PCR. The CCRI 1974 mutants were also shown to be cross-resistant to
ciprofloxacin. However, when patA or patB were inactivated in one of the CCRI 1974
mutants, linezolid resistance was only partially decreased, leading the authors to con-
clude that PatA and PatB have a role in linezolid resistance but that it is only minor
compared to the effect of mutations in 23S rRNA.
A subsequent study by the same group used whole genome transformation to analyse the
role of patAB over-expression in linezolid resistance (Billal et al., 2011). Genomic DNA
from a new linezolid resistant mutant selected from CCRI 1974 was used to transform a
linezolid sensitive CCRI 1974 and R6 recipient strains. Two to three rounds of transfor-
mation were required to recreate the previously observed increases in linezolid resistance
in both genetic backgrounds, indicating that transfer of more than one mutation was
required. Genome sequencing of the transformants and original mutant revealed that
increases in linezolid resistance at each stage of transformation correlated with accu-
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mulation of mutations in the four copies of the 16S rRNA, followed by acquisition of
mutations in the 50S ribosomal proteins L3 and L16. The transformant with the CCRI
1974 genetic background also acquired a mutation in the ABC transporter gene spr1021
on the third round of transformation. The mutation 32 bp upstream of patA, which
was present in the original mutant, was not transferred to either of the transformants
tested, and transfer of this mutation to a linezolid susceptible strain by transformation
with a specific PCR amplimer did not increase linezolid resistance. However, the muta-
tions in the 23S rRNA genes conferred a growth defect, which was exacerbated by the
acquisition of the spr1021 mutation. Transfer of the mutation upstream of patA into
strains carrying these mutations was shown to significantly reduce this growth defect,
although growth was not restored to the level of the linezolid susceptible parental strain.
Over-expression of patAB therefore appears to compensate for fitness defects conferred
by mutations causing linezolid resistance. The molecular basis for this compensatory
effect has not been determined.
A similar mutation upstream of patA causing patAB over-expression was identified in a
clinical isolate taken from the cerebrospinal fluid (CSF) of a meningitis patient (Croucher
et al., 2013). This mutation was not found in an isogenic isolate found in the bloodstream
of the same patient, leading to the suggestion that upregulation of patAB contributes
to pneumococcal survival in the CSF.
1.7.2.4 Structure of PatAB
Functional characterisation of PatA and PatB was carried out by Boncoeur and co-
workers (2012). In this study, PatA and PatB were over-expressed in E. coli, purified and
incorporated singly and in combination into inside-out vesicles. Sodium orthovanadate-
sensitive transport of the fluorescent dye Hoechst 33342 was observed only when PatA
and PatB were combined. This transport was abolished when the Walker A motif of
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either PatA or PatB was mutated, showing that transport is ATPase-dependent, as
expected. The oligomerisation state of purified PatA and PatB, both singly and in
combination, was also assessed by Boncoeur et al using three methods: gel filtration,
analytical ultracentrifugation and size exclusion chromatography. The results were similar
and showed that PatA and PatB together produced stable and functional heterodimers,
while PatA alone formed stable but non-functional homodimers. When PatB was purified
alone it formed a mixture of monomers and non-functional homodimers, suggesting that
PatB homodimers are unstable.
1.7.2.5 Homologues of patA and patB in S. suis
Over-expression of the satA and satB genes, which are homologues of patA and patB, has
been reported in the zoonotic pathogen S. suis (Escudero et al., 2011). The SatA and
SatB proteins are 66% and 67% identical to PatA and PatB respectively. Escudero and
co-workers examined a S. suis isolate with resistance to ciprofloxacin and norfloxacin
that was reversed by addition of reserpine. They showed that satA and satB were
upregulated in this isolate, but expression of smrA, which encodes a MFS transporter
with 58% sequence identity to PmrA, was unchanged. Heterologous expression of satAB
in Bacillus subtilis conferred increased resistance to norfloxacin and ciprofloxacin, but not
to enrofloxacin, levofloxacin, moxifloxacin or naladixic acid. In contrast, heterologous
expression of smrA did not alter the resistance of the B. subtilis host to any of the
agents tested, and no substrates were identified using a Biolog phenotype microarray.
The authors concluded that SatAB is a narrow spectrum ciprofloxacin and norfloxacin
transporter. SmrA is not involved in fluoroquinolone transport in the strain tested, and
its natural substrate remains unidentified. This situation is very similar to that observed
in the pneumococcus. However, the genetic organisation of the satAB locus is different
from the patAB locus in S. pneumoniae. Whereas patA and patB are separated by a
degenerate transposase, in S. suis satA and satB are contiguous, and Escudero et al
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(2011) showed that they are transcribed in the same mRNA molecule. Upstream of, but
slightly overlapping with satA there is a gene encoding a MarR superfamily regulator,
named satR. Further investigation of this gene showed that SatR is indeed a regulator
of SatAB (Escudero et al., 2013). However, no homologue of SatR is present in S.
pneumoniae.
1.8 Hypotheses tested in this project
The hypotheses to be investigated in this project are:
• Over-expression of patA and patB is a clinically relevant mechanism of fluoro-
quinolone resistance.
• Specific regulatory pathways exist in S. pneumoniae that control the expression of
patAB in response to stimuli such as DNA damage.
• Over-expression of patA and patB in S. pneumoniae be conferred by mutations in
regulatory genes.
1.9 Aims and objectives
• To complete experiments and data analysis on a set of fluoroquinolone-resistant
clinical isolates to determine the clinical relevance of over-expression of patA and
patB.
• To identify the mutated protein(s) responsible for up-regulation of patA and patB
expression in S. pneumoniae laboratory mutants and clinical isolates by whole
genome sequencing.
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• To further characterise identified regulators to elucidate parts of the regulatory
network controlling patAB expression.
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2 Materials and Methods
2.1 Bacterial strains and growth
All bacterial strains used in this study are shown in Table 2.1.
2.1.1 Growth conditions and media
S. pneumoniae strains and isolates were grown in Brain Heart Infusion (BHI) broth (Ox-
oid, Basingstoke, U.K.; cat. no. CM1135B), or on Columbia agar (Oxoid, Basingstoke,
U.K.; cat. no. CM0331B) plates supplemented with 5% horse blood (cat. no. HB034;
TCS Biosciences, U.K.). Broth cultures and plates were incubated statically at 37◦C
in an atmosphere of 7.5% CO2. Growth was monitored by measurement of the opti-
cal density at 660 nm (OD660) of a 1 ml sample of culture using a spectrophotometer
(Geneflow, UK), compared to a blank measurement from 1 ml of sterile BHI broth.
E. coli strains used for construction of the pBAV1K-gfp82 plasmid (section 2.9.1) were
grown in Luria Bertani (LB) broth, or on LB agar plates, supplemented with appropriate
antibiotics. Agar plates were incubated statically at 37◦C, and broth cultures were incu-
bated at 37◦C with shaking at 180 rpm. Growth was monitored by measurement of the
optical density at 600 nm (OD600) of a 1 ml sample, compared to a blank measurement
from 1 ml of sterile LB broth.
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2.1.2 Storage of bacterial strains
S. pneumoniae strains were stored at -80◦C on Protect beads (Technical Service Con-
sultants Ltd., cat. no. TS/80-MX). To resuscitate strains for use, beads were placed in
3 ml brain heart infusion (BHI) broth supplemented with 5% sterile defibrinated horse
blood and incubated statically overnight. Bacteria were then transferred to Columbia
agar plates supplemented with 5% defibrinated horse blood under sterile conditions, us-
ing the streak plate method to obtain pure colonies, and incubated overnight. BHI broth
(5 ml) was inoculated with up to ten pure colonies, and the culture was grown until an
OD660 of 0.4-0.6 was reached (mid-logarithmic phase). Sterile glycerol was added to a
final concentration of 10%, and 1 ml aliquots were frozen at -80◦C for use as starter
cultures in all subsequent experiments.
E. coli strains were also stored at -80◦C on Protect beads. Beads were rubbed on the
surface of an LB agar plate (Sigma-Aldrich Ltd., U.K.; cat. no. L2897) containing
appropriate antibiotics, and the plates were incubated overnight at 37◦C. Plates were
sealed with parafilm and stored at 4◦C for up to two weeks.
2.2 DNA extraction
2.2.1 Extraction of genomic DNA
DNA was extracted from all S. pneumoniae strains using the Promega Wizard Genomic
DNA Purification kit according to the manufacturer’s instructions, as follows. Frozen,
logarithmic phase cells were diluted 1:10 in sterile prewarmed BHI broth (10 ml) and
grown statically at 37◦C in 5% CO2 to an OD660 of 0.6. Cells were harvested by
centrifugation (10 mins, 2200 x g, room temperature), resuspended in 480 µl EDTA
(50 mM) and transferred into a microcentrifuge tube. A 120 µl volume of lysozyme (10
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mg/ml) was added and the mixture was incubated at 37◦C for 30-60 minutes. Lysozyme-
treated cells were harvested by centrifugation (12,100 x g, 3 min), resuspended in 600 µl
of Promega Nuclei Lysis Solution and lysed by heating (80◦C, 5 min). After cooling to
room temperature, 3 µl Promega RNase was added and the lysates incubated at 37◦C for
15-60 minutes. To remove proteins, 200 µl Promega Protein Precipitation Solution was
added, the sample was incubated on ice for five minutes, then the precipitated protein
was pelleted by centrifugation (12,100 x g, 3 min). The supernatant was transferred
to a microcentrifuge tube containing 600 µl isopropanol, and mixed by inversion until
precipitated DNA formed a visible mass. DNA was pelleted by centrifugation (1 min,
12,100 x g), washed with 70% ethanol and resuspended in 100 µl of sterile nuclease-free
water (Gibco). Prepared DNA was stored at -20◦C for up to four months. To assess
yield and quality, 5 µl of prepared DNA was visualised on a 1% agarose gel.
2.2.2 Extraction of plasmid DNA
High copy number plasmid DNA was harvested from E. coli strains using the QIAgen R©
Miniprep kit (QIAgen, UK, Cat. no. 27104), according to the manufacturer’s instruc-
tions. Purified plasmid DNA was stored at -20◦C.
Plasmid DNA was extracted from S. pneumoniae strains using a QIAgen R© Miniprep
kit following the QIAgen R© user-developed protocol for isolation of plasmid DNA from
Bacillus subtilis. This protocol differs from the standard miniprep protocol by adding
a lysozyme treatment to break down the thick Gram-positive cell wall. Cells from 10
ml of mid-logarithmic phase (OD660 0.4-0.6) culture were harvested by centrifugation
(10 minutes at 2,200 x g). Cells were resuspended in 250 µl of QIAgen R© Buffer P1
containing a final concentration of 1 mg/ml lysozyme, and incubated for 10 minutes at
37◦C. Plasmid extraction was then continued as described from step two of the standard
QIAgen R© miniprep protocol.
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2.2.3 Agarose gel electrophoresis
Genomic DNA and plasmid preparations were visualised by electrophoresis on a 1%
agarose gel. To prepare agarose gels, 1 g of electrophoresis grade agarose (Life Tech-
nologies, cat. no. 75000-500) was dissolved in 100 ml of 1% Tris-Borate-EDTA (TBE;
Ambion, cat. no. AM9864) by heating in a 650 W microwave for 5 minutes. After
allowing the solution to cool, either ethidium bromide (final concentration 0.1 µg/ml)
or Midori Green Advance DNA Stain (5 µl; Geneflow, cat no. S6-0022) was added as
a fluorescent dye to allow DNA visualisation. The agarose solution was poured into a
gel tray, allowed to set and immersed in 1% TBE in a gel tank. Five µl of each sample
was mixed with 2 µl of 5x Blue DNA loading buffer (Bioline, cat. no. BIO-37045)
and loaded into individual wells of the gel along with HyperLadderTM 1kb (Bioline, cat.
no. BIO-33053) Samples were separated by electrophoresis for one hour at 100 V. DNA
fragments were visualised by UV trans-illumination using a Gene Genius image analyser
(Syngene, Cambridge, UK) and were quantified, where appropriate, using the GeneTools
software package (Syngene).
2.3 Transformation of whole genomic DNA from
patAB over-expressing strains into R6
2.3.1 Transformation
Donor DNA was extracted from the appropriate strain as described above. A 1 ml frozen
stock of R6 was thawed and diluted in 9 ml BHI broth. The culture was incubated at
37◦C until an OD660 of 0.4 was reached, corresponding to log-phase growth. The culture
was then diluted 1:20 in 10 ml sterile Competence Medium, which consisted of 37 g/L
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Todd-Hewitt broth (Oxoid, cat. no. CM0189), 5 g/L Yeast Extract (Oxoid, cat. no
CM0019), 1.2 mM calcium chloride and 2 g/L bovine serum albumin (BSA; Sigma, cat.
no. B6917). Competence stimulating peptide 1 (CSP1; Mimotopes) was then added to
a final concentration of 100 ng/ml. For each transformation reaction a 500 µl aliquot
of the diluted culture was transferred to a microcentrifuge tube, and up to 1 µg of the
required donor DNA was added. In parallel, a control transformation was set up where
the donor DNA was replaced with an equivalent volume of sterile water or R6 genomic
DNA. The mixtures were incubated statically for three hours (37◦C), and then 100 µl
of each mixture was spread onto Columbia blood agar plates containing an appropriate
selective agent and incubated overnight (37◦C, 7.5% CO2). Resulting transformants
were sub-cultured onto fresh Columbia blood agar and again incubated overnight (37◦C,
7.5% CO2).
2.3.2 Confirmation of patAB over-expression phenotype of
transformants
2.3.2.1 Antibiotics and determination of minimum inhibitory concentrations
The minimum inhibitory concentrations (MICs) of all antibiotics, dyes and eﬄux pump
inhibitors used in this study were determined by the agar doubling dilution method, per-
formed according to the BSAC guidelines (Andrews, 2001). Stock solutions (10 mg/ml)
of the antibiotics ciprofloxacin, norfloxacin, chloramphenicol, tetracycline, spectinomycin
and kanamycin (Sigma Aldrich, Dorset, U.K.) were made up according to the manufac-
turer’s instructions. Stock solutions (10 mg/ml) of the dyes ethidium bromide and
acriflavine (Sigma Aldrich, Dorset, U.K.) were made by reconstitution in sterile distilled
water (SDW). To make a 1000 µg/ml stock solution of the eﬄux pump inhibitor re-
serpine (Sigma Aldrich, Dorset, U.K.), 0.01 g reserpine powder was dissolved in 8 ml
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DMSO by vigorous vortexing (10 min), and then made up to a final volume of 10 ml
by addition of SDW. Plates were prepared by adding appropriate volumes of 10000,
1000 and 100 µg/ml stock solutions of antibiotics, dyes or eﬄux pump inhibitors to 30
ml universal tubes to give a doubling dilution series in a final volume of 20 ml of agar.
Twenty ml Iso-Sensitest agar (ISA) was added to each tube using an automatic dispenser
(Jencons, U.K.), poured into a Petri dish and allowed to set. Solidified agar plates were
then dried for 30 minutes in a 60◦C oven. A 1 µl spot of each bacterial strain, grown
to an OD660 of 0.4 in BHI broth, was inoculated onto the surface of each plate using
a multipoint inoculator (Denley Tech Ltd., Sussex, U.K.). Inoculations were allowed to
dry, then the plates were incubated overnight. The MIC of each agent for a particular
strain was defined as the lowest concentration of antibiotic (µg/ml) at which no growth
was observed; a faint haze of growth was ignored.
2.3.2.2 Measurement of intracellular accumulation of ethidium bromide
Ethidium bromide fluoresces when intercalated into DNA, meaning that its intracellular
accumulation can be monitored by measuring the increase in fluorescence of a culture
over time when exogenous ethidium bromide is added. Mid-logarithmic phase cultures
(OD660 of 0.4) were pelleted by centrifugation at 2200 x g and resuspended in an equiva-
lent volume of sterile PBS. Cell suspensions were adjusted to an OD660 of 0.1 by addition
of more sterile PBS, then added in triplicate to a black microtitre tray as follows. For
fluorescence readings without addition of ethidium bromide, 200 µl of cell suspension
was added. For measurements with addition of ethidium bromide, 180 µl cell suspension
was used. Sterile PBS was used to provide blank readings throughout. Fluorescence
was measured every two minutes for a total of 30 minutes using a FLUOstar Optima
plate reader (BMG Labtech, Aylesbury, UK; excitation wavelength: 530 nm, emission
wavelengths: 600 nm). Twenty µl of a 250 µM stock of ethidium bromide was injected
into each of the wells containing 180 µl of culture on the second cycle of measurement.
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To analyse the data, average blank readings with and without ethidium bromide were
calculated and subtracted as appropriate from the fluorescence readings for each well, and
average blank corrected fluorescence with and without ethidium bromide was calculated
from the three technical replicates for each tested strain. To examine ethidium bromide
accumulation over time, the average and standard deviation of fluorescence from three
biological replicates was calculated for each time point. To identify significant differences
in steady-state levels of ethidium bromide accumulation between strains, a time-point
was chosen such that fluorescence of all strains had reached a steady-state (10 minutes
after addition of ethidium bromide unless stated otherwise), and strains were tested for
a significant difference (p<0.05) from the wild-type strain using a two-tailed Student’s
t-test on three biological replicates. If more than five comparisons were performed
simultaneously, a Bonferroni correction for multiple testing was applied.
2.3.2.3 Measurement of growth kinetics
For measurement of growth rates of strains under standard pneumococcal culture condi-
tions (static incubation at 37◦C, 7.5% CO2), frozen starter cultures of the strains to be
tested were thawed and diluted 1:100 in 50-100 ml BHI broth. Cultures were incubated
statically at 37◦C in 7.5% CO2, and the OD660 of a 1 ml sample was measured every
hour using a spectrophotometer. To calculate generation times, two time points were
chosen during the exponential phase of growth (named t0 and t1), and generation times
were calculated using the formula: Gt = (t1 − t0)× ln(2)/ln(OD1/OD0), where OD0
and OD1 are the measured OD660 values at t0 and t1 respectively.
Growth of some strains and isolates was measured in a high-throughput manner in a
microtitre tray using the Fluostar Optima plate reader (BMG Labtech). Growing cultures
were diluted to an OD660 of 0.1 in fresh sterile BHI broth, then diluted 1:10 in more
sterile BHI. For each culture to be tested, three 200 µl aliquots of the diluted culture
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were added to wells of a clear microtitre tray. The microtitre tray was sealed with a clear,
breathable membrane (Sigma Aldrich, cat. no. Z380059), and incubated overnight in
the Fluostar Optima at 37◦C. Absorbance at 600 nm was measured every ten minutes,
with five seconds of shaking before each reading to redistribute cells.
2.4 Measuring gene expression by quantitative real-
time PCR
2.4.1 Extraction of total RNA
Three biological replicates of each strain to be tested were grown to an OD660 of 0.4
in BHI broth. Total RNA was extracted using a Promega SV Total RNA Isolation kit
according to the manufacturer’s instructions provided for RNA extraction from Gram
positive bacteria, as follows. All procedures were carried out on ice, unless otherwise
stated. One ml of each culture was transferred to an RNase-free microcentrifuge tube
and the cells pelleted by centrifugation (14,000 x g, 2 minutes). The supernatant was
discarded and the cells were resuspended in 100 µl freshly prepared TE buffer containing 3
mg/ml lysozyme. Resuspended cells were incubated for 10 minutes at room temperature,
then 75 µl of RNA lysis buffer was added, followed by 350 µl RNA Dilution buffer, and
the suspension was mixed by inversion. Two hundred µl of 95% ethanol was added
to the lysate, which was then mixed by pipetting three to four times and transferred
to a spin column held in a collection tube. Nucleic acids were bound to the columns
by centrifugation (14,000 x g, 60 seconds). The flow-through was discarded and the
columns were washed with 600 µl RNA Wash Solution (centifugation for 60 seconds,
14,000 x g). The flow-through was discarded and 50 µl of DNase incubation mix (40
µl Yellow Core Buffer, 5 µl 90 mM MnCl2, 5 µl DNase I) was added to each column.
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The columns were incubated for 15 minutes at room temperature. To stop the reaction,
200 µl DNase Stop Solution was added to each column. This solution was removed by
centrifugation (14,000 x g, 60 seconds) and the columns were washed with 600 µl RNA
Wash Solution as above. The flow-through was discarded and the column was washed
with 250 µl RNA Wash Solution by centrifugation (14,000 x g, 2 min). The spin column
was transferred to a fresh RNase-free microcentrifuge tube containing 1 µl RNaseOUT
(Invitrogen). RNA was eluted in 100 µl nuclease-free water (Promega) by centrifugation
(14,000 x g, 60 seconds). Prepared RNA was divided into aliquots and stored at -80◦C
until required.
Concentrations of RNA and contaminating DNA were measured using a Qubit fluorom-
eter. Samples were prepared using the Qubit RNA Assay kit for RNA quantification,
and the Qubit dsDNA HS Assay kit for DNA quantification, according to the manu-
facturer’s instructions. Residual DNA contamination was removed by DNase using the
TURBO DNA-freeTMkit (Ambion, cat. no. AM1907) according to the manufacturer’s
instructions.
2.4.2 cDNA synthesis
Prepared RNA was reverse-transcribed into cDNA using SuperScript R© III First-Strand
Synthesis System for RT-PCR (Invitrogen, cat. no. 18080-051) using random priming.
RNA preparations were adjusted to the same concentration using nuclease-free water.
For each RNA preparation to be reverse-transcribed, a reaction mixture was prepared
containing up to 5 µg RNA, 1 µl random hexamers (10 mM) and 1 µl dNTP mix (10
mM) in a final volume of ten µl. The mixtures were incubated at 65◦ for five minutes,
then on ice for five minutes. A cDNA Synthesis Mix was prepared that contained 2 µl
10X RT buffer, 4 µl MgCl2 (25 mM), 2 µl DTT (0.1M), 1 µl RNaseOUTTM (40 U/µl)
and 1 µl SuperScript R© III reverse transcriptase (200 U/µl) for each reaction to be carried
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out. Components were added to the cDNA Synthesis Mix in the indicated order. Ten
µl of the cDNA Synthesis Mix was added to each RNA and primer mixture and mixed
by brief centrifugation. The reaction mixtures were incubated for 10 minutes at 25◦C,
then for 50 minutes at 50◦, and finally the reaction was terminated by incubating for
five minutes at 85◦C. The reactions were cooled on ice, and then stored at -20◦C until
required.
2.4.3 Primer design
Primers for qRT-PCR were designed using Primer3 software (Rozen and Skaletsky, 2000)
with the following settings: product size between 60 and 120 nucleotides, GC content
between 50 and 60%, optimum primer length of 20 bp, optimum primer melting temper-
ature of 60◦C, maximum 3’ end self-complementarity score of one, and maximum allowed
mononucleotide repeat length of 3. These settings were derived from the built-in qPCR
settings of Primer3Plus, the web-based implementation of Primer3 (Untergasser et al.,
2007). For each gene to be tested, ten possible primer pairs were designed and, from
these, a set of primer pairs were selected such that the predicted annealing tempera-
tures of primers for all the tested genes were within 0.5◦C of the annealing temperature
of the primers for the reference gene (Table 2.2). Primer specificity was checked by
comparing each primer sequence against the R6 genome using BLAST. Selected primers
were synthesised by Invitrogen, and checked for specificity and function by carrying out
a standard PCR reaction using R6 genomic DNA as a template.
2.4.4 Quantitative real-time PCR
All quantitative real-time PCR reactions contained 12.5 µl IQTM SYBR R© Green 2X su-
permix (Biorad), 1 µl each of forward and reverse primers (12.5 µM), 1 µl of appropriately
diluted cDNA, and 9.5 µl nuclease-free water. To reduce pipetting errors, for each primer
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combination used, IQTM SYBR R© Green 2X supermix, primers and water were combined
in the proportions given above to make a master mix of sufficient volume for the number
of cDNA samples to be tested. For each reaction, 24 µl of the master mix was trans-
ferred to a well of a white 96-well PCR plate (BioRad) and 1 µl of cDNA was added.
On each PCR plate tested, three replicates of a reaction where the cDNA was replaced
with nuclease-free water was included as a no-template control.
Real-time PCR reactions and fluorescence measurements were carried out using a CFX96
Real-Time PCR Detection System (BioRad), using the following conditions: 95◦C for
three minutes, followed by 40 cycles of 95◦C for 10 seconds, 54.5◦C for 30 seconds.
Fluorescence of each well was measured at the end of each amplification cycle. A melt
curve analysis was carried out after completion of the amplification cycles to check for
the presence of non-specific amplification products. To do this, samples were heated
from 55◦C to 95◦C in 0.5◦C increments every five seconds, with a fluorescence measured
following each temperature increase.
To measure the amplification efficiency of the primers and to determine the cDNA
concentration to use in subsequent reactions, three biological replicates of cDNA from
R6 were serially diluted 1:10 in nuclease-free water to give dilutions ranging from 1:1 to
1:106. For each primer combination to be tested, two technical replicate reactions for
each dilution of each biological replicate were prepared as described above. Real-time
PCR was carried out as described above and the average Cq values for each cDNA dilution
for each primer combination were plotted against the log10 of the starting quantity of
cDNA using CFX Manager software (BioRad). Primer efficiency (E) was calculated as
described by Pfaﬄ (2001) as the E = 10−1/slope, where slope is the slope of the best fit
line through the Cq values. The cDNA dilution to be used in subsequent experiments for
each primer combination was chosen such that the Cq value obtained using R6 cDNA
was close to 30 cycles. This value was chosen to ensure that Cq values from strains with
markedly higher or lower levels of gene expression than R6 would be detectable within
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the 40 cycles of the experiment.
To measure gene expression, two technical replicate real-time PCR reactions were pre-
pared as described above for each primer combination, biological replicate and strain
to be tested. The cDNA dilution used was the optimal dilution determined during the
primer efficiency measurement described above. Real-time PCR was carried out as de-
scribed above. Relative expression of genes of interest in each strain relative to the
control strain (R6, unless stated otherwise) was calculated from the Cq values according
to the Pfaﬄ method (Pfaﬄ, 2001), as follows. First, the mean Cq value of the two
technical replicates was calculated. Then, for each primer combination used, the dif-
ference in Cq value between the control and the sample strain (∆Cq) was calculated.
The relative expression ratio for each target gene was the calculated using the formula
ratio = (Etarget)
∆Cqtarget/(Eref )
∆Cqref , where Etarget and Eref are the primer efficien-
cies and ∆Cqtarget and ∆Cqref are the ∆Cq values for the target gene and the reference
gene, respectively.
For visualisation of endpoint concentration of PCR amplimers by gel electrophoresis,
PCR was carried out using the same cDNA and primer combinations as described above,
but substituting Reddymix (Abgene, U.K.) for the IQTM SYBR R© Green 2X supermix.
Each PCR reaction consisted of 22.5 µl Reddymix, 0.5 µl each of forward and reverse
primers (25 µM) 0.5 µl of cDNA and 1 µl of nuclease-free water. Forty cycles of PCR
were carried out in a standard thermal cycling PCR machine using the same conditions
as above, but without fluorescence measurements. Five µl of each reaction was loaded
into the wells of a 1% agarose gel, and PCR amplimers were separated by electrophoresis
at 100 V for one hour. PCR amplimers were visualised using the Gene Genius image
analyser.
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2.5 Whole-genome sequencing and data analysis
2.5.1 Illumina sequencing and quality control
Extraction of genomic DNA for whole genome sequencing was carried out as described
above. Whole genome sequencing was performed by GenePool (Edinburgh, U.K.) on two
occasions. Genepool carried out Illumina sequencing library preparation using standard
Illumina procedures. On the first occasion (2009), 50 cycles of paired-end sequencing
were carried out on Illumina Solexa Genome Analyser IIx sequencing system, for two S.
pneumoniae strains multiplexed in a single lane with eight other samples. On the second
occasion (2012), 100 bp paired-end reads were generated using an Illumina HiSeq system
for nine pneumococcal genomes multiplexed in a single lane. De-multiplexing of samples,
conversion from Illumina image files to Fastq format, and preliminary quality control was
carried out by Genepool.
The Fastq files obtained from Genepool containing the read sequences were checked for
overall quality using FastQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/;
Babraham Institute, Cambridge, UK), a tool that performs various quality control checks
on raw high-throughput sequencing data.
2.5.2 Mapping reads against reference genome
Illumina sequencing reads were aligned against the R6 reference genome (Genbank ac-
cession: NC_003098) and single nucleotide polymorphisms and small indels detected by
two methods.
Initial analysis of sequencing carried out in 2009 was carried out using the My xBase
next generation sequencing pipeline (ng.xbase.ac.uk/my, Centre for Systems Biology,
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University of Birmingham, U.K.). This pipeline uses the Maq alignment program to align
reads against the reference sequence and to identify single nucleotide polymorphisms
(SNPs) and small insertions and deletions (indels) (Li et al., 2008). The pipeline was
run in paired-end mode, using an estimated paired-end insert length of 250 bp. The
output from this process is a table of mutations, which was then filtered by quality score
(> 100) and depth of reads covering a putative mutation (> 50).
For later analyses, including reanalysis of the sequencing data from 2009 and analysis of
new sequencing data generated in 2012, alignments and mutation detection were carried
out locally as follows. If required, the base quality scores in the Fastq files were converted
from phred64 (Illumina 1.5) encoding to phred33 (Sanger) encoding using a Python
script written by Nick Loman. Alignment of reads was carried out using Bowtie2 version
2.0.0-beta5 (Langmead and Salzberg, 2012) using the –very-sensitive-local pre-set
parameter set (equates to settings -D 20 -R 3 -N 0 -L 20 -i S,1,0.50 –local).
The reads were aligned against an indexed version of the R6 (NC_003098) genome, gen-
erated using Bowtie2-build. Sam format alignments generated by Bowtie2 was piped to
Samtools version 0.1.18 (Li and Durbin, 2009) and sorted using the Samtools sort com-
mand (command used: bowtie2 -t –very-sensitive-local -x <R6 reference>
-1 <reads1.fastq> -2 <reads2.fastq> | samtools view -bS - | samtools
sort - <out.bam>). Resulting Bam format alignments were then indexed using samtools
index <file>. To detect mutations relative to the reference genome, a consensus
pileup was generated from each sorted and indexed Bam file using Samtools mpileup
against the published R6 genome indexed with Samtools faidx. The output of this com-
mand was piped to BCFtools version 0.1.17-dev to detect all putative SNPs and small
indels (commmand used: samtools mpileup -uf <faidx referenced R6 genome>
<bam file> | bcftools view -bvcg - > <output file>). The resulting set of
variations was filtered based on desired quality score and/or read depth covering a vari-
ation using a custom Python script.
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Read alignments and positions of detected variations were visualised by loading indexed
Bam and Bcf files respectively into Artemis version 14.0.0 (Carver et al., 2012).
To calculate the normalised depths of reads mapping to each gene in the genome, reads
per kilobase per million reads mapped (RPKM) was obtained for each gene using Artemis.
For each read alignment to be tested, the respective Bam file was loaded into Artemis
against the R6 genome. All CDS features in the genome were selected, and RPKM
values calculated using the "Analyse RPKM value of selected features" option in the
Bamview window. RPKM values calculated from strains M184, M500, M501 and M503
were plotted against those from R6 using R.
For strains generated by transformation of R6 recipient cells with genomic DNA from
a different genetic background, clusters of SNPs representing putative recombination
events were defined using the following procedure. The number of SNPs in a 5 kb, centre-
aligned sliding window was calculated for every position in the R6 reference genome using
the rollsum function in the R package ’zoo’ (?). Clusters were then defined as regions
where this rolling sum of SNPs was consistently greater than two.
2.5.3 Local and global de novo assembly
The Velvet sequence assembler (version 1.2.03; Zerbino and Birney, 2008) was used to
generate draft de novo assemblies of both whole genomes, or parts thereof.
To prepare sequencing reads for whole genome assembly, the paired end reads were
combined into a single file where the first and second reads were interleaved using
the shuﬄeSequences_fastq Perl script included with the Velvet distribution. Reads
containing undefined bases (’N’) and reads with low average quality (<20) were removed
using the eliminate_n_paired.py and filter_reads.py Python scripts written by Nick
Loman (github.com/nickloman/xbase). Where necessary, reads were trimmed to 75 bp
using the trim_reads.py script written by Nick Loman (github.com/nickloman/xbase).
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The prepared reads were then assembled with Velvet, using the VelvetOptimiser script
written by Simon Gladman (included with the Velvet distribution) to determine optimal
parameter settings. This script automates the assembly process as follows. First, velveth
is used to generate hash tables from the prepared fastq file for all kmer values in a given
range. Then draft assemblies are generated using velvetg for each velveth output using
default settings. The assembly with the largest length-weighted median contig length
(N50) is chosen and several iterations of velvetg with differing values for the expected-
coverage and coverage-cutoff parameters are carried out to improve the assembly.
To generate local assemblies, reads meeting the desired criteria were extracted from the
read alignment using Samtools and assembled as above.
To generate an assembly from M184 reads that did not align to the R6 reference genome,
unaligned reads were extracted from the M184 read alignment using Samtools, and
assembled as above.
2.6 Further characterisation of mutations identi-
fied by genome sequencing
2.6.1 Primer design and PCR
Sequences of primers used in this study are shown in tables 2.3 and 2.4. Unless specified
otherwise, primers were designed using Primer3Plus, the web interface to the Primer3
program (Untergasser et al., 2007), and synthesised by Invitrogen. Lyophilised primers
were reconstituted in sterile nuclease-free water (Gibco) to a concentration of 100 µM
and stored at -20◦C. For use in PCR reactions, 25 µM working stocks were prepared and
also stored at -20◦C.
Unless otherwise specified, PCR reaction mixtures consisted of 22.5 µl of 1.1x ReddyMix
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PCR Master Mix (Thermo Scientific), 0.5 µl genomic DNA, 0.5 µl of each of the forward
and reverse primers, and 1 µl of SDW to give a total reaction volume of 25 µl. In
contamination controls, the genomic DNA was replaced with 1 µl SDW. PCR reactions
were carried out in a thermal cycler. The standard reaction conditions consisted of the
following stages: an initial denaturation (5 minutes at 95◦C), 30 cycles of thermal cycling
(95◦C for 30 seconds, 51◦C for 30 seconds, 72◦C for two minutes), then a final extension
(72◦C for 10 minutes). Resulting PCR products were separated by electrophoresis on a
1% agarose gel, and visualised using the Genius image analyser (Syngene, Cambridge,
U.K.).
2.6.2 PCR purification and sequencing
PCR purification was performed using a QIAquick R© PCR purification kit (Qiagen) fol-
lowing the manufacturer’s instructions. Purified PCR products were separated by elec-
trophoresis on a 1% agarose gel, and visualised using the Genius image analyser (Syn-
gene, Cambridge, U.K.). Sequencing of purified PCR amplimers was carried out using
the appropriate PCR primers by the Functional Genomics department of the University
of Birmingham, unless otherwise specified.
2.6.3 Protein structure prediction using SWISS-MODEL
The structure of the HrcA protein was predicted using the SWISS-MODEL automated
protein structure homology-modelling server (Arnold et al., 2006). Templates for mod-
elling were found using a PSI-BLAST search of the spr0453 gene against the PDB
database. A sequence-structure alignment between the target protein and template pro-
tein was produced using the FUGUE sequence-structure homology recognition program
(Shi et al., 2001) and the model was produced by the SWISS-MODEL server using the
alignment mode.
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2.6.4 Prediction of promoters and terminators
Putative promoter sequences were predicted using the prokarotic promoter prediction
(PPP) webserver (http://bioinformatics.biol.rug.nl/websoftware/ppp). This program
scans DNA sequences for Lactococcal-like Sigma A binding sites, using Hidden Markov
models constructed from alignments of known Sigma A binding sites (Zomer et al.,
2007).
For analysis of the position of predicted Rho-independent terminators in the R6 genome
sequence, a set of pre-computed Rho-independent terminator predictions were used that
had been predicted by TransTermHP (Kingsford et al., 2007). These were downloaded
from http://transterm.cbcb.umd.edu/index.php on 31/12/2012.
2.6.5 PCR and sequencing of short interspersed repeats
Genomic positions of short interspersed repeats in the R6 genome were obtained from
predictions made by Croucher et al (Croucher et al., 2011b, supplementary data), and
visualised in Artemis. Repeats to be checked for mutations were chosen by visual in-
spection of the M184 read alignment against R6, according to the following criteria:
a) repeats were located between divergently transcribed genes or genes transcribed in
the same direction, and b) the depth of reads aligned to a repeat sequence was at least
twice that of the flanking sequence. Primers were designed to amplify each repeat region
using Primer3 as described above (Appendix 2). PCR was carried out as described above
using an annealing temperature of 51◦C and an extension time of two minutes. PCR
amplimers were visualised by agarose gel electrophoresis and purified as described above.
Sanger sequencing of amplimers was carried out by Source Biosciences (Nottingham,
UK).
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2.7 Measuring segregation rate of patA-spr1880
duplication
To prepare starter cultures of M184 and the R6M184 transformants where 100% of the
cells should contain the duplication, cultures were grown overnight on agar plates con-
taining 8 µg/ml ethidium bromide. Cells were then scraped off the plates using sterile
swabs, resuspended directly in 1 ml BHI broth containing 10% glycerol and frozen for
future use.
To measure loss of the patA-spr1880 duplication over time, ethidium bromide-selected
stocks of each culture were diluted into ten ml fresh BHI broth and grown for 12-14
hours. Growth was monitored by measurement of OD660 and cultures were diluted
1:1000 in fresh BHI broth when they approached an OD660 of 0.6, which corresponds
to late logarithmic phase. At the start and end of the growth period 20 µl samples
were taken and serially diluted in 180 µl PBS to a final dilution of 1:108. Fifty µl
samples of each dilution were spotted onto plain agar plates and incubated overnight to
obtain single colonies. Approximately 60 colonies per strain were picked using a sterile
inoculation loop and streaked in duplicate onto one plate containing 8µg/ml norfloxacin
and one plain agar plate. Following overnight incubation, the percentage of colonies in
the sample that retained norfloxacin resistance (Pret) was calculated by comparing the
number of colonies that grew on the selective plates compared to the control plates.
For each value of Pret, a 95% confidence interval was determined. As Pret is a ratio of
probabilities, and is therefore not normally distributed, the confidence interval (CI) was
calculated for log(Pret) using the formula CI = ±zα/2
√
V ar(log(Pret). V ar(log(Pret)
was estimated using the delta method, which is defined as V ar(log(pˆ1/pˆ2)) = (1 −
pˆ1)/pˆ1n1 + (1 − pˆ2)/pˆ2n2. The final confidence interval for Pret was then derived by
taking the exponential of the upper and lower bounds of the CI for V ar(log(Pret)).
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Average probabilities of loss of the patA-spr1880 duplication per cell per generation,
and their associated confidence intervals, were calculated essentially as described by
Brochet et al. (2008). If each cell in a population has a probability p of losing the
duplication in each generation, then Pret after n generations will be given by the formula
Pret = (1 − p)n. The half-life of the duplication within the population was calculated
by finding the number of generations (n) required for Pret to reduce to 0.5, which was
then converted to a time in days by multiplying by the generation time of the strain.
2.8 Inactivation of patA in M184
Inactivation of patA in M184 was carried out by transforming M184 recipient cells with a
PCR amplimer corresponding to patA containing a magellan2 mini-transposon inserted
between bases 833 and 834. This was derived from the previously described strain M246
(R6 patA::magellan2 Garvey and Piddock, 2008). To avoid including patA upstream
sequence, an internal region of patA, which included the transposon insertion, was am-
plified from M246 by PCR using primers 608 and 1357 (Table 2.4).
M184 recipient cells were grown to an OD660 of 0.4 in BHI broth, then diluted 1:20
in competence medium (section 2.3.1) containing 100 ng/ml CSP. Purified M246 patA
amplimer was serially diluted 1:10 six times in nuclease-free water. Twenty microlitres of
each dilution was added to 500 µl M184 competent cells in a microcentrifuge tube, and
these transformation reactions were incubated for three hours at 37◦C. A transforma-
tion where nuclease-free water was added instead of DNA was prepared and incubated
in parallel. Following incubation, 100 µl of each transformation reaction was spread
onto Columbia blood agar plates containing 100 µg/ml spectinomycin, and incubated
overnight. Colonies for further investigation were selected from the plates correspond-
ing to the lowest concentrations of donor DNA that resulted in spectinomycin resistant
colonies.
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2.9 Measuring fluorescence from wild-type and mu-
tated patA promoters by transcriptional fusion
with promoterless gfp.
2.9.1 Construction of plasmid pBAV1K-gfp82
Plasmid pBAV1K-T5-gfp (Bryksin and Matsumura, 2010) was kindly provided by Andrea
Mitchell (University of Birmingham). This plasmid contains a gfp gene controlled by
a T5 promoter. This results in continuous expression of GFP, allowing this plasmid to
be used as a fluorescent marker to study cellular localisation (Bryksin and Matsumura,
2010). To generate a plasmid that can be used to monitor activity of cloned promoters,
this constitutive promoter needed to be removed. It was also desirable for the plasmid
to encode an unstable variant of GFP, such that accumulation of GFP does not obscure
subtle variations in expression from the promoter.
To fulfil these requirements, the T5 promoter and gfp gene from pBAV1K-T5-gfp were
replaced by a gfp gene from plasmid pMW82, which has previously been used to measure
inducible activity of promoters in Salmonella (Lawler et al., 2013). The pBAV1K-T5-
gfp plasmid was propagated by transformation into One Shot R© E. coli TOP10 cells
(Life Technologies, cat. no. C4040) by heat shock according to the manufacturer’s
instructions. The pMW82 and pBAV1K-T5-gfp plasmids were digested with restriction
enzymes EcoRI and PstI (New England Biolabs) as follows. 30 µl of each purified plasmid
was added to 5 µl of the supplied restriction enzyme buffer, 1 µl BSA (10 mg/ml), 4 µl
nuclease-free water, 5 µl EcoRI and 5 µl PstI. This reaction was incubated at 37◦C for
one hour, then terminated by heating to 80◦C for 10 minutes. Digested fragments were
separated by electrophoresis on a 1% agarose gel, and bands corresponding to the 2800
bp plasmid backbone of pBAV1K-T5-gfp and the 824 bp gfp gene from pMW82 were
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cut out of the gel and extracted using a QIAgen R© gel extraction kit, according to the
manufacturer’s instructions. The plasmid backbone and the gfp gene were ligated using
QuickStick R© ligase (Bioline, cat. no. 27027), as follows. The purified fragments were
combined in a 1:10 vector:insert ratio, and mixed with 5 µl 4x QuickStick ligase and
1 µl QuickStick ligase in a total reaction volume of 20 µl. The reaction was mixed by
pipetting, and incubated at room temperature for 5 minutes. E. coli TOP10 cells were
transformed with 2 µl of this ligation reaction, and cells containing the ligated plasmid
were selected on LB agar containing 50 µg/ml kanamycin. Plasmids were extracted from
transformants using the QIAprep R© Miniprep kit, and screened for correct insertion of the
pMW82 gfp gene by PCR using primers 982 and 1797, and sequencing of the resulting
PCR amplimer.
2.9.2 Construction and cloning of promoter fragments
Wild-type and mutated DNA fragments corresponding to the region 12 to 144 bp up-
stream of patA were cloned into an EcoRI -XbaI cloning site upstream of the gfp gene in
pBAV1K-gfp82 as follows. Wild-type and mutated patA upstream regions, with added
5’ EcoRI and 3’ XbaI sites, were synthesised by GeneArt (Life Technologies). These
fragments were supplied by GeneArt as inserts in pMA-T plasmids. The patA promoter
fragments were amplified from pMA-T plasmids using primers 1850 and 1851. The re-
sulting PCR amplimers were purified, and digested using EcoRI and XbaI as described
above. XbaI digestion is blocked by DNA methylation by the Dam methylase, so to
remove this methylation from the pBAV1K-gfp82 vector, purified plasmid DNA was
transformed into E. coli JJA cells (kindly provided by Yanina Sevastyanovich, University
of Birmingham), which are dam-. Plasmid pBAV1K-gfp82 was extracted from JJA cells
following overnight growth, and digested with EcoRI and XbaI. Digested plasmid and
insert were combined in a 1:100 molar ratio, and ligated using QuickStick ligase as de-
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scribed above. Two microlitres of ligation mixture was used to transform E. coli TOP10
cells, and transformants containing ligated plasmid were selected on LB agar containing
50 µg/ml kanamycin. Colonies were screened for plasmid containing the correct insert
by PCR using primers 982 and 1797.
To add the duplicated tRNAGlu gene from M184 upstream of the patA promoter in
plasmid pBAV1K-gfp82 -ppatA, to give plasmid pBAV1K-gfp82 -tRNA-ppatA, the tRNA
gene from M184 was amplified by PCR using the 3’ primer 1892, and the 5’ primer 1893
which incorporates an EcoRI site. A naturally occurring SpeI site exists upstream of
the patA promoter sequence. The tRNA PCR amplimer and pBAV1K-gfp82 -ppatA were
therefore digested with EcoRI and SpeI (New England Biolabs) as described above.
Digested plasmid and insert fragments were purified with a QIAquick PCR purification
kit, mixed in a 100:1 insert:vector molar ratio, and ligated using QuickStick ligase as
described above. E. coli TOP10 cells were transformed with 2 µl of ligation reaction,
and transformants were selected on LB agar containing 50 µg/ml kanamycin. Colonies
were screened for plasmid containing the inserted tRNA by PCR using primers 982 and
1797.
The pBAV1K-gfp82 constructs were extracted from E. coli cells using a QIAprep R©
Miniprep kit, and transformed into S. pneumoniae R6 as follows. R6 recipient cells
were grown to an OD660 of 0.4 in BHI broth, then diluted 1:20 in competence medium
(section 2.3.1) supplemented with 100 ng/ml CSP. Twenty microlitres of each pBAV1K-
gfp82 contruct was added to 500 µl competent R6 cells, and the transformation mixtures
were incubated for three hours at 37◦C. R6 cells containing the desired plasmid were
selected on Columbia blood agar plates containing 200 µg/ml kanamycin.
80
2.9.3 Fluorescence assays
To take single fluorescence readings from mid-logarithmic phase cultures that had been
grown under normal laboratory conditions, the following method was used. Three bio-
logical replicates of each strain were grown statically to an OD660 of 0.5 in BHI broth
(37◦C, 7.5% CO2). Cells from 1 ml aliquots of each culture were pelleted by centrifu-
gation (14,000 x g, 3 min) and resuspended 200 µl PBS. Each resuspended culture was
added to a well of a black microtitre tray, and fluorescence was measured using a Flu-
ostar Optima using excitation and emission wavelengths of 492 and 520 nm respectively
and a gain of 1452. Significant differences in fluorescence between strains (p<0.5) were
determined using a two-tailed Student’s t-test on at least three biological replicates. A
Bonferroni correction for multiple testing was applied if more than five comparisons were
performed simultaneously.
To study GFP expression over the whole growth cycle, fluorescence and growth measure-
ments were taken simultaneously from cultures growing in BHI broth. Three biological
replicates of each culture to be tested were grown to stationary phase (OD660 of 0.6-0.8)
in BHI broth supplemented with 100µg/ml kanamycin. Cultures were then diluted 1:1000
in fresh BHI broth containing kanamycin and 200 µl of each culture was added to two
wells of a black microtitre tray with a clear base. The plate was incubated in the Flu-
ostar Optima at 37◦C for twelve hours, and the script mode of the Optima software was
used to take fluorescence and absorbance readings simultaneously every three minutes.
Fluorescence was measured using the top optic with excitation and emission wavelengths
of 492 and 520 nm respectively, and a gain of 1452. Absorbance was measured at 600
nm using the bottom optic. The plate was shaken for 5 seconds prior to each reading
to evenly distribute the cells.
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3 Over-expression of patA and patB is observed
in clinical isolates
3.1 Background
Prior to this study it was well established that a subset of pneumococcal clinical iso-
lates with fluoroquinolone resistance showed a phenotype indicative of increased eﬄux
(Baranova and Neyfakh, 1997; Brenwald et al., 1997, 1998; Piddock et al., 1997, 2002).
However, it had been shown that production of PmrA, the first fluoroquinolone eﬄux
pump to be discovered in S. pneumoniae, was not strongly associated with eﬄux medi-
ated fluoroquinolone resistance in clinical isolates (Piddock et al., 2002).
At the start of this study in 2009 it had been shown that, in laboratory mutants of S.
pneumoniae, increased expression of patA and patB resulted in decreased susceptibility
to the fluoroquinolones ciprofloxacin and norfloxacin and the dyes ethidium bromide
and acriflavine (Garvey and Piddock, 2008; Marrer et al., 2006b). This resistance was
reversed by addition of the eﬄux inhibitors reserpine and sodium orthovanadate, and the
overall phenotype was similar to that observed in clinical isolates with increased eﬄux
(Garvey and Piddock, 2008). This observation led to the suggestion that PatAB could
be the predominant transporter conferring eﬄux-mediated fluoroquinolone resistance in
pneumococcal clinical isolates. However, a clear link between increased expression of
patAB and eﬄux-mediated fluoroquinolone resistance in clinical isolates had not been
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definitively shown.
Also, the effect of patAB over-expression had not been investigated in S. pneumo-
niae isolates carrying mutations in the topisomerase genes. Topoisomerase mutations
cause high-level resistance to fluoroquinolones, particularly when both parC and gyrA
are mutated (Janoir et al., 1996). In contrast, the increase in resistance caused by
over-expression of patAB is much smaller (Garvey and Piddock, 2008; Marrer et al.,
2006b). Therefore, it was unclear whether PatAB-mediated fluoroquinolone eﬄux would
be important in a clinical setting. Eﬄux pumps in several other organisms have been
implicated in intrinsic resistance to antibiotics, such that their inactivation reduced re-
sistance even in the presence of other resistance mechanisms (Baucheron et al., 2002;
Luo et al., 2003; Markham and Neyfakh, 1996). However, it is also possible that posses-
sion of topoisomerase mutations could supercede any effect of patAB over-expression,
rendering it irrelevant in the clinical environment.
To answer these questions, an analysis was carried out on unpublished data that had been
previously collected by Mark Garvey and Ryan Wong for a set of 57 clinical isolates of S.
pneumoniae. Of these, 46 had been included in a previous study that analysed the con-
tribution of pmrA expression to fluoroquinolone resistance, during which fluoroquinolone
MICs and sequences of the topoisomerase genes had been determined (Piddock et al.,
2002).
The dataset consisted of:
• MICs of ciprofloxacin, norfloxacin, ethidium bromide and acriflavine for all 57
isolates in the presence or absence of 20 µg/ml reserpine or 50 µM sodium ortho-
vanadate.
• Expression levels of patA and patB for all isolates. These were determined by
comparative reverse transcription-PCR, followed by quantification of amplimers by
denaturing high-pressure liquid chromatography (Garvey and Piddock, 2008).
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• Levels of intracellular accumulation of the fluorescent dye Hoechst 33342 for 28
representative isolates, determined by measurement of fluorescence as described
previously (Garvey and Piddock, 2008).
• Sequences of the QRDRs of parC, parE, gyrA and gyrB for 55 isolates (Piddock
et al., 2002)
• MICs of ciprofloxacin, ethidium bromide and acriflavine, in the presence or absence
of reserpine or sodium orthovanadate, for 21 isolates following inactivation of patA
and patB by in vitro Mariner mutagenesis
The sequences of patA and patB had been determined for 21 of the clinical isolates,
of which 13 over-expressed patAB and eight did not. Comparison of these sequences
had not revealed any mutations in either the transporters themselves or the promoter
regions that were associated with the isolates over-expressing patA and patB (Garvey
and Wong, unpublished data).
3.2 Aims and Hypotheses
Based on the phenotypes of laboratory mutants over-expressing patA and patB (Garvey
and Piddock, 2008; Marrer et al., 2006b), it was hypothesised that clinical isolates
with cross-resistance to both fluoroquinolones and dyes would show significantly higher
expression of patA and patB. It was also predicted that this over-expression would result
in decreased accumulation of the fluorescent dye Hoechst 33342.
Furthermore, it was hypothesised that PatAB contributes to intrinsic resistance of S.
pneumoniae to fluoroquinolone antibiotics, meaning that inactivation of patA or patB
should affect fluoroquinolone resistance in clinical isolates, despite the coexistence of
topoisomerase mutations.
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Therefore, the aim of this section of the study was to analyse the data collected from
the clinical isolates to:
• Determine whether there is a significant association between expression of patA
and patB and resistance to fluoroquinolones and dyes in these isolates
• Determine whether over-expression of patAB in these isolates is associated with
decreased accumulation of Hoechst 33342
• Investigate the effect of chemical or genetic inactivation of the PatAB eﬄux pump
on fluoroquinolone and dye resistance in this set of isolates
3.3 Grouping of isolates based on antibiotic resis-
tance profile
Isolates were sorted into four groups based on their resistance to the fluoroquinolones
ciprofloxacin and norfloxacin and the dyes ethidium bromide and acriflavine. Ciprofloxacin
resistance was defined as a ciprofloxacin MIC of more than 2 µg/ml, and norfloxacin re-
sistance as and MIC of more than 8 µg/ml. Ethidium bromide and acriflavine resistance
were defined as MICs of more than 2 µg/ml. Isolates resistant to at least one fluo-
roquinolone and both dyes were defined as fluoroquinolone and dye resistant (FQDR).
Isolates susceptible to dyes but resistant to one fluoroquinolone were designated as fluo-
roquinolone resistant (FQR), while isolates susceptible to fluoroquinolones but resistant
to both dyes were defined as dye resistant (DR). Susceptible (S) isolates were defined as
those that were susceptible to all four agents. Overall, 15 isolates were FQDR, 24 were
FQR, 2 were DR and the remaining 16 isolates were S.
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3.4 Analysis of patA and patB expression levels for
each group
Expression of patA and patB in each of the clinical isolates was compared to that of
the wild type strain R6 (Figure 3.1). In the group of 15 FQDR isolates, 14 isolates
over-expressed patA and patB compared to R6 (>1.5 times the R6 expression level),
while only 3 of the 24 FQR isolates did so. Both the DR strains also over-expressed
patA and patB, while no over-expression was observed in any of the S isolates.
There was a significant association between resistance to both fluoroquinolones and dyes
and high expression of patAB (p < 0.001, Fisher’s exact test).
3.5 Effect of chemical and genetic inactivation of
patA and patB
To determine the contribution of eﬄux mechanisms to the resistance phenotypes ob-
served, the effect of eﬄux inhibitors on the MICs of ciprofloxacin and ethidium bromide
was analysed for each isolate (Figure 3.2). Addition of reserpine (20 µg/ml) reduced
the MICs of ethidium bromide by more than two dilutions for all 15 FQDR isolates
(100%), both DR isolates (100%), 21 out of 24 FQR isolates (88%) and 16 out of
17 S isolates (94%). Ethidium bromide MICs for the remaining four isolates were re-
duced by one dilution. Identical results were observed for FQDR and DR isolates when
sodium orthovanadate (50µM) was used, and for S isolates the proportion of isolates
with MICs reduced by two or more dilutions was slightly reduced to 88% (15 out of 17).
A greater difference between reserpine and sodium orthovanadate was observed in FQR
isolates, where MICs were reduced by two or more dilutions in 63% of isolates by sodium
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AB
Figure 3.1. Expression of A patA and B patB in clinical isolates grouped by
resistance profile. Boxes represent interquartile range (IQR) of expression values, and
whiskers represent 1.5 IQR. Box widths are scaled by number of isolates in each group
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orthovanadate.
The effect of eﬄux inhibitors on the MICs of ciprofloxacin was more variable (Fig-
ure 3.2B). In the presence of reserpine, ciprofloxacin MICs were reduced by two or more
dilutions for eight FQDR isolates (53%), and MICs were reduced by one dilution for
the remaining seven isolates. In the group of FQR isolates, three isolates (13%) had
MICs reduced by two or more dilutions, 17 had MICs reduced by one dilution (71%)
and MICs of the remaining four isolates were unaffected by reserpine. None of the S
isolates had ciprofloxacin MICs reduced by two or more dilutions by reserpine, but six
out of the 17 isolates (35%) had MICs reduced by one dilution. In the presence of
sodium orthovanadate, ciprofloxacin MICs for FQDR isolates were again reduced by two
or more dilutions for eight isolates, but only four isolates (23%) showed a reduction of
one dilution, compared to 46% when reserpine was used. For FQR isolates, a greater
proportion of the isolates had ciprofloxacin MICs reduced by two or more dilutions by
sodium orthovanadate (38%, compared to 13% with reserpine), but there were also more
isolates unaffected by sodium orthovanadate (33% compared to 16% with reserpine). A
similar result was observed for S isolates, with four isolates (24%) having ciprofloxacin
MICs reduced by two or more dilutions compared to 0% with reserpine. Five of the
S isolates (29%) had ciprofloxacin MICs reduced by one dilution, while eight isolates
(47%) were unaffected. Ciprofloxacin MICs in the two DR isolates were not affected by
addition of either inhibitor.
Eﬄux inhibitors will inhibit any eﬄux pump to which they can bind. Therefore, to more
specifically observe the effect of loss of PatAB, the distribution of MICs of ciprofloxacin
and ethidium bromide was analysed in mutants made from eight FQDR and five FQR
isolates in which either the patA or patB gene had been inactivated by insertion of a
magellan2 minitransposon (Figure 3.3). The two DR isolates and one of the S isolates
were also tested. Inactivation of patA resulted in an increase in susceptibility to ethidium
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Figure 3.2. Number of isolates where MICs of (A) ciprofloxacin and (B) ethidium bromide
were reduced by <1 ( ), 1-2 ( ) or >2 ( ) dilutions by addition of eﬄux inhibitors
reserpine or sodium orthovanadate (NaO).
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bromide of two or more dilutions in all isolates apart from the S isolate, in which the
MIC of ethidium bromide was reduced by one dilution. When patB was inactivated,
MICs of ethidium bromide were reduced by two or more dilutions for seven of the eight
FQDR isolates and four of the five FQR isolates, and both DR isolates. The MIC of
ethidium bromide for the S isolate was unaffected by patB inactivation. The effects of
inactivating patA or patB on ciprofloxacin resistance were identical. MICs of ciprofloxacin
were reduced by 2 or more dilutions in five FQDR isolates and four FQR isolates by
inactivation of either patA or patB. The MICs of ciprofloxacin and ethidium bromide for
the mutant isolates with inactivated patA or patB were not affected by more than one
dilution by addition of reserpine or sodium orthovanadate.
3.6 Hoechst 33342 accumulation and relation to
patA and patB expression level
To determine whether over-expression of patA and patB was linked to increased eﬄux,
the steady-state intracellular accumulation of Hoechst 33342 was measured in a subset of
isolates representing all combinations of MIC phenotype and patAB over-expression, and
compared to that of the R6, M3 and M4 (Figure 3.4). Twenty-seven isolates were chosen
in total, consisting of twelve FQDR, nine FQR, one DR, and five S isolates. Of these,
eleven FQDR isolates, three FQR isolates and the DR isolate showed high expression of
patA (defined as >1.5-fold higher expression of patA than in R6). Following addition
of 2.5 µM Hoechst 33342, fluorescence increased rapidly for all tested isolates due to
intracellular accumulation of the dye, and a steady state was reached in all cultures
within four minutes. The average fluorescence of the control strains R6, M3 and M4
after ten minutes of measurement was was 123 arbitrary units (standard deviation =
3.4). Average steady-state accumulation of Hoechst 33342 in the group of isolates with
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Figure 3.3. Number of isolates where MICs of (A) ciprofloxacin and (B) ethidium bromide
were reduced by <1 ( ), 1-2 ( ) or >2 ( ) dilutions by inactivation of either patA or
patB by insertion of a magellan2 minitransposon.
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high expression of patAB was 78 units (standard deviation = 23), which was significantly
lower than the control strains (p < 0.05, one-tailed Student’s t-test; Figure 3.4). There
was no statistically significant difference between average accumulation in the control
strains and the group of isolates not over-expressing patAB (124 units, standard deviation
= 18; Figure 3.4). Fluorescence of all isolates was increased on addition of 20 µg/ml
reserpine, but the mean fold increase observed for isolates with high expression of patA
was significantly higher than that of isolates with low expression of patA (4.8±0.7 and
3.4±0.3 respectively, p<0.01, one-tailed Student’s t-test; Figure 3.4).
In the groups of isolates over-expressing and not over-expressing patAB there were some
outliers with Hoechst 33342 accumulation levels that did not fit the general pattern
observed for the group. These were identified as isolates with fluorescence values lying
outside a 95% confidence interval calculated for each group. For isolates not over-
expressing patAB, 95% of the observed fluorescence values were between 112 and 136
units, with the exception of isolate M96, which had a fluorescence value of 68 units,
similar to the majority of the patAB over-expressing isolates. Conversely, the 95%
confidence interval for Hoechst accumulation in the isolates with high patA expression
was 66 to 91 fluorescence units, but two patAB over-expressing isolates, M42 and M99,
accumulated significantly more Hoechst than this (134 and 131 units, respectively).
3.7 Mutations in topoisomerase genes
The sequences of the QRDRs of the topoisomerase genes, parC, parE, gyrA and gyrB
had been previously determined for 46 isolates by Piddock et al (2002). This dataset
contained topoisomerase QRDR sequences from a further 11 isolates determined by
Garvey and Wong (unpublished data). The sequences of the QRDRs from the clinical
isolates were compared to those of R6 to identify base substitutions that caused an
amino acid change in the protein sequence of the enzyme.
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Figure 3.4. Fluorescence due to intracellular accumulation of Hoechst 33342 for
isolates grouped by patA expression level. Distribution of fluorescence values for groups
of isolates with high (>1.5 fold higher than R6) or low expression of patA with (red boxes)
or without (black boxes) addition of 20 µg/ml reserpine.
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In the 17 strains tested that were susceptible to all four agents, two were found to carry
mutations in the topoisomerase genes. One isolate (M295) had an Ile460Val change in
ParE, and the other (M77) carried a Lys137Asn mutation in ParC. These mutations were
found in combination with other topoisomerase mutations in FQDR and FQR isolates.
The ParE Ile460Val mutation was found in 12 isolates, and the Lys137Asn mutation
in five. However, as these mutations did not cause fluoroquinolone resistance when
present in isolation, they were assumed to not contribute significantly to fluoroquinolone
resistance and excluded from further analysis. No topoisomerase mutations were found
in the two DR isolates.
Following exclusion of non-functional topoisomerase mutations, the distribution of dif-
ferent genotypes in isolates with fluoroquionolone resistance was analysed. Overall, of
the 15 FQDR and 24 FQR isolates, seven FQDR and 16 FQR isolates carried mutations
in two or more topoisomerase genes (Table 3.1). A further five FQDR isolates and eight
FQR isolates had carried a mutation in a single topoisomerase gene. There was no sig-
nificant difference in the frequency of isolates carrying single topoisomerase mutations,
or two or more topoisomerase mutations between the groups of isolates over-expressing
or not over-expressing patAB (p=0.7, Fisher’s exact test). Three FQDR isolates with
increased patAB contained no functional topoisomerase mutations, while none of the
FQR isolates showed this phenotype. This association was significant at the 10% level
(p < 0.1), but a larger sample size would be needed to determine whether this is robust.
Mutations in ParC are the most common topoisomerase mutations observed in fluoro-
quinolone resistant S. pneumoniae (Muñoz and De La Campa, 1996). In this dataset,
nine FQDR and 17 FQR isolates carried mutant parC alleles (60% and 70% respec-
tively). Twenty-one of these encoded proteins where serine 79 was mutated to tyrosine
or phenylalanine, which is well established as the most commonly observed ParC muta-
tion causing fluoroquinolone resistance. Four other ParC mutations were observed in six
isolates, either singly or in combination with serine 79 mutations.
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Table 3.1. Mutations in topoisomerase genes detected in FQDR and FQR clinical
isolates.
Strain Group parC parE gyrA gyrB
M101 FQDR - - S81F -
M296 FQDR - I460V - -
M297 FQDR S79Y I460V - -
M42 FQDR S79F I460V - -
M44 FQDR - - - -
M45 FQDR - - - V163I, R169K, E181K
M50 FQDR S79F - S81F -
M70 FQDR S79F I460V S81F -
M74 FQDR S79F - S81F -
M86 FQDR K137N - - -
M87 FQDR S79F, K137N I460V S81F -
M89 FQDR S79F - S81F A639Q
M92 FQDR S79F I460V S81F -
M96 FQDR K137N I460V S81F -
M99 FQDR S79F I460V S81F -
M100 FQR D78N, R95C - S81F -
M37 FQR S79F - - V163I, R169K, E181K
M38 FQR N91D - - V163I, R169K, E181K
M40 FQR S79F - - -
M41 FQR S79F - - -
M49 FQR S79F - S81F -
M52 FQR - - S81F -
M67 FQR - - - V163I, R169K, E181K
M69 FQR - - - V163I, R169K, E181K
M75 FQR S79F - - -
M76 FQR - D435N S81F -
M78 FQR S79F - - -
M79 FQR S79F - S81F -
M80 FQR - D435N S81F -
M83 FQR S80P, D83Y - S81F -
M85 FQR - D435N S81F -
M88 FQR S79F - S81F T177I, E181K, I188T
M90 FQR S79F, K137N D435N, I460V S81F -
M91 FQR S79F, N91D, E125D - - T177I, E181K, I188T
M93 FQR - - S81F -
M94 FQR S79F - S81F -
M95 FQR S79F I460V S81F -
M97 FQR N91D, K137N I460V S81F -
M98 FQR D83N I460V S81F -
-, no mutation detected
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GyrA mutations were found in nine FQDR and 15 FQR isolates, and all of these changed
serine 81 to phenylalanine, which is the most commonly observed GyrA mutation as-
sociated with fluoroquinolone resistance (Janoir et al., 1996; Pan et al., 1996). In S.
pneumoniae, gyrA mutations commonly arise secondarily to parC mutations, and in this
dataset 70% of the isolates with a gyrA mutation also possessed a parC mutation (nine
FQDR isolates and eight FQR isolates).
Five different gyrB alleles were observed in eight isolates (two FQDR and six FQR). In
three isolates (one FQDR and two FQR) the change in GyrB was the only topoisomerase
mutation present. A mutation of aspartate 435 to asparagine in ParE was found in three
FQR isolates, but always in combination with a mutation in ParC and GyrA.
The possibility of an association between patAB over-expression and the number and
type of topoisomerase mutations possessed by an isolate was also considered. A posi-
tive correlation might be observed if increased patAB expression promotes selection of
further fluoroquinolone resistance mutations. Alternatively, selection of secondary topoi-
somerase mutations may be relatively less advantageous in an isolate over-expressing
patAB, which could result in a negative correlation between patAB expression and pres-
ence of topoisomerase mutations. To investigate this, isolates with fluoroquinolone
resistance were grouped by patA expression level as before and also by whether they
possessed mutations in both parC and gyrA, parC only, gyrA only, or in neither gene.
There was no significant difference in the distribution of parC and gyrA genotypes be-
tween isolates with high or low patAB expression (p=0.2, Fisher’s Exact test). There
was also no significant association between possession of a mutation in GyrB and high
or low expression of patAB (p=0.4, Fisher’s exact test).
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3.8 Growth kinetics
In previous studies of laboratory selected mutants over-expressing patA and patB, no
differences were observed in growth rate in broth culture between the mutant and parent
strains (Garvey and Piddock, 2008). To confirm that this was also the case in clinical
isolates, where in most cases the over-expression of patA and patB was combined with a
mutation in one or more of the topoisomerase genes, the generation times of a randomly
chosen set of 18 isolates were determined. In this set, nine isolates showed high expression
of patA and patB.
Cultures were grown in triplicate in a microtitre tray on at least two occasions, and
growth was monitored by measurement of optical density at 600 nm at ten minute
intervals. The microtitre tray was incubated in the plate reader, without a CO2-enriched
atmosphere, and was shaken for five seconds before each absorbance reading. Under
these conditions the generation times of the control strains R6 and M4 were 75 and 67
minutes, respectively. Generation times of the clinical isolates varied widely between 27
and 94 minutes (Figure 3.5) and there was no statistically significant difference between
the groups of isolates with high and low patAB expression (p=0.65, two-tailed Student’s
t-test).
3.9 Discussion
This set of clinical isolates could be readily categorised into four groups based on re-
sistance to the fluoroquinolone antibiotics ciprofloxacin and norfloxacin and the toxic
dyes ethidium bromide and acriflavine. Decreased susceptibility to the ethidium bromide
and acriflavine has been shown in previous studies to be indicative of increased eﬄux
activity (Brenwald et al., 2003; Pestova and Millichap, 2002; Piddock et al., 2002).
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Figure 3.5. Generation times of 18 clinical isolates and the laboratory strains R6
and M4, plotted agains patA expression level.. Points are coloured according to isolate
group. Error bars represent standard deviation of three biological replicates.
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It was hypothesised that strains with the fluoroquinolone and dye resistant phenotype
would be significantly associated with over-expression of patA and patB, since the PatAB
transporter has been shown to confer resistance to all four of the tested agents in pre-
vious studies (Garvey and Piddock, 2008; Marrer et al., 2006b). The results support
this hypothesis, with 14 of the 15 FQDR isolates over-expressing patA and patB. In all
cases, when patA and patB were over-expressed they were up-regulated together. This
adds further support to previous reports suggesting that patA and patB are co-regulated
(Garvey and Piddock, 2008).
The majority of the isolates investigated here were tested for pmrA in a previous study
(Piddock et al., 2002). No strong correlation was found between eﬄux activity and
pmrA expression, which led to the conclusion that PmrA is not the predominant eﬄux
pump associated with eﬄux-mediated fluoroquinolone resistance in clinical isolates of S.
pneumoniae. Prior to this study, it had been hypothesised that this role was fulfilled
by PatAB based on the phenotype of laboratory mutants (Garvey and Piddock, 2008;
Marrer et al., 2006b). The strong association between FQDR and patAB expression
presented here provides support for this hypothesis.
However, some isolates showed phenotypes which did not fit the general pattern. Two
isolates which over-expressed patA and patB had decreased susceptibility to dyes, but
not to fluoroquinolones. Conversely, three isolates that were resistant to fluoroquinolones
but not dyes nevertheless showed increased expression of patA and patB. The reasons
for this are not clear, but could be due to differences in the genetic background of the
isolates. One possibility is that an isolate could be naturally more susceptible to the effect
of dyes than is standard for S. pneumoniae strains, such that increased expression of
patAB is not sufficient to raise the MIC to the level above which isolates were designated
dye resistant in this analysis. However, if this were true, it would be expected that FQR
isolates over-expressing patAB would show particularly high susceptibility to dyes in the
presence of an eﬄux inhibitor, which was not the case. An alternative explanation could
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be that strain-specific differences in the PatAB transporter itself affect its efficiency at
exporting different substrates.
Isolates over-expressing patA and patB accumulated significantly lower levels of the flu-
orescent dye Hoechst 33342 than wild-type strains and isolates not over-expressing these
genes. This dye is frequently used as a marker of eﬄux activity (Garvey and Piddock,
2008; Velamakanni et al., 2008; Venter et al., 2008), so this result shows the expected link
between increased expression of patAB and increased eﬄux. Again, however, there were
outliers. Isolate M96, which had a FQDR phenotype but did not over-express patAB,
accumulated low levels of Hoechst 33342. It is possible that Hoechst 33342 eﬄux in
this isolate is mediated by over-expression of a different eﬄux pump. Although PmrA is
not the primary transporter causing eﬄux mediated fluoroquinolone resistance in clinical
isolates, over-expression of this pump has been observed in some isolates previously (Gill
et al., 1999), and has been shown to export ethidium bromide when over-expressed in R6
(Gill et al., 1999; Pestova and Millichap, 2002). It is possible that the relative contribu-
tions of PatAB and PmrA to fluoroquinolone eﬄux differ between genetic backgounds.
Additionally, the MATE transporter DinF has recently been identified as a third pneumo-
coccal transporter capable of fluoroquinolone eﬄux (Tocci et al., 2013). Inactivation of
dinF in an antibiotic susceptible pneumococcal strain conferred hypersusceptibility to the
fluoroquinolones ciprofloxacin, levofloxacin and moxifloxacin (Tocci et al., 2013). PatAB
does not affect moxifloxacin susceptibility (El Garch et al., 2010), which suggests that
PatAB and DinF have overlapping but non-identical substrate profiles. However, data
are not yet available regarding the ability of DinF to transport dyes, or the phenotype
of a mutant over-expressing dinF. Conversely, two of the FQDR isolates tested accumu-
lated levels of Hoechst 33342 similar to wild type, despite over-expressing patAB. This
could potentially be explained by strain-specific differences in the ability of the PatAB
transporter to export Hoechst 33342.
The main difference between the results presented here, and previous studies of patAB
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over-expression in laboratory mutants, is that the clinical isolates possessed topoiso-
merase mutations in addition to patAB over-expression. The role of PatAB in isolates
with coexisting topoisomerase mutations had not previously been investigated. Three
isolates which over-expressed patAB and had an FQDR phenotype did not contain func-
tional topoisomerase mutations. This suggests that over-expression of patA and patB
can cause fluoroquinolone resistance in clinical isolates in isolation. However, in the
remaining 12 FQDR and 24 FQR isolates topoisomerase mutations were present. There
was considerable variation in the combinations of topoisomerase gene alleles observed,
but there was no correlation between any particular genotype and expression of patAB.
Genetic inactivation of patA or patB, or addition of eﬄux inhibitors, decreased MICs of
ethidium bromide for the majority of the isolates by more than two dilutions, regardless
of the initial level of resistance or expression of patAB. This implicates PatAB in intrinsic
resistance to ethidium bromide, even in the absence of over-expression of the pump. For
ciprofloxacin resistance, the picture was more complicated, but MICs were still reduced
by one or more dilutions by either chemical or genetic inactivation of PatAB for the
majority of the isolates tested. Ciprofloxacin MICs for a subset of FQR and S isolates
were unaffected by addition of eﬄux inhibitors, and MICs of two FQDR isolates were
unaffected by sodium orthovanadate. These results suggest that, in general, inactiva-
tion of PatAB reduces ciprofloxacin resistance, even in the presence of topoisomerase
mutations. However, there is evidence of variation between strains, and PatAB may
contribute to fluoroquinolone resistance to different degrees depending on the genetic
background of the strain. Hoechst 33342 accumulation was also increased in all tested
isolates by the addition of the eﬄux inhibitor reserpine, indicating that there is a basal
level of eﬄux in all isolates, regardless of the expression level of patAB.
No significant difference in average generation time was observed between isolates that
over-expressed patA and patB and those that did not. This indicates that over-expression
of patAB does not confer a substantial fitness burden on pneumococcal isolates under
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laboratory growth conditions, even when combined with topoisomerase mutations. This
result complements previous work, which showed that over-expression of patAB did
not affect growth of laboratory mutants (Garvey and Piddock, 2008). However, the
generation times of the clinical isolates were highly variable, possibly because they were
not grown under ideal S. pneumoniae culture conditions. Also, growth under laboratory
conditions is only a crude measure of fitness. Further work would be needed to determine
whether over-expression of patAB has an impact on pneumococcal growth and survival
in vivo.
No mutations had been associated with the patA and patB genes in isolates that over-
expressed patAB compared to isolates that did not, suggesting that the increased activity
of patA and patB is not caused by a functional change in the transporter protein, or
increased expression caused by an altered promoter sequence. This confirmed previous
studies where no mutations had been found in patA and patB in laboratory mutants.
This suggests that increased expression of these genes must be caused by a mutation
elsewhere in the genome, possibly in a regulatory gene.
In conclusion, in this group of isolates over-expression of patA and patB was signif-
icantly associated with resistance to both fluoroquinolones and dyes. Inactivation of
the PatAB pump caused reductions in resistance to these agents in the majority of the
isolates, regardless of patAB expression level and possession of topoisomerase muta-
tions, suggesting that PatAB contributes to intrinsic fluoroquinolone and dye resistance.
These results have since been supported by other groups who have observed patAB over-
expression in clinical isolates. El Garch et al (2010) investigated two clinical isolates with
increased patAB expression, one of which possessed topoisomerase mutations and one
of which did not, and observed similar reductions in fluoroquinolone and dye resistance
by addition of reserpine or inactivation of patA or patB. Lupien and coworkers (Lupien
et al., 2013) identified a ciprofloxacin resistant clinical isolate which over-expressed patA
and patB and did not have any co-existing topoisomerase mutations, as was observed
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in three of the isolates in this study.
3.9.1 Further work
The main limitation of this study is that it was carried out using a set of isolates that
were collected over ten years ago. This means that the results may not reflect the
clinical situation now. Additionally, the clinical history of the patients from which these
isolates were taken is unknown, which means that correlations of expression of patAB
with disease state or treatment using a particular antibiotic cannot be assessed. It
would therefore be interesting to repeat this study using a modern set of clinical isolates
collected systematically with details of the clinical context included. It has previously
been shown that patAB over-expression can be selected by exposure to a variety of
fluoroquinolones, not just those that are good substrates for the PatAB pump (El Garch
et al., 2010). It could therefore be hypothesised that a similar proportion of isolates
would be found to over-express patAB despite declining use of ciprofloxacin. A mutation
causing over-expression of patA and patB was found in an isolate from the cerebrospinal
fluid of a meningitis patient, compared to an otherwise isogenic bloodstream isolate
(Croucher et al., 2013). It would therefore interesting to investigate whether there is
a correlation between pneumococcal isolates causing meningitis and over-expression of
patAB.
This study also identified some isolates with phenotypes that did not fit the expected pat-
tern. Three isolates that over-expressed patAB accumulated wild-type levels of Hoechst
33342 and were susceptible to ethidium bromide. A further two isolates over-expressed
patAB but showed wild-type susceptibility to fluoroquinolones. It would be interesting to
compare the transmembrane domain sequences of PatA and PatB in these isolates with
R6 to see if there are any differences that might alter the specificity of the transporter.
Conversely, one isolate that was resistant to fluoroquinolones and dyes and accumulated
103
low levels of Hoechst 33342 did not over-express patAB. This isolate could be screened
for increased expression of pmrA or dinF by qRT-PCR.
3.10 Key findings
• Over-expression of patAB was observed in 38% of the fluoroquinolone resistant
clinical isolates in this set.
• Over-expression of patAB was significantly associated with resistance to both flu-
oroquinolones and dyes.
• Clinical isolates over-expressing patAB accumulated significantly lower levels of the
fluorescent dye Hoechst 33342 than isolates not over-expressing the eﬄux pump.
• Chemical or genetic inactivation of PatAB reduced fluoroquinolone and dye re-
sistant in isolates where the pump was not over-expressed, and in isolates with
co-existing topoisomerase mutations, suggesting that PatAB is involved in intrin-
sic resistance to these agents.
• Over-expression of patAB did not affect growth of S. pneumoniae clinical isolates.
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4 Using whole genome sequencing to identify
mutations causing upregulation of patA and
patB in M184
4.1 Background
Previous studies showed that mutants over-expressing patA and patB can be easily
selected in the laboratory using ciprofloxacin (Marrer et al., 2006b) and the eﬄux inhibitor
reserpine (Garvey and Piddock, 2008). Results presented in chapter 3 suggested that
over-expression of patA and patB contributing to fluoroquinolone resistance is common
in clinical isolates (Garvey et al., 2011). However, genetic changes responsible for the
upregulation of patA and patB in these studies have not been identified.
M184 is a laboratory strain of S. pneumoniae that over-expresses patA and patB (Garvey
and Piddock, 2008). M184 was derived from M169, a mutant of the unencapsulated
laboratory strain R6 that was selected from increased resistance to the eﬄux inhibitor
reserpine (Garvey and Piddock, 2008). Reserpine-resistant mutants, including M169,
were selected from R6 following a single exposure to reserpine, at a frequency that
suggested that reserpine resistance was conferred by a single point mutation (Garvey
and Piddock, 2008). M184 was generated by transformation of genomic DNA from
M169 into R6, followed by selection of successful transformants on 100 µg/ml reserpine
(Garvey and Piddock, 2008). This was done to confirm that patAB over-expression was
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conferred by a single genetic change, and to isolate this mutation in a clean genetic
background.
M184 was previously shown to be less susceptible than R6 to fluoroquinolones (ciprofloxacin,
norfloxacin and levofloxacin), dyes (ethidium bromide and acriflavine), cetrimide and
reserpine (Garvey and Piddock, 2008). M184 was also shown to accumulate lower in-
tracellular levels of ciprofloxacin and ethidium bromide than R6 (Garvey and Piddock,
2008). However, no mutations were found in the patA and patB genes or their upstream
regions in M184 that might explain the observed phenotype, suggesting that a muta-
tion elsewhere in the genome was responsible. Constitutive expression of eﬄux systems
in several other bacteria has been shown to be caused by mutations in local or global
transcriptional regulators (Abouzeed et al., 2008; Webber et al., 2005).
4.2 Aims and Hypothesis
The primary aim of this section was to determine the genetic change responsible for
patAB over-expression in M184 using a whole genome sequencing approach. Following
detection of a causative mutation, a secondary aim was to characterise the mutated
gene(s) to begin to elucidate a regulatory pathway controlling expression of patA and
patB.
Based on the mutation frequencies observed when strain M169 was selected, and the
ease of transformation of the M169 phenotype into R6 (Garvey and Piddock, 2008),
it was hypothesised that over-expression of patA and patB in M184 is conferred by a
single point mutation. It was also hypothesised that the putative mutation would affect
a transcriptional regulator.
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4.3 Detection of mutations in M184 by whole genome
resequencing
Whole genome resequencing of M184 and our current laboratory stock of R6 was carried
out by GenePool (Edinburgh, UK) prior to the start of this project in 2009, as described
in Materials and Methods (section 2.5.1). Briefly, 50 cycles of paired-end sequencing
were carried out on an Illumina GAIIx system. This resulted in a set of 4,967,264 50bp
read pairs for M184 and 2,043,226 for R6, giving theoretical coverages of the 2 Mb R6
genome of approximately 240x and 100x respectively. The quality of the M184 and R6
forward and reverse reads were assessed using FastQC. Average per-base quality scores
were >20 along the entire length of the read for both M184 read sets and for the first
read of each R6 pair. For the second reads from R6, a sizeable proportion showed a
decline in quality in the final 10 bases.
4.3.1 Alignment
Sequencing reads obtained for each strain were mapped against the published R6 genome
(Genbank accession number: NC_003098; Hoskins et al., 2001) using the xBase next-
generation sequencing pipeline (http://ng.xbase.ac.uk/my/). This is an online server
allowing users to access the MAQ short-read alignment program (Li et al., 2008) without
the need to install and run the software locally. M184 and R6 reads were independently
mapped against the reference sequence in paired-end mode, using an estimated insert
size of 250bp. For M184, 9,161,550 out of 9,934,528 (92.2%) reads were successfully
mapped, giving an average coverage of 225x, while 3,373,036 out of 4,086,452 (82.5%)
R6 reads were mapped to give an overall coverage of 83x. In both cases, of the reads
that were successfully mapped, more than 97% of these mapped as pairs. For M184,
the majority of the genome positions were covered between 50 and 500 times, while for
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R6 coverage mainly varied between 25 and 150 times (Figure 4.1).
4.3.2 Mutation detection
The xBase pipeline detects mutations in the aligned reads relative to the reference
genome using the variation detection tools that are part of the MAQ program: cns2snp
for calling SNPs and indelpe for detecting small indels (Li et al., 2008). A set of SNPs
and small indels was obtained for each strain relative to the published R6 reference
genome, and these sets were compared to each other to find mutations unique to each
strain and mutations shared between the strains.
4.3.2.1 Comparison of the R6 sequence to the published R6 reference genome
Sixty-eight mutations were detected by Maq in our R6 relative to the published R6
genome (Appendix 1). Six of these were unique to R6, but the remaining 62 were also
found in the M184 sequence.
A cluster of ten mutations were predicted in the pbpX gene (spr0304). However, on
closer inspection, coverage in this region was unusually low and dropped to zero in several
places (figure 4.2). This read alignment pattern was also seen in the M184 data. This
suggests that in the laboratory stock of R6 used in this study there has been a change in
the pbpX region relative to the published R6 genome. This change could be a deletion
of the pbpX gene, or a recombination with a pbpX variant sufficiently different such
that reads generated from pbpX in the sequenced R6 cannot be aligned to pbpX in the
published R6 genome. Mutation calls from the few reads that do align in this region are
therefore unreliable, so mutations found in this region (302960 to 304013) were excluded
from all following analyses.
Two further small clusters of five and four SNPs, respectively, were predicted in genes
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Figure 4.1. Comparison of M184 and R6 read depth distributions. Frequency
distributions of read depths calculated for each genomic position when M184 and R6
Illumina reads were aligned against the published R6 genome
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Figure 4.2. Read depth coverage of the pbpX region in R6. Viewed in Artemis
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spr1675 and spr1721, both of which encode degenerate transposases. It is likely that
these genes are non-functional, so not subjected to purifying selection, so a higher
mutation rate than the surrounding genome would be expected. Alternatively, these
genes could have been altered by recombination with another strain of S. pneumoniae
at some point in the strain’s evolutionary history. The remaining 47 mutations were
distributed fairly evenly throughout the genome. Twenty-seven of these were predicted
to affect the amino acid sequence of the respective gene product.
4.3.2.2 Identification of mutations in M184
Mutations found in both M184 and R6 genomes were excluded as these are likely to be
pre-existing natural differences between the laboratory stock of R6 and the published R6
genome. In total, 36 SNPs and three small indels were found in M184 but not R6, and
six SNPs were found in R6 but not M184. To confirm that the M184 mutations were real
and not the result of sequencing error or mis-calling by the software, an area surrounding
each mutation was amplified from M184 and R6 by PCR and resequenced by Sanger
sequencing. The resulting sequences were examined for the presence or absence of the
expected mutation. Of the original 39 mutations, 27 (24 SNPs and all three indels)
were confirmed to be present in M184 and absent in R6 (Table 4.1). The remaining 12
mutations were not confirmed to be present in M184 and so were excluded from further
analyses.
4.4 Investigating truncation of hrcA
Of the 27 confirmed SNPs found in M184 compared to R6, the most initially intriguing
was a mutation in hrcA. HrcA is a negative regulator of the class I heat shock operons,
grpE-dnaK-dnaJ and groELS, which are widely conserved in bacteria (Narberhaus, 1999;
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Schulz and Schumann, 1996). Loss-of-function mutations in negative regulators have
been shown to cause derepression of eﬄux systems in other bacteria (Abouzeed et al.,
2008; Webber et al., 2005), so the role of mutation of hrcA in the phenotype of M184
was further investigated. The mutation found in hrcA in M184 changes a glutamine
codon to a stop codon, causing truncation of the HrcA protein. A comparative model of
the HrcA protein structure was generated using SwissModel (Arnold et al., 2006) using
the crystal structure of hrcA from Thermatoga maritima as a template (Liu et al., 2005).
Based on this model, the truncation deletes part of a central, GAF-like domain that is
thought to stabilise a dimerisation domain (Figure 4.3; Liu et al., 2005). This seems
likely to affect protein function.
4.4.1 Sequencing of hrcA gene from other patAB over-expressors
If HrcA is involved in regulation of patAB, it might be expected that other pneumococcal
isolates that over-express patAB would also carry mutations in this gene. To investigate
this, the sequence of the hrcA gene was determined from M168, a reserpine-selected
mutant of M4 (Garvey and Piddock, 2008) that has the same phenotype as M184. The
hrcA gene was also sequenced from eight of the patAB over-expressing clinical isolates
described in Chapter 3. No hrcA mutations were found in the clinical isolates, but M168
contained a glycine to arginine mutation located in the putative DNA binding domain
of HrcA (indicated in figure 4.3).
4.4.2 Transformation of R6 with mutated hrcA
To determine whether the truncation of hrcA in M184 is responsible for patAB over-
expression, the hrcA gene containing the truncation mutation was amplified from M184
by PCR (primers 902 and 903), and the PCR amplimer was transformed into R6. Trans-
formation of whole M184 genomic DNA into R6 was carried out in parallel as a positive
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Figure 4.3. Model of Sp_HrcA produced by SwissModel. Positions of mutations
found in M184 (E269→Stop) and M168 (G61→R) are indicated by arrows. WH-NTD:
Winged helix-turn-helix N-terminal domain. IDD: inserted dimerisation domain
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control. Transformation mixtures were spread onto agar plates containing 100 µg/ml re-
serpine. Two reserpine resistant transformants were recovered from transformation with
the M184 hrcA amplimer and sequencing of the hrcA gene from these transformants
confirmed that the truncation mutation had been transferred. One transformant was re-
tained for further study and named M499. The MICs of ciprofloxacin, ethidium bromide
and reserpine for M499, were measured and compared to R6 and M184 (Table 4.2). As
observed previously (Garvey and Piddock, 2008), M184 shows decreased susceptibility to
all three agents, and the resistance to ethidium bromide and ciprofloxacin was reversed
by addition of 20 µg/ml reserpine. For M499, the MIC of reserpine was increased from
64 µg/ml to 128 µg/ml, as observed in M184, but the MICs of ciprofloxacin and ethidium
bromide remained at the R6 levels of 2 and 4 µg/ml, respectively. This suggests that
the hrcA mutation is unlikely to confer patAB over-expression in M184.
To confirm that M499 did not over-express patA and patB, the expression of these genes
was measured by qRT-PCR from R6, M184 and M499 (Figure 4.4). Neither gene was
expressed in M499 at a level significantly higher than R6. In contrast, in M184, both
patA and patB were expressed at more that 100-fold higher levels than in R6.
4.5 Identifying mutations linked to the patAB over-
expression phenotype
Since mutation of hrcA was not the cause of patA and patB over-expression, the involve-
ment of the other mutations determined by the whole genome sequencing was assessed.
A similar transformation process to that used to transfer the hrcA mutation was used.
However, the resistance profile of M499 suggests that reserpine resistance can be con-
ferred separately from ethidium bromide and fluoroquinolone resistance. Therefore, in
the following experiments ethidium bromide and norfloxacin were used as selective agents
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Table 4.2. MICs (µg/ml) of ciprofloxacin, ethidium bromide and reserpine for R6, M184
and M499, in the presence or absence of 20 µg/ml reserpine.
Ciprofloxacin Ethidium bromide Reserpine
Reserpine (20 µg/ml) - + - +
R6 2 1 4 1 64
M184 8 1 32 1 128
M499 2 1 4 1 128
Bold text indicates MIC values greater than those of R6 by two or more
dilutions
Figure 4.4. Expression of patA (dark bars) and patB (light bars) in R6, M499 and
M184, determined by qRT-PCR. *, expression significantly higher than in R6, p<0.05,
one-tailed Student’s t-test on log10(expression).
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as these provided a better indication of patAB over-expression.
4.5.1 Transformation with PCR amplimers
The remaining 26 candidate mutations were reduced to an initial test set of ten (indicated
in table 4.1) based on the following criteria:
• the mutation occured within a gene and affected the protein coding sequence
• gene affected was part of the pneumococcal core genome, as defined by Hiller et
al. (2007)
• the mutation was not found in any of the 17 published S. pneumoniae genomes
described by Hiller et al. (2007). Conservation of a mutation in another genome
implies that the mutation is a natural polymorphism unrelated to the M184 phe-
notype.
A cluster of ten mutations identified in the gltX gene was also tested. Due to their
proximity, the ten mutations were counted as one genetic change, bringing the total set
of mutations to test to eleven.
A region containing each candidate mutation was amplified by PCR and transformed into
R6; the transformation mixtures were then cultured on agar plates containing 8 µg/ml of
either norfloxacin or ethidium bromide. No transformants were recovered following selec-
tion on either agent for any of the PCR products, but a positive control transformation
using M184 genomic DNA as the donor DNA consistently resulted in colonies resistant
to both agents. The mutated PCR amplimers were also transformed into M499 to de-
termine whether one of these mutations in combination with the HrcA truncation could
confer the M184 phenotype but, again, no ethidium bromide or norfloxacin resistant
transformants were recovered.
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4.5.2 Transformation of M184 phenotype into R6 background
using whole genomic DNA
None of the twelve mutations initially chosen for study could confer the M184 phenotype
to R6 cells when transformed singly or in combination with the truncation mutation in
hrcA. This implied that either one of the remaining five mutations not yet tested or a
combination of more than one mutation was the cause of the phenotype. To assess
the number of mutations required for over-expression of patA and patB, the frequency
of transformation to ethidium bromide or norfloxacin resistance when R6 cells were
transformed with whole M184 genomic DNA was measured and compared to that of a
spectinomycin resistance gene.
R6 cells were transformed with 0.2 µg/ml M184 DNA on two separate occasions, and
plated on either 8 µg/ml norfloxacin or 8 µg/ml ethidium bromide. In parallel, R6 cells
were transformed with 0.2 µg/ml DNA from M240, an R6 mutants that carries a specti-
nomycin resistance cassette in the patB gene, and plated on 200 µg/ml spectinomycin.
The number of colonies on each selective plate was counted to give the number of
successful transformants per ml of culture. As a negative control to check the back-
ground rate of spontaneous mutations, R6 cells were transformed with R6 DNA and
plated on spectinomycin, ethidium bromide and norfloxacin. For each transformation
mixture the total number of bacteria per ml of culture, expressed as colony forming
units (cfu) per ml, was determined by viable count, and transformation frequencies
were calculated by dividing the number of transformants per ml obtained on selective
media by the cfu/ml. The frequencies of transformation to ethidium bromide and nor-
floxacin resistance observed using M184 DNA were between 10-6 and 10-7, while the
frequency of transfer of the spectinomycin cassette from M240 was 10-5. These values
were compared to estimate how many mutations must be transferred to confer patAB
over-expression. The average norfloxacin/spectinomycin ratio was 0.08 and the aver-
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age ethidium bromide/spectinomycin ratio was 0.03. No spontaneous ethidium bromide
or spectinomycin resistant mutants were observed in the negative control, but a back-
ground mutation frequency to norfloxacin resistance of 10-8 was observed, presumably
due to mutations in topoisomerase genes. Three of the ethidium bromide-selected trans-
formants (M501, M502 and M503) and one norfloxacin-selected transformant (M500)
were randomly chosen and retained for further study.
4.5.3 Confirmation of successful transfer of patAB overex-
pression
To confirm that the norfloxacin and ethidium bromide resistance of the transformants
was caused by patAB expression, the MIC profiles of the four retained transformants
were determined in the presence and absence of reserpine and sodium orthovanadate
(Table 4.3). All four transformants showed similar susceptibility to the two antibiotics
and ethidium bromide as M184. The MICs of ciprofloxacin, norfloxacin and ethidium
bromide were higher then those of R6 by at least two dilutions, and this was reversed by
addition of 20 µg/ml reserpine or 50 µM sodium orthovanadate. However, norfloxacin
MICs for three of the transformants (M500, M501 and M503) appeared to be affected
to a greater extent by sodium orthovanadate than that of M184. Similarly, MICs of
ethidium bromide for all four transformants were also reduced to a greater extent by
sodium orthovanadate than for M184.
To confirm that the transformants showed increased eﬄux activity, as would be ex-
pected if they over-expressed patA and patB, intracellular accumulation of ethidium
bromide was measured by fluorescence assay. All four transformants accumulated sig-
nificantly lower levels of ethidium bromide after 10 minutes than wild type and M240
(R6 patB::magellan2 ; p<0.05, one-tailed Student’s t-test; Figure 4.5). Interestingly,
there was variation in the levels of accumulation between the transformants, with M500
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Table 4.3. MICs of ciprofloxacin, norfloxacin and ethidium bromide for four R6M184
transformants in the presence and absence of eﬄux inhibitors reserpine and sodium ortho-
vanadate.
Cip Cip Cip Nor Nor Nor EtBr EtBr EtBr
+ R + N + R + N + R + N
R6 0.5 0.25 0.25 1 1 <1 2 <1 <1
M184 2 0.5 0.5 8 2 2 16 2 <1
M500 2 0.5 0.25 8 2 <1 16 2 <1
M501 2 0.25 0.25 8 2 <1 16 2 <1
M502 2 0.5 0.5 16 2 4 32 2 <1
M503 2 0.25 0.25 8 2 <1 16 2 <1
Cip, ciprofloxacin; Nor, norfloxacin; EtBr, ethidium bromide; R, 20
µg/ml reserpine; N, 50 µM sodium orthovanadate; Bold text indicates
MIC values that are two or more dilutions greater than those of R6
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and M503 accumulating significantly more ethidium bromide than M184, and M502
accumulating significantly less (p<0.05).
Finally, the expression of patA and patB was measured directly by qRT-PCR, using
cDNA synthesised from total RNA extracted from mid-logarithmic phase cultures (OD660
= 0.4). Expression of patA and patB was determined relative to the control genes rpoB
and 16S rRNA using the Pfaﬄ method (section 2.4. M184 and all four transformants
expressed levels of patA and patB 100-1000-fold higher than those observed in R6
(Figure 4.6A). The levels of over-expression observed were surprisingly high, but were
ascribed to very low levels of basal patA and patB expression observed in R6, that could
be visualised by agarose gel electrophoresis of amplimers (Figure 4.6B).
Growth of M184 and the four R6M184 transformants in BHI broth over seven hours was
also measured and compared to that of R6 (Figure 4.7A). Generation times for each strain
were calculated from exponential growth between two and four hours (Figure 4.7B).
M184 grew significantly more slowly than R6 (generation time of 47±4 minutes compared
to 35±2 minutes, p<0.05, One-tailed Student’s t-test), but there was no significant
difference between generation times of R6 and the four R6M184 transformants.
4.5.4 Resequencing of known M184 mutations in R6M184 trans-
formants
To determine which, if any, of the M184 mutations detected by the genome resequencing
were involved in patAB expression, regions surrounding each candidate mutation were
amplified by PCR from all four of the transformants and sequenced by Sanger sequencing.
The sequence of each PCR amplimer was then checked for the presence or absence of
the candidate mutation. Surprisingly, none of the 27 candidate mutations detected in
M184 were present in any of the transformants tested, which indicated that they were
not the cause of patAB over-expression in these transformants. To check that the
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Figure 4.5. Ethidium bromide accumulation in M184 and four R6M184 trans-
formants compared to R6. Bars represent average steady state fluorescence of three
independent cell suspensions following 10 minutes of exposure to ethidium bromide (25
µM). Error bars represent standard deviation of three biological replicates. *, accumulates
significantly lower levels of ethidium bromide than R6, p<0.05, one-tailed Student’s t-test.
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AB
Figure 4.6. Expression of patA and patB from M184 and the four R6M184 transfor-
mants compared to R6 determined by qRT-PCR. (A) Fold expression of patA (dark
bars) and patB (light bars) normalised to rpoB. *, Expression significantly higher than in
R6, p<0.05, One-tailed Student’s t-test on log10(Expression). (B) Amplimers obtained
following 40 cycles of amplification of patA, patB and 16S rRNA from cDNA, visualised
by gel electrophoresis.
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AB
Figure 4.7. Growth of M184 and four R6M184 transformants in BHI compared to
R6. (A) Absorbance (660 nm) of cultures of R6 (green line), M184 (solid red line) and four
R6M184 transformants (dashed red lines). (B) Generation times per strain calculated from
exponential phase growth between two and four hours. Error bars represent the standard
deviation of three biological replicates. *, generation time significantly higher than that of
R6, p<0.05, One-tailed Student’s t-test.
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causative mutation had not reverted during antibiotic-free culture of the transformants,
genomic DNA from each transformant was transformed into R6 cells and transformants
were selected on 8 µg/ml ethidium bromide. Ethidium bromide resistant colonies were
recovered using DNA preparations from all four transformants, at frequencies equivalent
to that obtained with M184 DNA (106 – 107), confirming that the transformants still
carried the mutation(s) responsible for patAB over-expression.
4.6 Further analysis of genome sequencing data
As none of the mutations detected in M184 by the Maq analysis appeared to be re-
sponsible for the M184 phenotype, further analysis of the genome sequencing data was
carried out to determine the genetic change causing upregulation of patA and patB.
It was hypothesised that the causative mutation had been missed in the original SNP
analysis, either due to a failure of the software, or due to the mutation being located in
a region to which read mapping is complicated, such as a repetitive element.
4.6.1 Recalling SNPs using different software
Firstly, to rule out the possibility that the Maq software had failed to detect the causative
SNP, the mutation detection analysis was repeated using the short-read aligner Bowtie2
(Langmead and Salzberg, 2012) to align reads against the R6 reference genome, and
Samtools to identify variant genome positions. Identified variations were then filtered
to keep only mutations with a Phred-scaled quality score of more than 50, resulting
in 75 mutations in M184 and 52 in R6. These were compared with the mutations
detected by Maq (figure 4.8). Of the 13 M184 mutations that had been detected by Maq
that were subsequently found to be false positives by PCR and resequencing, only five
were detected by the Bowtie2/Samtools approach. Visual inspection of read alignments
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covering all SNPs detected by the two methods suggested that 17 of the mutations
detected by Maq were false positives. Of these, only eight were also suggested to be
SNPs by Bowtie2, suggesting that Bowtie2 detected fewer false positives. However, six
of the mutations found by Maq, which appeared genuine on visual inspection, were not
detected by Bowtie2. Five new mutations were detected by Bowtie2 that had not been
found by Maq, four in both strains and one in M184 only. These new mutations were
all small insertions and deletions, reflecting the superior indel detection algorithms in
Bowtie2 compared to the older Maq program (Langmead and Salzberg, 2012).
One mutation was found in M184 by the Bowtie2 approach that had not previously been
detected by Maq. This was a small insertion in the pcpA gene. A region surrounding this
mutation was amplified from R6, M184 and the four R6M184 transformants and sequenced
by Sanger sequencing. The insertion was observed in M184, but not in R6 or any of
the transformants. This suggests that the pcpA mutation is a genuine polymorphism in
M184 relative to R6, but it is not the cause of over-expression of patA and patB.
4.6.2 Assembly of unaligned reads
A potential disadvantage of the genome resequencing approach used here is that it will
not detect large insertions relative to the reference genome that are greater than the
read length. Evidence of a potential recombination event affecting the pbpX gene had
already been observed in the R6 and M184 sequences. It was therefore possible that
other recombination events had occurred in the evolutionary history of R6 and/or M184
which could have led to insertion of extra DNA. This could mean that, either an insertion
had occurred recently in M184 which caused patAB over-expression, or an insertion had
occurred in the laboratory stock of R6 prior to selection of M184, and the mutation
causing patAB over-expression was located in the inserted DNA. In support of these
hypotheses, 8% of the M184 reads could not be aligned to the reference genome, which
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Figure 4.8. Comparison of numbers of mutations detected in M184 (red) and R6
(blue) from alignments of Illumina sequencing reads made by Maq (dotted border)
and Bowtie2 (solid border).
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equates to about 770,000 reads. Assuming the hypothetical extra DNA is covered to
the same average depth as the rest of the genome, these extra reads could potentially
represent 170 kb DNA. To investigate this, the M184 reads that did not align to the
R6 reference were assembled using the de novo assembly software, Velvet (Zerbino and
Birney, 2008). M184 reads were used for this analysis due to the higher overall quality
of the reads.
Using a Velvet kmer value of 45, 24 contigs with length of 100 bp or greater were
generated (Table 4.4). The 24 contigs were compared against the nr nucleotide database
to determine the most similar sequence. One 1149 bp contig matched to an internal
region of the pbpX gene from S. pneumoniae strain 670-6B (query coverage 100%,
sequence identity 99%). This corresponded to the region of pbpX gene to which reads
were not aligned in S. pneumoniae R6, implying that this region of the genome of the
laboratory stock of R6 has undergone a recombination with a strain related to 670-
6B. Twelve short contigs of median length 226 bp matched bovine microsatellite DNA,
and one further contig of length 210 bp matched equine microsatellite DNA (median
sequence identity 99%). Five contigs of median length 1129 bp matched transposase
sequences from Lactococcus lactis, and three contigs of median length 554 matched
sequences on lactococcal plasmids. Finally, a large 30 kb contig showed 79% sequence
identity with the Lactococcus lactis lytic bacteriophage ASCC506, which was isolated
from an Australian dairy factory.
Six sets of primers were designed to amplify regions of the putative bacteriophage se-
quence. However, no amplimers were observed when R6 or M184 genomic DNA was
used as the template DNA. This suggested that the bacteriophage sequence was a con-
taminant of the original M184 genomic DNA preparation, and was not inserted into the
R6 genome. The role of these extra sequences was therefore not investigated further.
S. pneumoniae was routinely grown in rich medium derived from enzymatic digestion
of beef products, meaning that the growth medium could have been the source of this
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Table 4.4. Putative origins of contigs assembled from M184 reads that did not
align to the published R6 genome.
Origin of sequence Number median length median coverage
of contigs (bp)
Bovine microsatellite DNA 12 226 273
Equine microsatellite DNA 1 210 145
Lactococcal phage 1 30774 301
Lactococcal plasmid 3 554 308
Lactococcal transposase 5 1129 181
Streptococcus pneumoniae
pbpX
1 1149 229
Unknown 1 1083 192
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extra DNA.
4.6.3 Sequencing of short repetitive regions
The S. pneumoniae genome contains many short interspersed sequences, such as BOX el-
ements, repeat unit of pneumococcus (RUP) elements, insertion sequence (IS) elements
and S. pneumoniae Rho-independent terminator-like elements (SPRITEs) (Croucher
et al., 2011b; Hoskins et al., 2001). Altogether, these repetitive elements comprise
more than 3% of the genome, which is an unusually high percentage compared to other
sequenced bacteria (Hoskins et al., 2001). It has been suggested that some pneumococ-
cal short interspersed repeats can affect expression of downstream genes. For example,
a BOX element upstream of the com operon was shown to activate gene expression
(Knutsen et al., 2006).
The positions of BOX, RUP and SPRITE elements in the R6 genome have been system-
atically determined by Croucher et al (2011b). Inspection of the alignment of R6 and
M184 reads against the R6 reference genome showed that many of these regions have
increased coverage relative to the surrounding genes due to reads from repetitive regions
aligning to the genome multiple times. A SNP occurring in one of these repetitive re-
gions could therefore be missed by the SNP calling software due to the mis-alignment
of reads from multiple copies of the repeat. To confirm whether M184 and its trans-
formants contained any mutations in short interspersed repeats, the sequences of 80
repeat regions were determined by PCR and Sanger sequencing from R6 and M184.
Repeats were chosen based on their location and sequencing coverage, according to the
following criteria. Candidate repeats were located between pairs of genes transcribed
either in the same direction or divergently, while repeats located between convergently
transcribed genes were excluded. Additionally, the average depth of reads mapped to
candidate repeats was more than twice that of the flanking genes. For each candidate
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repeat, primers were designed that bound in the unique sequence either side of the repeat
(Appendix 2). Repeats were amplified by PCR from M184 and R6 DNA, and amplimers
were sequenced by Sanger sequencing. No differences between R6 and M184 were found
in any of the tested repeats.
4.7 Identification of mutations in R6M184 transfor-
mants by new whole genome sequencing
The results so far confirmed that transfer of genetic material from M184 to R6 confers
patAB over-expression, but the SNPs and small indels identified in the M184 genome
sequence are not the cause of this phenotype, and instead seem more likely to be com-
pensatory mutations, or bystander mutations that are unrelated to the phenotype. This
raised two hypotheses:
Hypothesis 1: As upregulation of patAB in the transformants is caused by incor-
poration of genetic material from M184, it was hypothesised that the R6M184
transformants and M184 should all contain the same genetic change relative to
R6.
Hypothesis 2: If, as postulated, the mutations previously found in M184 have arisen
to compensate for a fitness cost imposed by the over-expression of patA and patB ,
then the R6M184 should have also acquired mutations affecting similar systems.
To investigate these hypotheses, further genome sequencing was carried out on three of
the four R6M184 transformants. Due to advances in Illumina technology since the original
M184 sequence was obtained, longer read lengths and greater sequencing depth were
possible.
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4.7.1 Genome sequencing
Genomic DNA extracted from R6, M184 and three of the four R6M184 transformants
(M500, M501 and M503) was sequenced by Genepool (Edinburgh, UK) using the Illumina
HiSeq system. For each strain approximately 25 million 100 bp read pairs were obtained
and quality was assessed using FastQC. For all five read sets, average per base sequence
quality was good (>28) for the majority of the read length, but dropped to average (20
- 28) in the final 20 bp. The second reads for all five read sets all showed poor average
quality (<20) in the final five bases of the read. To avoid poor quality bases confounding
the SNP analysis, all reads were trimmed to 75 bp using a Python script written by Nick
Loman (University of Birmingham), before aligning against the published R6 genome
using Bowtie2. Variations were then identified using Samtools and, as before, mutations
detected in the pbpX region were discarded. In contrast to the SNP sets identified by
the Bowtie2 approach from the 50 bp sequencing, fewer than 80 mutations for each
strain were identified with no filtering applied. Therefore, in the first instance, the raw
SNP sets were used for comparison with the initial sequencing data.
4.7.2 Reanalysis of M184 and R6 mutations using new se-
quencing data
Sixty mutations were identified in the new R6 sequence relative to the published R6
genome sequence. This included 47 of the 58 mutations previously detected by Maq
in the previous genome sequence (Section 4.3.2.1 and Figure 4.9A). Eleven mutations
detected by Maq were not found in the new analysis, but thirteen additional mutations
were found that had not been observed previously.
Seventy-nine mutations were detected in the new M184 genome sequence, of which
49 were also found in R6. These were excluded to give a set of 30 mutations unique
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to M184, of which 25 had been detected in the previous analysis (Figure 4.9B). Five
additional mutations were found that had not been detected previously, while fourteen
of the mutations found by Maq were not detected in the new analysis.
4.7.3 Mutations detected in R6M184 transformants
The mutations detected in the three R6M184 transformants were compared with those
found in R6 and M184 (figures 4.9C and 4.9D). Fifty-four of the 60 mutations found
in R6 were also detected in all three of the transformants. Mutations were found in
all three transformants that were not detected in R6 (six in M500, four in M501 and
20 in M503; summarised in table 4.5), but none of these were shared between all three
transformants and M184 (figure 4.9D). The cluster of ten mutations previously found
in gltX in M184 was also found in M503, suggesting that a recombination event may
have occurred in this region. However, these mutations were not found in the other
two transformants, and the lack of recovery of ethidium bromide-resistant transformants
when R6 cells were transformed with a gltX PCR amplimer from M184 (section 4.5.1)
suggests that this cluster of mutations is not responsible for patAB over-expression.
4.8 Detection of a novel gene duplication by anal-
ysis of improperly mapped read pairs
The previous analyses had suggested that over-expression of patAB in M184 and the
R6M184 transformants was not caused by a point mutation in either the unique part of the
genome or in a repetitive region, and could also not be explained by acquisition of foreign
DNA. However, a possiblity not yet investigated was a large genomic rearrangement in
M184 and the transformants relative to R6. Adaptive genomic rearrangements have
been observed previously in bacteria. For example, inversions and duplications of parts
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Figure 4.9. Comparison of mutations found in new and old sequences of R6
and M184, and three R6M184 transformants. (A) Mutations found in new and old
sequences of R6. (B) Mutations found in the new and old sequences of M184. (C)
Mutations in three R6M184 transformants compared to R6. (D) Mutations in three R6M184
transformants compared to R6 and M184.
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of the E. coli chromosome were observed in mutants selected for suppression of a growth
deficiency caused by dis-regulated transcription initiation (Skovgaard et al., 2011).
To investigate this, the alignment of M184 reads against the reference genome was exam-
ined for a larger scale genomic rearrangement. Specialised software exists to detect ge-
nomic rearrangements, such as BreakDancer (Chen et al., 2009) and CNVer (Medvedev
et al., 2010), but these are designed and optimised for detecting rearrangements in
diploid eukaryotic genomes. Therefore, as the S. pneumoniae genome is relatively small,
putative genomic rearrangements were identified more simply by filtering for "improp-
erly" mapped read pairs. Illumina read pairs are derived from either end of a fragment
of DNA of a known average size, in this case 250 bp. It was therefore expected that
both members of a read pair should map to opposite strands of the genome within a
defined distance of each other, facing each other in the 5’ to 3’ direction (Figure 4.10A).
Improper pairs were defined as pairs of reads not meeting these criteria (Figure 4.10B-
4.10E). To identify genomic regions with unusually high concentrations of improperly
paired reads, read alignments were filtered to remove properly paired reads using Sam-
tools, then filtered alignments were visually inspected using Artemis (Rutherford et al.,
2000).
All five read alignments showed regions containing high numbers of improperly paired
reads corresponding to repetitive regions such as the rRNA loci, IS elements and degen-
erate transposases. However, two interesting regions of improperly mapped pairs were
observed in the M184 alignment that were not seen in R6. The first was in two genes
annotated as hsdS, spr0445 and spr0448, which encode Type I restriction-modification
enzyme subunits. Although these hsdS genes were similar, they were not identical and
the improper mapping of read pairs observed in M184 suggests that a recombination
has occurred between these two genes in M184. However, improper mapping of reads
to the hsdS genes was not observed in the R6M184 transformants, so this putative re-
combination was not analysed further. The second cluster of improperly paired reads
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Figure 4.10. Possible mappings of Illumina read pairs (red arrows) to a reference genome
(black line). (A) Read pairs are expected to map facing each other with an average
insert size (dotted line) of 250 bp. Genomic rearrangements may cause improper
mapping of read pairs by (B) increasing or (C) decreasing the insert size, or by
causing reads to map (D) divergently or (E) to the same DNA strand. sd, standard
deviation
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mapped between patA and the upstream hexA gene in M184 (figure 4.11). This region
of improperly paired reads was also observed in all three of the transformants. The
absolute number of reads mapping to the hexA-patA intergenic region (genomic posi-
tion 1865730-1865874) in M184, normalised for the total number of reads mapped, was
63 reads per million reads mapped, compared to 27 reads per million reads mapped in
R6. This approximate doubling of normalised read depth suggests that the hexA-patA
intergenic region may be duplicated in M184.
4.8.1 Investigation of putative rearrangement in the patA re-
gion of M184 and its transformants
The mapping of improperly paired reads in the intergenic region between hexA and patA
suggests that a genomic rearrangement may have occurred involving the upstream region
of patA. Three approaches were taken to investigate this further. Firstly, draft genomes
were assembled for M184 and R6 and contigs containing patA and hexA were compared.
Secondly, a local assembly was generated using the reads mapping to the intergenic
region as improper pairs. Finally, the relative copy numbers of all genes in the R6 and
M184 genomes were compared.
4.8.1.1 De novo assembly of R6 and M184 genomes
Draft genomes for R6 and M184 were assembled using the Velvet short-read assembly
software (section 2.5.3). A range of Velvet kmer values were tested, and assemblies
were ranked according to the size of the largest contig and the median length-weighted
contig length (N50; Zerbino and Birney, 2008). Using a kmer size of 51, the R6 reads
could be assembled into 1560 contigs, with an N50 of 5004 and maximum contig size
of 22674, using 89% of the reads. The M184 reads were assembled into 508 contigs,
with an N50 of 54708 and a maximum contig size of 168913, using 97% of the reads.
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AB
Figure 4.11. Alignment of improperly paired reads from (A) M184 and (B) R6
against the published R6 genome. Viewed in Artemis.
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Megablast (Altschul et al., 1997) was used to search both assemblies for contigs con-
taining sequences matching patA, hexA and the intergenic region between the two. In
M184, patA and hexA sequences were found on two contigs which overlapped in the
intergenic region, while in R6 all three query sequences were only found once, on one
contig spanning the whole hexA-patA region. The fact that the patA and hexA contigs
could not be joined by Velvet in the M184 assembly suggests that a rearrangement has
occurred in this genome, possibly involving duplication of the intergenic region between
patA and hexA. However, it was not possible to determine the nature of the rearrange-
ment from this assembly as sequences matching the intergenic region were not found in
any other contigs in the assembly.
4.8.1.2 Realignment and local assembly of improperly mapped read pairs
Analysis of read depth in the intergenic region between patA and hexA suggested that
this sequence had been duplicated elsewhere in the M184 genome. To identify the
location of the postulated second copy, the improperly paired reads that aligned to the
hexA-patA intergenic region were extracted from the read alignment using Samtools.
The corresponding pair of each read was then extracted from the original sequencing
data files using a custom Python script. These extracted reads were then re-aligned
against the R6 reference genome using Bowtie2 in single-end mode. In the resulting
alignment reads mapped to five distinct genomic regions. These corresponded to the
intergenic region between hexA and patA, and regions about 400 bp upstream of each
of the four copies of the 16S rRNA gene. The read extraction and alignment process
was repeated for the three R6M184 transformants and the same pattern was observed.
This suggests that a rearrangement has occurred in M184 causing the upstream region
of patA to be duplicated in close proximity to one or more of the rRNA loci.
To further determine the nature of this rearrangement, a local assembly was performed
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with Velvet using the same set of extracted M184 reads. Using a kmer value of 69,
a single contig of 608 bp was assembled using 88% of the reads. The contig was
compared against the R6 genome using Megablast. As predicted, 389 bp of the 3’ end
of the contig matched the region upstream of patA and 373 bp at the 5’ end matched
regions upstream of the rRNA loci. The 5’ end of the contig matched most closely to
rRNA loci two and four (285 out of 286 bp identical; figure 4.12). When compared to
the sequence upstream of copies one and three of the rRNA locus, the sequence identity
was slightly lower (284 out of 286 bp). The predicted join between the two distinct parts
of the contig occurred at 182 bp upstream of the patA start codon (36 bp from the end
of hexA) and 453 bp upstream of the 16S rRNA genes.
A PCR assay was used to confirm the presence of the predicted genomic rearrangement
in M184 and the R6M184 transformants. To determine wich rRNA locus was associated
with the rearrangement, primers were designed which bound uniquely upstream of each
rRNA locus (primers rRNA-1, rRNA-2, rRNA-3 and rRNA-4). These were combined with
a primer that annealed to the 5’ end of patA to attempt to amplify a region of DNA
corresponding to the contig predicted by the local assembly (Figure 4.13A). No amplimers
were obtained using any primer combination when R6 DNA was used as the template,
but an amplimer was observed from the primer combination corresponding to rRNA
locus four (primers 1772 and rRNA-4) when M184 DNA was used. Amplimers were also
obtained when this PCR was repeated using DNA from the four R6M184 transformants
(Figure 4.13B).
This, combined with previous results suggesting that the hexA-patA intergenic region is
duplicated, suggests that a duplication of part of the genome has occurred in M184 and
the transformants. The 5’ extent of this duplication maps to 182 bp upstream of patA,
and a region of unknown size has been duplicated between spr1880 and the fourth copy
of the 16S rRNA gene.
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AB
Figure 4.13. Investigation of a putative rearrangement in M184. (A) Location of
primers in patA and rRNA loci. (B) amplification of rearranged region from R6, M184
and four R6M184 transformants. Well 1: Hyperladder 1kb (Bioline). Wells 2-7: amplimers
obtained from PCR using primers 1d and 2. Wells 8-13: amplimers obtained from control
PCR using primers 2 and 3. Template DNA used was R6 (wells 2 and 8), M184 (wells 3
and 9), M500 (wells 4 and 10), M501 (wells 5 and 11), M502 (wells 6 and 12) or M503
(wells 7 and 13) genomic DNA preparations.
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4.8.1.3 Comparative read depth analysis to determine extent of putative
duplication
To determine the 3’ extent of the putative duplication, the relative copy number of
each gene in M184 was estimated compared to R6. To do this, normalised read depths,
expressed as reads per kilobase per million reads mapped (RPKM), for each gene larger
than 250 bp from M184 were plotted against those from R6 (figure 4.14). Interestingly,
seven genes had RPKM values in M184 that were approximately two times higher in
M184 than genes in R6. These genes were were co-located in a near-contiguous locus and
consisted of patA (spr1887), spr1886, patB (spr1885), guaA (spr1884), gpi (spr1882),
gltX (spr1881) and spr1880. Spr1883 was not included in the initial RPKM comparison
as it is shorter than 250 bp in length. RPKM comparisons were repeated using per gene
RPKM values from the three sequenced R6M184 transformants and the same pattern
was observed (figure 4.15). This suggests that the genetic change responsible for over-
expression of patA and patB in M184 and its derivatives is a duplication of a 9.2 kb
genomic region including all genes between patA and spr1880.
4.8.1.4 PCR analysis of putative duplication
The PCR analysis carried out previously demonstrated that there is a join present in M184
and its derivatives between the upstream region of patA and the region between spr1880
and rRNA locus 4. This suggests that the patA–spr1880 region has been tandemly
duplicated in place, resulting in two copies of the locus side by side in the genome. To
confirm whether this is the case, the whole duplicated region was amplified by PCR.
To do this, a primer binding upstream of the duplicated region in hexA (primer 1771)
was combined with a primer binding within patA (primer 1772) in a PCR cycle with
an extension time of ten minutes (Figure 4.16). Using a DNA template containing the
hypothesised duplication of the patA – spr1880 region, this reaction would result in two
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AB
Figure 4.14. Comparisons of per gene RPKMs of M184 against R6. (A) Rep-
resentation of genomic region around patA and patB (B) Per-gene RPKMs from M184
plotted against those of R6. Points representing genes included in patAB genomic region
are coloured as in (A).
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amplimers, one short amplimer corresponding to amplification between hexA and the
first copy of patA, and one amplimer that is 9.2 kb larger corresponding to amplication
from primers annealing to the second copy of patA. In contrast, from template DNA
without the postulated duplication, only the short amplimer would be observed. As
expected, only the short amplimer was observed when R6 DNA was used as a template.
However, both short and long amplimers were obtained when DNA from M184 or the
R6M184 was used, confirming the hypothesis that the patA – spr1880 locus is tandemly
duplicated in these strains. The large PCR amplimer from M184 was extracted from
the agarose gel and sequenced from either end to confirm that it corresponded to the
predicted sequence.
M168 and nine of the patAB-over-expressing clinical isolates described in chapter 3 were
screened for the presence of the duplication by PCR for the duplication junction (primers
rRNA-4 and 1772). No amplimers were obtained from any of the tested isolates.
4.8.2 Measuring segregation rate of duplication
Several examples of gene duplications have been observed in other bacteria (Sandegren
and Andersson, 2009). In all cases, gene duplications were unstable and were lost from
the genome at varying rates in the absence of selective pressure. This instability is
thought to be caused by RecA-dependent homologous recombination between copies of
repeated regions, which results in deletion of one copy (Andersson and Hughes, 2009).
To determine the stability of the patA-spr1880 duplication the rates of loss of norfloxacin
resistance from populations of M184 and the R6M184 transformant M502 were measured
following growth in BHI broth in the absence of a selective agent. After zero and 12-
14 hours of exponential growth, approximately 60 colonies per strain were tested for
norfloxacin resistance. The proportions of the samples that were norfloxacin resistant
before and after the growth period were compared to calculate percentage retention
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Figure 4.16. Investigation of putative patA-spr1880 tandem duplication by PCR. A
Location of PCR primers in patA and hexA, assuming the existence of a tandem duplication
of the patA-spr1880 region. B Amplification from R6 (well 1), M184 (well 2), M500 (well
3), M501 (well 4), M502 (well 5) and M503 (well 6) genomic DNA using the primers
indicated in (A) and an extension time of ten minutes. Wells 1 and 8 contain Hyperladder
1kb (Bioline)
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of norfloxacin resistance (Pret). This was used to calculate the probability of loss of
norfloxacin resistance per cell per generation, p(loss), and the half life of the norfloxacin
resistance within the population, using the equation Pret = (1 − p)n where n is the
number of generations (section 2.7; Brochet et al., 2008). Calculated values and 95%
confidence intervals (CIs) are shown in Table 4.6.
Norfloxacin resistance was retained in approximately 76% of the M184 population (95%
CI: 66-89%) and 71% (95% CI: 58-86%) of the M502 population, giving estimated
probabilies of loss per cell per generation of 0.017±0.010 and 0.015±0.009, respectively.
The half-life of the duplication within the populations was estimated to be between 17
hours and three days. The calculated confidence intervals of these measurements are
large (±15 to 20% of log(Pret)) as 60 is a relatively small sample size. The dependence
of confidence interval on sample size for different final proportions of norfloxacin-resistant
cells is shown in Figure 4.17. To obtain a 95% confidence interval of ±5%, using the
formula CI = ±zα/2
√
V ar(log(Pret) (section 2.7 of Materials and Methods), a sample
size of about 1500 colonies would be needed, assuming that the percentage of norfloxacin
resistant cells in the start population is about 100% and is ≥ 50% in the end population.
To confirm that loss of norfloxacin resistance correlated with loss of the patA-spr1880 du-
plication, seven norfloxacin resistant and seven norfloxacin sensitive isolates were tested
for presence or absence of the duplication junction by PCR. PCR amplimers correspond-
ing to the duplication junction were obtained for all of the resistant isolates, but not
from the sensitive isolates.
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Table 4.6. Retention of norfloxacin resistance by M184 and M502 in the absence of
antibiotic selection
Num Colony counts Half life
Strain gens (norR/total) % retention p(loss) (days)
start end average CI average±CI average CI
M184 15 57/58 45/60 76 66-89 0.017±0.010 1.3 0.8-2.9
M502 22 56/60 39/59 71 58-86 0.015±0.009 1.2 0.7-2.7
CI, 95% confidence interval
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Figure 4.17. Dependence of the precision of measurement of the percentage
retention of norfloxacin resistance in populations (Pret) on sample size. Precision
of measurement is expressed as ± a 95% confidence interval. The sample size required to
measure Pret to a precision of ± 5% (indicated by dashed lines) varies depending on the
true value of Pret in the population. Red line, Pret=90%; Green line, Pret=70%; Blue line,
Pret=50%
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4.9 Effect of gene duplication on expression of patA
and patB
It might be expected that duplication of the patA and patB genes would lead to a
doubling of their expression. However, expression levels of patA and patB in M184
and the R6M184 transformants were determined previously (section 4.5.3) and found to
be 100- to 1000-fold higher than in R6. This is higher than would be expected if the
over-expression of these genes were caused by the duplication alone, and implies that
the formation of the duplication must alter the regulation of patA and patB as well
as changing their copy number. Three hypotheses could be suggested to explain this
observation.
Hypothesis 1: The observed over-expression of patAB could be due to read-through
from a highly expressed gene at the end of the first copy of the duplicated region
into the second copy of the patAB locus.
Hypothesis 2: Although the duplicated region contains the intergenic region between
patA and hexA, which includes the predicted patA promoter, there may be an im-
portant cis-regulatory sequence, such as a repressor binding site, located upstream
of the 5’ end of the duplicated region that is not included. Lack of this sequence
upstream of the second copy of the duplication could cause unregulated expression
of the second copy of patAB.
Hypothesis 3: Alternatively, the unexpectedly high levels of patAB expression ob-
served could be due to a positive feedback loop activated by a small initial increase
in the level of the PatAB transporter caused by the duplication itself.
To test these three hypotheses expression levels of other genes in the duplicated region
were measured, and an attempt was made to inactivate individual copies of patA.
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4.9.1 Measuring expression of genes contained within the du-
plication
As well as patA and patB, the duplicated region in M184 includes six other genes (fig-
ure 4.14A) and it is possible that transcription of these could also be changed by the
duplication. Expression levels of five genes within the duplicated region, spr1886, spr1884
(guaA), spr1882 (gpi), spr1881 (gltX ) and spr1880, were measured relative to rpoB as
described for patA and patB. Expression of hexA, which is directly upstream of patA and
outside of the duplicated region, was also measured. Transcription of spr1883, which is
a small annotated open reading frame of unknown function that contains several regions
of low-complexity sequence, could not be assessed as suitable qPCR primers could not
be designed for this gene.
Measured expression levels for the tested genes are shown in Figure 4.18B. The gene im-
mediately following patB, guaA, was significantly upregulated relative to R6 in M184 and
the four R6M184 transformants (p<0.05, two-tailed Student’s t-test of log10(expression)
with Bonferroni correction for multiple testing). Observed levels of over-expression were
30±5-fold in M184, 59±18-fold in M500, 50±10-fold in M501, 26±8-fold in M502
and 69±44-fold in M503. Levels of cDNA corresponding to spr1886, which is encoded
between patA and patB on the opposite DNA strand, were also significantly higher
in transformants M500 and M501 than in R6 (21±8-fold and 12±2-fold respectively;
p<0.05). The gpi gene was also slightly over-expressed in M500, M501 and M503
(4±1-fold, 4±1-fold and 5±2-fold, respectively; p<0.05). Expression of hexA, gltX and
spr1880 was not significantly different from R6 in any of the tested strains.
GuaA is annotated as a glutamine amidotransferase enzyme in the published R6 genome
sequence (Pfam domain: PF07722). While some glutamine amidotransferases exist
as domains of larger proteins, such as CTP synthetase (Weng and Zalkin, 1987) and
153
A B
F
ig
ur
e
4.
18
.
E
xp
re
ss
io
n
of
ge
ne
s
w
it
hi
n
th
e
du
pl
ic
at
ed
re
gi
on
in
M
18
4
an
d
fo
ur
R
6M
18
4
tr
an
sf
or
m
an
ts
,d
et
er
m
in
ed
by
qR
T
-P
C
R
.
(A
)
R
ep
re
se
nt
at
io
n
of
ge
no
m
ic
re
gi
on
ar
ou
nd
pa
tA
an
d
pa
tB
.
(B
)
G
en
e
ex
pr
es
si
on
re
la
tiv
e
to
R
6
(r
ep
re
se
nt
ed
by
ba
rs
sh
ad
ed
by
ge
ne
as
in
pa
ne
lA
)
de
te
rm
in
ed
by
qR
T
-P
C
R
in
M
18
4
an
d
th
e
fo
ur
R
6M
18
4
tr
an
sf
or
m
an
ts
,
M
50
0-
3.
Er
ro
r
ba
rs
re
pr
es
en
t
th
e
st
an
da
rd
de
vi
at
io
n
of
th
re
e
bi
ol
og
ic
al
re
pl
ic
at
es
.
*,
ex
pr
es
si
on
si
gn
ifi
ca
nt
ly
di
ffe
re
nt
fr
om
th
at
of
th
e
sa
m
e
ge
ne
in
R
6,
p<
0.
05
,
tw
o-
ta
ile
d
St
ud
en
t’
s
t-
te
st
on
lo
g 1
0
(e
x
p
re
ss
io
n
)
w
ith
B
on
fe
rr
on
ic
or
re
ct
io
n
fo
r
m
ul
tip
le
te
st
in
g.
154
carbamoyl phosphate synthase (Raushel et al., 1999), guaA appears to encode a single
domain protein. Blast searches against the RefSeq and SwissProt protein databases did
not reveal any further information about the function of GuaA in the pneumococcal cell,
or its potential substrate.
The output of the TransTermHP program for S. pneumoniae R6 was examined for Rho-
independent transcriptional terminator predictons in the intergenic region between patB
and guaA. A terminator was predicted eight bp from the end of patB, but was located
on the opposite DNA strand. Promoter predictions for this region were made using
the Prokaryotic Promoter Prediction program, and no putative promoters upstream of
guaA were found. It therefore looks likely that guaA forms an operon with patA and
patB and is cotranscribed, although this would need to be confirmed experimentally
as computational prediction of promoter and terminator sequences is not completely
reliable.
4.9.2 Inactivation of individual copies of patA
Hypotheses one and two described above imply that over-expression of patA and patB is
caused by loss of regulatory control of the second copy of the locus, while the expression
of the first copy remains unchanged. If this is the case, it would be predicted that the
antibiotic resistant phenotype of M184 would be reversed by inactivation of the second
copy of patA, while inactivation of the first copy of patA would have no effect. In
contrast, if the third hypothesis is true, the antibiotic resistant phenotype should be
reversed by inactivation of either copy of patA.
To test this, an attempt was made to inactivate individual copies of patA in M184 by
transformation with a PCR amplimer of patA from M246, an R6 mutant that contains
a magellan2 minitransposon insertion in patA (Garvey and Piddock, 2008). The PCR
amplimer was generated using primers 608 and 1357, which amplify an internal region of
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patA. As the patA-specific sequences flanking the minitransposon insertion were internal
to the gene, and no upstream sequence was included, it was expected that the PCR
amplimer should recombine with equal frequency with the first and second copies of
patA. It is known that multiple recombination events can take place simultaneously in a
pneumococcal cell (Croucher et al., 2012). Therefore, to reduce the chances of recov-
ering mutants with insertions in both copies of the gene, M184 cells were transformed
with serial dilutions of the donor DNA (ranging from 1:10 to 1:106). Candidate transfor-
mants were then picked from the lowest two dilutions for which spectinomycin-resistant
colonies could be isolated. Recovered transformants were tested for the presence of the
magellan2 insertion by PCR using primer 1357, which anneals internally to patA down-
stream of the minitransposon insertion site, and primers 604 and rRNA-4, which anneal
upstream of copy one and copy two of patA, respectively.
In total, 52 candidate transformants from three separate experiments were tested for
minitransposon insertion. Unexpectedly, the minitransposon insertion was found in the
first copy of patA in all tested candidates, and no mutants were obtained with an insertion
in the second copy. A further ten transformants were tested from a transformation
where the donor DNA was not diluted, but the same result was observed. Three M184
patA1::magellan2 mutants were picked at random and retained for further experiments
(strains M508, M509 and M510; Table 2.1).
To determine the effect of the inactivation of the first copy of patA on the M184
phenotype, MICs of ciprofloxacin, norfloxacin and ethidium bromide were measured for
the three retained M184 patA1::magellan2 mutants in the presence and absence of
sodium orthovanadate (Table 4.7). All three mutants retained resistance to all three
agents, and this resistance was reversible by addition of sodium orthovanadate. The
resistance phenotype of the mutants was therefore identical to that of M184, which
suggests that the first copy of the duplicated locus is not the major source of patAB
over-expression. This observation supports hypotheses one and two, which both ascribe
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over-expression of patAB to loss of regulatory control of the second copy.
4.9.3 Measuring readthrough from the promoter of a tRNA
gene located upstream of patA copy 2
The first hypothesis suggested above suggests that duplication of the patA-spr1880
locus places the second copy of the locus under the control of the promoter of a highly-
expressed upstream gene, resulting in over-expression of the second copy of patAB.
The closest protein-coding gene upstream of the second copy of patA is the first copy
of spr1880, but gene expression analysis in section 4.9.1 showed that this gene is not
highly expressed. However, a glutamate-specific tRNA gene (tRNAGlu) located between
spr1880 and 16S rRNA in R6 is also included in the duplicated region in M184 and
the R6M184 transformants. A copy of this gene is therefore found 365 bp upstream of
the second copy of patA. In its native location, this tRNA lies upstream of the rRNA
gene locus that follows spr1880, and identical copies are also found in the same relative
position upstream of the three other copies of the rRNA genes found in S. pneumoniae.
There is also a fifth identical copy of tRNAGlu located between genes spr2040 and
spr2041. As there are five identical copies of tRNAGlu in R6, (increasing to six in M184
and the R6M184 transformants due to the duplicated genomic region), specific primers
for direct measurement of the expression of the copy of tRNAGlu associated with the
duplicated region by qRT-PCR could not be designed.
To identify putative promoters, the PPP webserver was used to scan the genomic region
between tRNAGlu and spr1889 of R6 for putative lactococcal-like Sigma A binding sites,
using Hidden Markov Models (HMMs) constructed from known lactococcal Sigma A
binding sites (Zomer et al., 2007). A promoter was predicted between 102 and 72
bp upstream of patA (-10 box: TAGAAT, -35 box TTGACA, separated by 17 bp, E-
value=0.01), confirming previous predictions (Garvey and Piddock, 2008; Wasserscheid
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Table 4.7. MICs of ciprofloxacin, norfloxacin and ethidium bromide for four R6M184
transformants in the presence and absence of eﬄux inhibitors reserpine and sodium
orthovanadate.
Cip Cip + N Nor Nor + N EtBr EtBr + N
R6 1 0.5 4 1 2 1
M184 4 1 32 2 32 1
M508 4 0.5 32 2 16 1
M509 4 1 32 2 32 1
M510 4 1 32 2 32 1
Cip, ciprofloxacin; Nor, norfloxacin; EtBr, ethidium bromide; N,
50 µM sodium orthovanadate. Bold text indicates MIC values two
or more dilutions higher than those of R6.
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et al., 2009). A promoter sequence was also predicted between 53 and 24 bp upstream of
tRNAGlu (-10 box: TATAAT, -35 box TTGACA, separated by 16 bp, E-value = 0.0058).
To test whether expression of the second copy of patA could be increased by tran-
scriptional read-through from tRNAGlu, two promoter-GFP transcriptional fusions were
constructed in a modified version of plasmid pBAV1K-T5-gfp (pBAV1K-gfp2). This plas-
mid was contructed by replacement of the T5 promoter-gfp cassette with a promoterless
gfp allele encoding an unstable version of GFP (section 2.9.1). To make the first con-
struct, a 144 bp synthesised DNA fragment (corresponding to genomic region 1865738
to 1865871 on the minus strand) that contained the predicted patA promoter region was
cloned upstream of the promoterless GFP gene in pBAV1K-gfp2 (ppatA; Figure 4.19A).
In the second construct (tRNA-ppatA), the tRNAGlu gene was inserted upstream of the
cloned patA promoter (Figure 4.19A). This was done by amplifying the duplicated tRNA
gene using primers 1892 and 1893, and cloning into the pBAV1K-gfp2-ppatA vector using
an EcoRI site encoded by primer 1893 and a naturally occurring SpeI site found 134 bp
upstream of the start of patA. Use of this naturally occuring restriction site meant that
the sequence between the tRNA gene and the patA promoter in the plasmid construct
was identical to that found between these two sequences in M184.
The two plasmid constructs and the empty pBAV1K-gfp2 vector were transformed into
R6, and cells containing plasmids were selected with 200 µg/ml kanamycin. These strains
were grown in triplicate to mid-logarithmic phase (OD600 0.5), and then one ml of each
culture was resuspended in 200 µl PBS and fluorescence was measured (Figure 4.19B).
Fluorescence from R6 cells containing pBAV1K-gfp2-ppatA plasmid was 2.4-fold higher
than from cells containing empty pBAV1K-gfp2 vector, which suggests that the up-
stream region of patA indeed contains a promoter sequence that mediates expression
of downstream genes. Addition of the tRNA gene upstream of the patA promoter
(pBAV1K-gfp2 -tRNA-ppatA) resulted in a six-fold increase in fluorescence compared to
pBAV1K-gfp2-ppatA, suggesting that transcriptional read-through from the tRNA gene
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into the second copy of patA can occur. However, the strain containing the pBAV1K-
gfp2 -tRNA-ppatA construct showed a growth defect compared to R6 and strains con-
taining the other tested constructs (generation time of 55±6 minutes for R6 containing
pBAV1K-gfp2 -tRNA-ppatA, compared to 34±1 minutes for R6 containing pBAV1K-gfp2-
ppatA).
4.10 Discussion
The genetic change causing patAB over-expression in M184 was a duplication of a 9.2
kb region of the genome, which contained the patA and patB genes (Figure 4.20). This
was unexpected, as it was originally hypothesised that patAB over-expression would
be caused by mutation of a regulatory gene. The duplication in M184 and the R6M184
transformants is novel, and represents the first time that a large adaptive gene duplication
has been observed in S. pneumoniae.
Spontaneous duplication of genomic regions has been shown to occur frequently within
bacterial populations (Anderson and Roth, 1981; Reams and Neidle, 2004; Sun et al.,
2012). Once formed, amplification of duplications can further increase gene copy number
(Andersson and Hughes, 2009). Antibiotic resistance caused by increases in copy number
of resistance determinants has been observed previously (reviewed in Sandegren and
Andersson, 2009). Examples include five-fold amplification of the blaA gene in Yersinia
enterocolitica causing β-lactam resistance (Seoane et al., 2003), four-fold amplification
of folate synthesis genes in S. agalactiae causing sulfonamide and trimethoprim resistance
(Brochet et al., 2008), and duplication of a large genomic region containing acrAB in
E. coli, causing transient multidrug resistance (Nicoloff et al., 2006, 2007). There is
considerable variation between gene duplications and amplifications involved in antibiotic
resistance in terms of the size of the region amplified, copy number, stability of the
amplification and the proposed mechanism of formation (Sandegren and Andersson,
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Figure 4.19. Measurement of transcriptional read-through from tRNAGlu using a
ppatA-gfp transcriptional fusion. (A) Organisation of promoter elements and tRNA in the
ppatA (upper) and tRNA-ppatA (lower) constructs. (B) Fluorescence of 1 ml mid-logarithmic
phase cells (resuspended in 200 µl PBS) containing empty vector, pBAV1K-gfp-ppatA or
pBAV1K-gfp-tRNA-ppatA constructs. Error bars represent the standard deviation of three
biological replicates. *, fluorescence significantly higher than from cells containing empty
vector, p<0.05, one-tailed Student’s t-test. **, fluorescence significantly higher than from
cells containing pBAV1K-gfp-ppatA, p<0.01, one-tailed Student’s t-test.
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2009).
Formation of duplications can be mediated by both RecA-dependent and RecA-independent
mechanisms (Andersson and Hughes, 2009). RecA-mediated duplication formation re-
quires regions of homology at either end of the duplicated region, such as directly re-
peated rRNA operons or IS elements (Anderson and Roth, 1981; Haack and Roth, 1995;
Lehner and Hill, 1980). RecA-dependent recombination is therefore unlikely to be the
mechanism of formation for the duplication in M184, as the duplicated region is not
flanked by repetitive elements. Two mechanisms have been proposed to explain RecA-
independent duplications (Andersson and Hughes, 2009). The first is strand-slippage dur-
ing DNA replication, and requires short regions of homology at the duplication endpoints
(Lovett et al., 1993; Trinh and Sinden, 1993). The second is illegitimate ligation of DNA
ends by DNA gyrase, which occurs by exchange of DNA gyrase subunits while they are
bound to double-stranded breaks in the DNA (Ikeda et al., 2004). This mechanism does
not require homology at the duplication end points, so is therefore the most likely mecha-
nism by which the duplication observed in M184 was formed. The sequence surrounding
the duplication endpoints in M184 does not match an experimentally-determined con-
sensus sequence of the DNA gyrase cleavage site (Leo et al., 2005). However, DNA
gyrase cleavage sites are degenerate, so this observation does not rule out involvement
of DNA gyrase in formation of the M184 duplication (Leo et al., 2005).
Following duplication of genomic regions, the copy number of duplicated regions can
be further increased by amplification, either by RecA-mediated recombination between
repeat copies, or by rolling circle replication (Andersson and Hughes, 2009). Under
appropriate selective conditions, tandem arrays of up to 200 repeats can be formed by
this mechanism, and the DNA content of the cell may be almost doubled (Andersson
et al., 1998; Tlsty et al., 1984). More commonly, in examples where gene amplification
has been linked to antibiotic resistance, tandem arrays of between two and 40 repeat
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copies have been observed (Brochet et al., 2008; Nilsson et al., 2006; Seoane et al.,
2003; Yanai et al., 2006). Further gene amplification does not appear to have occurred in
M184, or in the R6M184 transformants. The slope of the regression line fitted to M184:R6
RPKM ratios for genes inside the proposed duplicated region was approximately double
that for the genes outside of the duplicated region, and similar results were observed
for all three sequenced transformants. As the number of reads mapping to a repeated
region is expected to correlate with copy number, this strongly suggests that the copy
number of the patA–spr1880 region is no more than two. Higher level amplifications in
a small proportion of cells cannot be ruled out, however. The true distribution of copy
numbers of the repeat could be confirmed by Southern blotting.
Expression of patA and patB in M184 and the four transformants was between 100- and
1000-fold higher than in R6. This is much higher than previously reported by Garvey
and Piddock (2008). The methods used to measure patAB expression differed between
the two studies. Garvey and Piddock used comparative reverse transcription PCR (C-
RT-PCR) followed by quantification of amplimers using denaturing high-pressure liquid
chromatography, whereas the more recently developed technique of qRT-PCR was used
in the current study. Real-time PCR measures accumulation of PCR amplimers over
the whole amplification cycle, and because of this has a much larger dynamic range
than conventional PCR-based methods, such as cRT-PCR, which only quantify PCR
amplimers at the end point of the RT-PCR cycle (Schmittgen et al., 2000). This could
explain the much larger expression difference detected in this study.
The high levels of patAB transcripts observed suggested that the doubling in copy num-
ber of these genes could not fully explain their over-expression. One proposed explanation
for this was that the formation of the duplication caused dis-regulation of the expres-
sion of the second copy of the patAB genes due to the change in upstream sequence.
Supporting this hypothesis, inactivation of the first copy of patA by insertion of the
magellan2 minitransposon did not affect resistance of M184 to ciprofloxacin, norfloxacin
164
or ethidium bromide. Transposon insertions in copy two of patA could not be obtained.
This could be explained in two ways. The transposon insertion inactivates PatA by trun-
cation of the protein. While transposon insertion has been previously used successfully to
inactivate patA in wild-type strains (El Garch et al., 2010; Garvey and Piddock, 2008),
it is possible that insertion of the transposon into a gene that is being highly transcribed
might result in toxic accumulation of truncated polypeptide. Alternatively, if the second
copy of patA is being highly transcribed, then recombination of the patA::magellan2
amplimer with this locus may be physically blocked by the presence of RNA polymerase
complexes bound to the DNA. This would make recombination with the first copy of the
locus more energetically favourable than recombination with the second.
The proposed mechanism for increased expression of the second copy of patA is tran-
scriptional read-through from the tRNAGlu gene located directly upstream. Expression
of a GFP reporter was increased when the tRNA gene was inserted upstream of the
patA promoter in plasmid pBAV1K-gfp82. This demonstrates that there are no termi-
nation signals in the sequence between tRNA and patA promoter, which implies that
transcriptional read-through is possible. The increase in fluorescence when the tRNA
gene was added also suggests that, as predicted, the promoter controlling expression
of the tRNA is more transcriptionally active than the patA promoter. This is plausible
because tRNAs have a housekeeping function, and in its native location the tRNAGlu
gene is closely associated with the highly expressed rRNA locus.
However, further work will be required to definitely show co-transcription of tRNAGlu and
the second copy of patA. In particular, the increase in fluorescence from the GFP reporter
when the tRNA gene was inserted was much smaller than the observed over-expression
of patA in M184. The GFP assay used has some limitations. Firstly, the unstable GFP
used is not necessarily an ideal reporter gene, as it was taken from a plasmid used to
measure promoter activity in E. coli, and has therefore not been validated for use in S.
pneumoniae. It may have been preferable to use the GFP reporter gene used by Ruiz-
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Cruz et al (Ruiz-Cruz et al., 2010) to measure expression from various pneumococcal
promoters, as this version of GFP has been more extensively tested in S. pneumoniae.
Secondly, the growth of R6 cells containing the pBAV1K-gfp82 -tRNA-ppatA construct
was impaired relative to growth of cells containing empty vector or the ppatA construct.
This suggests that accumulation of GFP in cells contining the tRNA-ppatA construct is
having toxic effects. These two factors may prevent the GFP fluorescence assay from
being a quantitative measure of gene expression, and further optimisation of the assay
is therefore required.
Finally, to definitively conclude that upregulation of patAB is caused by transcriptional
read-through from tRNAGlu, other mechanisms of upregulation related to the duplication
of the tRNA gene would need to be ruled out. It is possible that duplication of the
tRNAGlu gene, which increases the total number of tRNAGlu genes in the genome from
five to six, could affect the cellular ratio of charged to uncharged tRNA. This might
affect expression of genes controlled by T-box regulatory mechanisms, where interaction
of uncharged tRNA with an RNA leader sequence affects transcription of the downstream
gene (Henkin, 1994). Whether a mechanism such as this could be indirectly causing
patAB upregulation in M184 remains to be investigated.
Expression of guaA, which directly follows patB, was also significantly increased in M184
and all four transformants. This over-expression has not been seen previously in studies
where the expression of this gene was measured. Over-expression of guaA was not
observed in microarray analyses of the patAB over-expressing mutant M22 (Marrer et al.,
2006a). Feng et al (2009) measured guaA expression by qRT-PCR in a linezolid resistant
mutant that over-expressed patAB, and found that guaA expression was not increased.
Expression of guaA was not measured in studies by Garvey and Piddock (2008) or by El
Garch et al (2010). It is therefore unclear whether the over-expression of guaA detected
in this study represents true co-transcription of patB and guaA, or whether increased
guaA transcript levels is due to leaky termination of patB. The expression of patB in
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M184 was much higher than in the strain analysed by Feng et al (120-fold vs 11-fold),
which could explain why leaky termination of patB was not observed in the latter study.
The relative over-expression of patA, patB and guaA in M184 and the transformants
decreased approximately exponentially across the locus, which may reflect a decrease in
the effect of the upstream tRNA as intergenic distance increases.
If co-transcription of patB and guaA was genuine, this would be interesting. GuaA
encodes a glutamine amidotransferase of the GATase II family (PFAM domain:), which
catalyse transfer of an amide group from glutamine to a variety of recipient substrates
(Raushel et al., 1999). Glutamine amidotransferases are often domains within larger
proteins, but can be encoded separately, as is the case for guaA. Glutamine amido-
transferase domains are found in CTPase enzymes, which are involved in nucleotide
biosynthesis (Weng and Zalkin, 1987). PatAB is upregulated in response to DNA dam-
age, and co-transcription of guaA with patB could provide a causal link. There is also
a small open reading frame directly downstream of guaA, spr1883. Expression of this
gene was not measured in this study, and its function is unknown, but its location next
to guaA suggests that it might be co-transcribed.
The levels of RNA corresponding to spr1886 were significantly higher than in R6 in two
out of the four R6M184 transformants. However, in both cases transcription was several
hundred-fold lower than patA and patB, and spr1886 was not over-expressed in M184 and
the remaining two R6M184 transformants. It has been suggested several times previously
that patA and patB are co-expressed (El Garch et al., 2010; Garvey and Piddock, 2008;
Marrer et al., 2006b). This hypothesis is based on the lack of reports of strains that
over-express one gene without over-expressing the other, and the observation that both
genes are upregulated together in induction experiments (El Garch et al., 2010; Marrer
et al., 2006b). However, it has not previously been shown whether patA and patB genes
are co-transcribed, or whether they are transcribed separately but co-regulated. The low
levels of transcript corresponding to spr1886 would suggest that the genes are not co-
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transcribed. If co-transcription occurred, rRNA corresponding to the patAB intergenic
region would be produced at levels equivalent to the flanking genes. Following conversion
to double-stranded cDNA, this region would be recognised by the qRT-PCR primers for
spr1886, since the qRT-PCR method used does not differentiate between strands. If patA
and patB are not co-transcribed, this is in contrast to the situation in S. suis where co-
transcription of the patAB homologues satA and satB has been shown (Escudero et al.,
2011, 2013; ?). It is not clear whether the increased transcription of spr1886 observed
in M500 and M501 is due to a genuine increase in expression of spr1886, or from leaky
termination of transcription of patA. Determination of the direction of transcription in
this region and accurate determination of transcription start sites would be required to
distinguish these two scenarios.
Genomic duplication was shown to be the cause of patAB over-expression in M184, but
was not found in another reserpine-selected mutant, M168, which was selected in the
same study that gave rise to M184 (Garvey and Piddock, 2008). The duplication was also
not found in nine tested clinical isolates that over-expressed patAB. This indicates that
duplication of the patAB region is not the only mechanism that causes over-expression of
patA and patB. Over-expression of patAB mediated by mutations in an upstream Rho-
independent terminator has been observed in linezolid resistant mutants (Billal et al.,
2011; Feng et al., 2009) and in a clinical isolate from a meningitis patient (Croucher
et al., 2013). It would be interesting to ascertain whether duplication-mediated patAB
over-expression is prevalent among patAB-over-expressing isolates, or whether it is a rare
event observed only in this particular strain. The duplication could be easily transformed
into R6 recipient cells, was originally selected by a single exposure to reserpine, and does
not appear to confer a fitness defect. These observations, taken together, imply that
formation of the duplication is not genetically difficult or energetically unfavourable,
which suggests that other examples may be found in a wider screen of patAB over-
expressing isolates. The PCR assay used to detect duplication junctions in this study
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could be expanded such that duplication junctions that are not identical to the example
in M184 could be detected. As discussed above, the duplication in M184 is associated
with very high levels of patAB expression. While no other incidences of this duplication
have been reported to date, a ciprofloxacin resistant mutant was recently described by
Lupien et al (2013) that had high patAB expression (60-fold increase compared to R6).
It is therefore possible that a similar genomic duplication might be found in this strain.
Gene duplications are often unstable and can be lost from the genome by homologous
recombination between copies of the repeats (Andersson and Hughes, 2009; Galitski and
Roth, 1997). An estimate of the stability of the patA–spr1880 duplication was calculated
by measuring the rate of loss of norfloxacin resistance from M184 and M502. The prob-
ability of loss of the duplication per cell per generation was estimated as being between
0.006 and 0.027 (Table 4.6). A range of stabilities of between 0.003 and 0.15 loss events
per cell per generation have been observed for genomic duplications in other bacteria
(Brochet et al., 2008; Sandegren and Andersson, 2009). The duplication in M184 is
therefore towards the more stable end of this range. In particular, the M184 duplication
is much more stable than the duplication of acrAB in E. coli, the only previously observed
example of duplication of an eﬄux pump (Nicoloff et al., 2006). In this strain, the 149
kb duplication carrying the acrAB genes was lost following two passages on agar plates
in the absence of naladixic acid selection. In contrast, the stability of the duplication in
M184 in this study suggests that several days of continuous exponential growth would be
required for complete loss of the duplication in the population. However, the precision of
measurement of the duplication stability was quite low, and a larger sample size would
be required to quantify duplication stability more accurately.
Before identification of the genomic duplication as the cause of patAB over-expression
in M184, several other hypotheses were investigated and rejected. It was originally
hypothesised that patAB over-expression would be caused by a point mutation in a
regulatory gene, as upregulation of eﬄux pumps caused by mutation of transcriptional
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regulators has been frequently observed in other bacteria. For example, mutations in the
local repressor AcrR or the global regulators MarR, SoxS and Rob causes over-expression
of AcrAB-TolC in clinical isolates of E. coli (Alekshun and Levy, 1997; Webber et al.,
2005).
Twenty-seven confirmed SNPs and small indels present in M184 relative to R6 were
initially identified by whole genome resequencing of M184. Transformation of R6 cells
with M184 DNA was carried out to distinguish mutations causing the phenotype from
compensatory mutations and bystander mutations, and also to determine how many
mutations might be required to confer the M184 phenotype. This whole genome trans-
formation approach was also used successfully by Billal et al (Billal et al., 2011) to
identify mutations causing linezolid resistance. This approach allowed these authors
to determine that linezolid resistance was conferred by 23S rRNA mutations, while a
mutation causing patAB over-expression relieved a fitness cost but did not contribute
towards resistance. In the study by Billal et al multiple rounds of transformation were
required to fully reconstitute the linezolid resistant phenotype. In the current study,
the genetic change conferring over-expression of patAB, which is now known to be the
patA–spr1880 duplication, was transferred in a single step, but at a lower frequency than
a spectinomycin resistance cassette. This suggested that the phenotype was not caused
by a single transversion mutation, which are transformed with high efficiency (Claverys
et al., 1983), but could have been caused by a low efficiency mutation such as a tran-
sition, a combination of more than one point mutation or, as was eventually shown, a
larger genomic rearrangement.
None of the 27 point mutations identified in M184 were shared by all four of the trans-
formants, which showed that they were not directly involved in upregulation of patAB.
The only M184 mutation that was transferred to any of the transformants was a cluster
of ten mutations in gltX (spr1881), which was found in the genome sequence of M503.
This gene is part of the duplicated region in M184 and the four transformants. The
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transfer of the gltX mutations to M503 only suggests that formation of the duplication
does not require transformation with a DNA fragment that covers the whole duplicated
locus, as otherwise the gltX mutations would have been found in all four transformants.
Reams and Neidle (Reams and Neidle, 2004) showed that transformation with DNA
fragments corresponding to junctions between duplications could induce duplication for-
mation in a wild-type Acinetobacter strain. It is likely that this is also the mechanism
of transfer of the duplication from M184 to the four transformants. The transfer of
the gltX mutations from M184 to M503 may have occurred through co-transfer of the
duplication junction and the gltX gene on the same donor DNA fragment.
The roles of the 27 mutations found in M184 have not been determined. Although
all four of the transformants over-expressed patA and patB their phenotype was not
identical to that of M184. Ethidium bromide and norfloxacin resistance was reduced to
a greater degree by sodium orthovanadate in the transformants than in M184. Three
of the transformants (M500, M501 and M503) expressed higher levels of patA and
patB than M184 (figure 4.6), but accumulated more ethidium bromide (figure 4.5).
This suggests that some of the mutations detected in M184 may be involved in either
modulating patAB expression and/or affecting ethidium bromide resistance. Growth
of M184 was attenuated compared to R6, but this growth defect was not seen in the
transformants. This implies that patAB over-expression does not confer a major fitness
defect, and suggests that the growth defect in M184 is probably caused by one of the
other mutations carried by this strain. The extra mutations possessed by M184 compared
to the transformants may be a result of the difference in selective agents used. M184 was
selected using reserpine, which has been shown to affect a variety of cellular processes
(Marrer et al., 2006b). The interaction of reserpine with the PatAB transporter is also
ambiguous. Garvey and Piddock (2008) showed that reserpine resistance in M184 was
reversed only by inactivation of patA and not patB, and in the current study it was shown
that truncation of HrcA caused reserpine resistance but not patAB over-expression. In
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contrast, the transformants generated in this study were selected using ethidium bromide
and norfloxacin, which are known substrates of PatAB. Some of the mutations in M184
may have been selected to counteract the pleiotropic effect of reserpine, so are unrelated
to over-expression of patAB.
The presence of an insertion in the genome of the laboratory stock of R6 relative to the
published R6 genome was considered as a possible explanation for why mutations causing
patAB over-expression were not initially discovered by the whole genome transformation
approach. This was considered plausible because inserted prophages have been previously
observed in S. pneumoniae (Romero et al., 2009a,b), and the distributed genome hy-
pothesis suggests that pneumococci can acquire accessory genes by transformation from
a wider pool of pneumococcal genes (Hiller et al., 2007). It has also been over ten years
since the R6 genome sequence was published, and the laboratory stock of R6 may have
evolved over that time. In particular, there was already evidence that a recombination
had occurred in the pbpX gene. Assembly of unaligned reads from M184 using Velvet
identified some non-pneumococcal sequences, including a large contig that resembled a
lytic bacteriophage associated with the dairy industry (Castro-Nallar et al., 2012). PCR
using primers specific for this phage did not yield any amplimers. While not conclusively
shown, it is likely that this phage was a contaminant of the M184 DNA preparation, pos-
sibly originating from the growth medium. Bovine and equine microsatellite sequences
were also assembled, which are also likely to have come from the rich media and horse
blood supplement used to grow the bacteria. This demonstrates the high sensitivity of
Illumina genome sequencing.
Another hypothesis that was considered to explain why mutations causing patAB expres-
sion were not initially detected by the transformation approach was that the causative
SNP was located in a repetitive region. Repetitive elements are particularly common in
pneumococcal genomes, comprising over 3% of the R6 genome (Hoskins et al., 2001).
Mapping of reads from multiple genomic locations to each repeat sequence could have
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prevented detection of a SNP. It was considered possible that mutation in a short inter-
spersed repeat could cause patAB over-expression because some short repeat elements
have been shown to affect expression of nearby genes. For example, expression of the
competence operons comAB and qsrAB is modulated by upstream BOX elements (Knut-
sen et al., 2006), and SPRITEs resemble transcriptional terminators (Croucher et al.,
2011b). However, a subset of short interspersed repeats was examined for the presence
of mutations by PCR and Sanger sequencing approach and no mutations were found.
Overall, several hypotheses were considered to explain patAB over-expression in M184
and the four R6M184 transformants. The genetic change causing patAB was ultimately
identified as a tandem duplication of a 9.2 kb region of the genome containing the
patA and patB genes. The results presented here suggest that the formation of this
duplication leads to a high level of patAB over-expression via a promoter-switching
mechanism, which has not been observed in previous examples of duplication-mediated
antibiotic resistance.
4.11 Further work
The conclusion that over-expression of patA and patB came initially from the observation
that insertional inactivation of the first copy of patA had no effect on resistance of M184
to ciprfloxacin, norfloxacin and ethidium bromide. However, inactivation of the second
copy of patA would be required to fully confirm this hypothesis, and this could not be
achieved by the transposon insertion method used here. This may be because transposon
insertion into the second copy leads to accumulation of toxic levels of truncated PatA
protein. If this is the case, inactivation patA copy two might be accomplished using a
method that completely replaces the gene with an antibiotic resistance gene, meaning
that no truncated PatA is produced. This approach was used by Boncoeur et al (2012),
who completely replaced the patA gene in R6 with a chloramphenicol resistance gene.
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Alternatively, recombination of the patA::magellan2 PCR amplimer with the first copy
of patA may have been favoured due to the presence of more transcription complexes
bound to copy two, or a difference in tertiary DNA structure in the copy two region. If
this is the case, recombination of a patA::magellan2 amplimer could be encouraged by
addition of copy two-specific upstream sequence to the donor PCR amplimer by overlap
extension PCR (Horton et al., 1989).
The proposed explanation for increased expression of the second copy of patA was tran-
scriptional read-through from a tRNAGlu gene located at the 3’ end of the duplicated
region. The GFP assay carried out in this study suggests that read-through is possible.
However, full confirmation of this hypothesis require demonstation that the tRNA and
the second copy of patA are co-transcribed. This could be shown by Northern blotting,
or by mapping of transcription start sites of patA using 5’ rapid amplification of cDNA
ends. Another way to investigate co-transcription of tRNAGlu and patA would be to
determine the whole transcriptome of M184 using RNA-Seq. This would also allow in-
vestigation of whether or not patA and patB are encoded on the same transcript, and
whether guaA and spr1883 are co-transcribed with patB.
The copy number of the duplication identified in M184 was determined to be two based
on comparison of the slopes of regression lines fitted to M184:R6 RPKM ratios for genes
located inside and outside the duplicated region. However, this does not rule out the
possibility that a subpopulation of cells may have contained higher level amplifications of
the patA–spr1880 region. The distribution of copy numbers of the patA–spr1880 region
within a population of M184 cells could be determined by Southern blotting.
In a study investigating 72 gene amplification mutants of Acinetobacter with increased
ability to grow on benzoate, certain duplication junctions were observed multiple times
(Reams and Neidle, 2004). This indicated that formation of some amplifications was
particularly favourable. Some of these common duplication junctions could be detected
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at low levels in wild-type unselected populations of cells. This suggested that these
duplications formed spontaneously within the population at a low frequency, and then
cells containing these duplications were selected by exposure to the selective condition.
The duplication in M184 could be a similar common spontaneous duplication in R6 pop-
ulations that is selected by exposure to fluoroquinolones, ethidium bromide or reserpine.
This possibility could be investigated by attempting to amplify the duplication junction
by PCR from high concentrations of R6 genomic DNA, as was done by Reams and Neidle
(2004), or by using the padlock probing method for validating low frequency genomic
rearrangements that was used in a recent study by Sun et al (2012). Additionally, a
larger collection of isolates or mutants over-expressing patA and patB could be screened
for the presence of the duplication identified in M184 to determine whether formation
of this duplication is a common mechanism of patAB over-expression.
The duplication identified in M184 and the R6M184 transformants resulted in 100-1000-
fold increases in transcription of patA and patB. However, changes in levels of PatAB
protein were not measured in this study. It would be interesting to investigate the
proportion of the patA and patB mRNA that is translated into functional protein, as it
might be expected that a 1000-fold increase in production of a particular protein would
be toxic to the cell. Protein production could be measured by Western blotting, either by
raising antibodies that recognise PatA and PatB directly, or by adding HIS- or FLAG R©-
tags (Sigma Aldrich, UK) to the protein sequences. Tagging the proteins could also
provide confirmation of the amount of protein originating from each copy of the patAB
locus, as the two copies of patA could be modified to encode different tags.
Finally, an estimate of the stability of the patA–spr1880 duplication was obtained by
monitoring the loss of norfloxacin resistance from a population. However, the 95%
confidence interval of this estimate was large as the sample size tested was quite small
(60 colonies). Repetition of this experiment using a larger number of colonies (up to
1500) would enable a more accurate determination of the half-life of the duplication
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within the population.
4.12 Key Findings
• The patAB over-expression phenotype from M184 can be readily transferred into
antibiotic susceptible R6 cells by genetic transformation
• The genetic change responsible for over-expression of patA and patB is not a point
mutation
• Over-expression of patA and patB in M184 is caused by a duplication of a 9.2 kb
region of the genome, which includes patA and patB
• The duplication confers 100-1000-fold over-expression of patAB, which is much
higher than would be expected from the increase in gene copy number alone
• The duplication was lost from the population at a rate of approximately 0.01-0.03
loss events per cell per generation, but several days of exponential growth would
be required for complete elimination from the population
• Inactivation of the first copy of patA did not affect antimicrobial resistance in
M184, suggesting that the phenotype is mainly conferred by expression from the
second copy of patAB .
• Formation of the duplication results in the location of the second copy of patA
downstream of a tRNAGlu gene
• Transcriptional read-through from the tRNA gene into the downstream patA gene
is possible
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5 Identification of mutations causing
over-expression of patAB in different genetic
backgrounds
5.1 Background
Duplication of a genomic region including the patA and patB genes was shown to be
the mechanism for patAB over-expression in M184 (Chapter 4). However, evidence of
this mechanism was not found in the set of clinical isolates screened (section 4.8.1.4)
or in M168, a second reserpine-selected laboratory mutant selected from the serotype 1
strain M4 (NCTC7465; Garvey and Piddock, 2008). It is also unclear whether the gene
amplification observed in M184 can explain the observation that patAB expression is
inducible by subinhibitory concentrations of fluoroquinolones and mitomycin C (El Garch
et al., 2010; Marrer et al., 2006b). Therefore, to identify other mechanisms of regulation
of patAB, M168 and three clinical isolates (chapter 3 and Piddock et al., 2002) were
further investigated to identify mutations causing patAB up-regulation.
5.2 Aims and hypotheses
The aim of this study was determine the genetic cause of patAB over-expression in
M168, and three clinical isolates, M101, M87 and M74, by whole genome sequencing
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of R6 transformants of these strains. It was hypothesised that recombinations would be
detected in or near genes involved in the regulation of patAB expression.
5.3 Transformation of patAB over-expression phe-
notype from M168 and three clinical isolates
into R6
The non-susceptible parental strains of the three clinical isolates are not available, so
the approach of resequencing and comparing mutant and parental strains could not be
carried out due to the lack of a suitable reference genome. The parental strain of M168
(M4) was available, but both M4 and M168 produce a mucoid capsule and therefore
extraction of sufficient good quality DNA for genome sequencing was difficult.
Instead, the natural transformation ability of the pneumococcus was exploited to transfer
DNA regions containing causative mutations into the R6 genetic background. Pneumo-
cocci can take up DNA from the environment by the competence pathway, and integrate
segments of DNA with a mean size of about four to six kb (Croucher et al., 2012). In-
corporated DNA of foreign origin can be seen as a region with a high density of SNPs
compared to the recipient genome, named recombinant sequence segments (RSSs) by
Croucher et al (2012).
This approach was chosen due to previous reports which found that there were no
mutations in the patA promoter region in M168 or the clinical isolates (Garvey and
Piddock, 2008, Garvey and Wong, unpublished data), suggesting that the mutation
causing patAB over-expression were located elsewhere in the genome.
The three clinical isolates, chosen at random from the set of isolates resistant to both
fluoroquinolones and dyes (Chapter 3), were M101, M87 and M74. The patA and patB
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genes from M101 had been sequenced previously and no mutations were reported when
compared against sequences from R6, M4 and M3 (Garvey and Wong, unpublished data).
M87 and M74 had not been previously sequenced. The patA and patB sequences from
M168 were previously reported to be identical to those from M4 (Garvey and Piddock,
2008).
Whole genomic DNA preparations extracted from M168, M101, M87 and M74 were used
to transform CSP-treated R6 cultures, and transformants over-expressing patA and patB
were selected on eight µg/ml ethidium bromide. No ethidium bromide resistant trans-
formants were isolated from a control experiment where an R6 culture was transformed
with R6 DNA, indicating that spontaneous ethidium bromide resistant transformants
were not selected under the conditions used.
5.3.1 Confirmation of patAB over-expression in transformants
If the selected transformants have successfully acquired a genetic change that causes
upregulation of patA and patB in the R6 genetic background, it would be expected
that they should have a phenotype similar to M184. This means that they should
have a reduced susceptibility to ciprofloxacin, norfloxacin and ethidium bromide, which
is reversible by addition of the ABC transporter inhibitor sodium orthovanadate. They
should also accumulate lower levels of ethidium bromide.
The minimum inhibitory concentrations of ciprofloxacin, norfloxacin and ethidium bro-
mide were determined for 19 transformants (6x R6M168, 5x R6M101, 5x R6M87 and 3x
R6M74) in the presence and absence of sodium orthovanadate, and compared to those
of R6 and M184. The MICs of each agent for the tested transformants are summarised
in Table 5.1.
The levels of intracellular accumulation of ethidium bromide were measured following in-
cubation of the transformants for 14 minutes in the presence of 25 µM ethidium bromide.
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Table 5.1. MICs of ciprofloxacin, norfloxacin and ethidium bromide for selected
R6 transformants of M168, M101, M87 and M74 in the presence and absence of
sodium orthovanadate.
Transformant Cip Cip + N Nor Nor + N EtBr EtBr + N
R6 - 1 0.5 4 1 4 <1
M184 - 4 0.5 32 2 64 <1
R6M168 1 2 0.5 16 1 32 <1
2 2 0.5 16 2 32 <1
3 2 0.5 16 2 32 <1
4 2 0.5 16 2 32 <1
5 2 0.5 16 2 32 <1
6 2 0.5 16 2 32 <1
R6M101 1 4 0.5 32 2 64 <1
2 4 0.5 32 2 64 <1
3 4 0.5 32 2 64 <1
4 4 0.5 32 2 64 <1
5 4 0.5 32 2 64 <1
R6M87 1 4 0.5 32 2 64 <1
2 4 0.5 32 2 64 <1
3 4 0.5 32 2 64 <1
4 4 0.5 16 2 64 <1
5 4 0.5 16 2 64 <1
R6M74 1 4 0.5 32 8 16 <1
2 16 0.5 128 2 16 <1
3 4 0.5 32 8 16 <1
Cip, ciprofloxacin; Nor, norfloxacin; EtBr, ethidium bromide; N, 50 µM
sodium orthovanadate. Bold text indicates MIC values that are two or
more dilutions higher than those of R6
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This experiment was carried out on two separate occasions using the same transformants
as for the MIC measurements. The level of accumulation of ethidium bromide differed
within each group of transformants (Figure 5.1). Two of six R6M168 transformants, one
of five R6M101 transformants, four of five R6M87 transformants and one of three R6M74
transformants accumulated significantly less ethidium bromide than R6 (p<0.05, pair-
wise Student’s t-test with Benjamini-Hochberg correction to control the false discovery
rate; Figure 5.1). All the tested transformants accumulated significantly more ethidium
bromide than M184 (p<0.05). For each donor strain, the transformant that accumu-
lated the lowest level of ethidium bromide was retained for further experiments; these
were named M504 (R6M168 transformant two), M505 (R6M101 transformant four), M506
(R6M87 transformant five), and M507 (R6M74 transformant two).
Expression levels of patA and patB were measured by qRT-PCR (Figure 5.2) as described
for M184 and its R6 transformants. As over-expression of guaA and spr1886 had also
been observed in some of the R6M184 transformants, the expression of these genes was
also measured (Figure 5.2). In M504, M505 and M506, transcription of patA, patB and
guaA was significantly increased compared to R6 (p<0.05, one-tailed pairwise Student’s
t-test on log(expression), with Bonferroni correction for multiple testing). Levels of
transcript corresponding to spr1886 were also significantly increased in M505 and M506
(p<0.05). Over-expression of patA varied from 3.3±0.5-fold in M504 to 6.4±1.4-fold in
M506, while over-expression of patB ranged between 3.5±0.7-fold in M504 to 8.2±1.9-
fold in M506. Unexpectedly, neither patA or patB was significantly over-expressed in
M507, the R6M74 transformant. However, guaA was significantly over-expressed in this
strain (4.2±1.6-fold, p<0.05).
Growth of the four chosen transformants in BHI broth was measured over six hours and
no significant differences in generation time were observed compared to R6.
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5.4 Whole-genome sequencing of R6 transformants
of clinical isolates
Whole genomic DNA of the transformants from the three clinical isolates and M168
was sequenced using by Illumina sequencing as described in Materials and Methods
(section 2.5.1) to give sets of 100 bp paired end reads. Theoretical coverage levels of
the 2.0 Mb R6 genome of 2856, 1756, 1453 and 2057 were achieved for R6M74, R6M101,
R6M87 and R6M168 respectively.
Read sets were assessed for quality using FastQC. All read sets had high average quality
per read. However, all reads were trimmed to 75 bp, using a Python script written by
Nick Loman, as in some of the read sets per-base quality scores dropped below 20 at
the 3’ end of the read.
Reads were mapped against the R6 genome using Bowtie2, and SNPs and small indels
relative to the reference sequence were identified using Samtools mpileup and BCFtools
(Materials and Methods, section 2.5.2). Identified SNPs were filtered to retain only
those with a Phred scaled quality score greater than 100 and a covering read depth
greater than 50. Polymorphisms that were found in the sequence of the R6 laboratory
stock (Appendix 1) were also discarded.
The total numbers of polymorphisms identified in R6M74, R6M101, R6M87 and R6M168
were 95, 668, 631 and 189 respectively, excluding SNPs shared with R6. As expected,
the polymorphisms were found in clusters, identifying regions of recombinant DNA orig-
inating from the donor strain. In all four strains, more than one distinct cluster of
polymorphisms was observed, suggesting that more than one recombination event had
occurred in each strain (figure 5.3). Clusters were defined as genomic regions for which
the average number of SNPs in a 5 kb sliding window was consistently greater than
184
two. Using this definition, four clusters were identified in R6M74, 14 in R6M101, 24 in
R6M87 and one in R6M168. Comparison of the locations of clusters between the four
strains revealed that all four contained a large cluster mapping between chromosomal
positions 1855000 and 1875000. This region is roughly centred around the patA gene
(Figure 5.4). As these overlapping clusters were found in all four transformants, it was
hypothesised that these represent the primary recombination event that conferred patAB
over-expression in the transformants. Furthermore it was postulated that the other ob-
served clusters of mutations were secondary recombinations that do not contribute to
the observed phenotype.
5.4.1 Determination of the extent of primary recombination
events
The full extent of the polymorphic clusters in the patA region, as measured from the first
polymorphism in the cluster to the last, ranged from 9.7 kb in R6M74 to 12.2 kb in R6M168.
This is larger than the average recombination sizes that have been previously reported,
which range between 2 and 6 kb (Croucher et al., 2012; Feil et al., 2000; Fox and Allen,
1964; Gurney Jr. and Fox, 1968; Lacks, 1966). However, it has been shown that a
high density of secondary recombination events can occur around a primary selected
recombination due to multiple, non-contiguous recombinations occurring simultaneously
from the same molecule of donor DNA (Croucher et al., 2012).
To investigate this, the polymorphic clusters were resolved into regions representing
putative recombination events using an approach similar to that of Croucher et al (2012).
The patA and patB nucleotide sequences from each donor strain were compared against
the RefSeq genome database using MegaBlast to determine the most closely related
genome. M101 and M74 most closely matched strains JJA and ATCC700669 (sequence
identity: 99% patA and 100% patB), M87 was closest to strain OXC141 (sequence
185
Figure 5.3. Positions of putative recombination events in genome sequences of
R6M168, R6M101, R6M87 and R6M74. Rings 1 and 2 represent positions of coding
sequences on the forward and reverse strands of the R6 genome, respectively. Positions
SNP clusters representing putative recombinations are indicated by green segments for
R6M74 (ring 3), R6M101 (ring 4), R6M87 (ring 5) and R6M168 (ring 6). A recombination
had occurred in the patAB region (indicated by the black arrow) in all four transformants.
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identity 100% for patA and patB), and M168 most closely matched 670-6B (sequence
identity: 100% for patA and patB). The regions corresponding to R6 region 1855700
to 1875200 were extracted from each of these genome sequences and aligned with the
R6 sequence and that of the corresponding transformant. At each polymorphic site in
the alignment the allele present in the transformant sequence was classified as "donor"
or "R6" based on whether it matched the donor strain sequence of the R6 sequence. A
recombinant donor segment was defined as an unbroken series of donor alleles with no
intervening R6 alleles, and the recombination sites were tentatively defined as the median
distance between the first or last donor allele of the segment and the next recipient
allele. By this method, between eight and thirteen putative recombinant segments were
identified for each transformant (Figure 5.4). However, it is possible that the sizes
of some segments may be under- or overestimated due to mis-calling of bases in low
quality regions, particularly around the spr1886 gene and in the intergenic region between
spr1889 and 1890 (mapping quality across the region is depicted in figure 5.4).
5.5 The region upstream of patA contains genetic
changes responsible for patAB over-expression
Examination of predicted primary recombinations (Figure 5.4) revealed overlapping seg-
ments in all four transformants, which mapped to a region spanning the 5’ end of the
patA gene and the 3’ end of the hexA gene. Additionally, smaller overlapping segments
mapped to two intergenic regions of the patB gene. There was also some overlap be-
tween segments mapping to guaA. This suggests that the genetic change responsible for
patAB over-expression in the four donor isolates is most likely to be localised in one of
these areas.
To investigate this, 3009 bp and 3005 bp regions encompassing patA and patB, respec-
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tively, were amplified from each transformant using primers 604 and 605 for the patA
amplimer and 606 and 607 for patB. These PCR amplimers were used to transform
R6 cells, and transformants were selected on eight µg/ml ethidium bromide. Ethidium
bromide resistant transformants were recovered from the transformation with the patA
amplimer, but not when the patB amplimer was used.
Further transformations with PCR amplimers corresponding to progressively smaller re-
gions were carried out to more precisely localise the patA mutation responsible for patAB
over-expression. The extents of these amplimers and the outcomes of transformation ex-
periments are summarised in Figure 5.5. Transformants were obtained with an amplimer
covering the 5’ half of the gene, including 600 bp upstream, generated with primers 604
and 1357, but not with an amplimer made using primers 605 and 1358 that covers the
3’ half of the genome. This was narrowed down with further transformation experiments
to a region between 1865302 and 1866325 (primers 604 and 609). For R6M101, R6M87
and R6M168, transformants were obtained using a PCR amplimer for a smaller region,
1865626 to 1865982, generated using primers 1771 and 1772. This region encompasses
the intergenic region between hexA and patA, suggesting that the cause of patAB over-
expression was a mutation in a cis-regulatory sequence. However, no transformants were
obtained using this PCR amplimer from R6M74, suggesting that the causative mutation
in this isolate lies outside of this region.
In R6M101 and R6M87, the DNA region identified as the source of patAB over-expression
contained only one mutation relative to R6 in each strain, at genomic positions 1865772
and 1865771 respectively. No mutation was initially found in this region in R6M168,
but when the raw, unfiltered SNPs were examined, a single mutation was found with
a quality score of 96 at genomic position 1865758. The mutations in all three isolates
were confirmed by PCR and Sanger sequencing of this region. The three mutations were
closely clustered within a 15 bp region, which suggests that they may disrupt a single
cis-regulatory element. A 100 bp DNA region containing these mutations was anal-
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R6M168 R6M101 R6M87 R6M74
Amplimer 1 + + + +
Amplimer 2 - - - -
Amplimer 3 + + + +
Amplimer 4 - - - -
Amplimer 5 + + + +
Amplimer 6 + + + -
Figure 5.5. Determination of the location of polymorphisms causing patAB over-
expression in R6M74, R6M101, R6M87 and R6M168. (A) Extent of PCR amplimers used
to transform R6 cells (B) Results of transformation experiments using different transfor-
mant DNA as the template for PCR. +, ethidium bromide resistant transformants isolated;
-, no ethidium bromide resistant colonies isolated.
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ysed bioinformatically to identified putative regulatory structures. The palindrome and
equicktandem tools from EMBOSS explorer (Rice et al., 2000) were used to search for
inverted or direct repeat sequences that might indicate a protein binding site. No convinc-
ing palindromic sequences (minimum length of ten bases, less than three mismatches),
or direct repeats (score >10) were found. A search against known riboswitch elements
using RibEx (Abreu-Goodger and Merino, 2005) revealed no significant matches, but did
predict a transcriptional attenuator structure between genomic positions 1865743 and
1865827 (18 to 102 bp upstream of patA), which encompasses all three identified muta-
tions. This prediction was supported by the independent prediction of a Rho-independent
terminator located between positions 1865753 and 1865774 in a set of pre-computed
Rho-independent terminator predictions for the S. pneumoniae R6 genome made by
TransTermHP (Kingsford et al., 2007).
A transcriptional attenuator is a sequence located upstream of a gene that, when tran-
scribed into RNA, can fold into two or more competing secondary structures that mod-
ulate the expression of the downstream gene by affecting the association of RNA poly-
merase with the DNA (Henkin and Yanofsky, 2002). The putative transcriptional atten-
uator upstream of patA was predicted by RibEx to consist of three overlapping parts: a
terminator, an anti-terminator and an anti-anti-terminator. Unexpectedly, however, the
patA promoter sequence that was predicted earlier (section 4.9.3) overlapped the attenu-
ator between the anti-anti-terminator loops. The mutations found in this region in trans-
formants R6M101, R6M87 and R6M168 all mapped to the predicted terminator structure.
To predict the effect that these mutations might have, the RNA secondary structure of
the terminator region from R6 was predicted using RNAfold, which is part of the Vienna
RNA package (Lorenz et al., 2011). A single stem-loop structure with a 3’ U-rich tail
was predicted, which is typical for a Rho-independent terminator (Henkin and Yanofsky,
2002). This is depicted in Figure 5.6A, along with the positions of the mutations found
in R6M101, R6M87 and R6M168. All three mutations mapped to predicted regions of base
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pairing in the terminator stem-loop. It was therefore hypothesised that the mutations in
R6M101, R6M87 and R6M168 cause patAB over-expression by disrupting the transcriptional
terminator, causing patA and patB to be constitutively expressed. When the modelled
RNA region was extended to include the whole attenuator, a second stem-loop structure
was predicted that was identical in structure to the anti-antiterminator loop suggested
by the RibEx server. Predicted energies of the wild type and mutated RNA structures
were calculated using RNAeval and are shown in Figure 5.6B.
Ethidium bromide resistance in R6M74 is not conferred by the same mechanism as in
R6M101, R6M87 and R6M168 as no mutations were found in the terminator region in this
strain. The narrowed-down region containing the causative mutation in this strain was
1864694 to 1866325, but excluding the internal region 1865626 to 1865982. Polymor-
phisms in these regions were compared against the sequence of the same region in the
closely related strain JJA. High-quality SNPs found at positions 1865339, 1865583 and
1865599 were found in both R6M74 and JJA, indicating that they are natural polymor-
phisms and are unlikely to be involved in the R6M74 phenotype. However, examination
of the raw, unfiltered SNPs in this region revealed a possible G:C to A:T mutation at
position 1865940. This had previously been filtered out as the SNP quality score was
only 25, but was confirmed to be a real polymorphism in R6M74 by PCR and sequencing.
The mutated base is in codon 836 of the hexA gene, but does not cause a change in
the protein sequence. A 600 bp region upstream of the start of patA was compared
against the Rfam database to search for matches to known functional RNA structures.
No significant matches were found.
5.6 Construction of a promoter probe plasmid
A plasmid vector was constructed to measure activity of cloned promoters by modification
of the broad host-range plasmid pBAV1K-T5-gfp (Bryksin and Matsumura, 2010). This
192
AB
wt v101 v101c v87 v87c v168 v168c
Folding Energy -10.6 -6.1 -11.9 -3.2 -8.2 -7.4 -8.8
Figure 5.6. Prediction of structure of the Rho-independent terminator upstream
of patA using RNAfold. (A) Predicted structure of the terminator. Mutations found in
R6M101, R6M87 and R6M168 sequences are indicated in red. Bases mutated to restore base
pairing in promoter probe constructs v101c, v87c and v168c are indicated in green. (B)
RNAeval prediction of free energy of folding for each terminator structure.
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vector contains a stable GFP reporter gene controlled by a constitutive T5 promoter.
This makes it ideal for applications such as monitoring the localisation of bacteria in
a host, where stable, continuous expression of GFP is required for imaging. However,
stable GFP is not suitable for promoter activity measurements as accumulation of active
GFP prevents subtle trends in GFP expression throughout the growth cycle from being
observed. Furthermore, in a promoter probe plasmid, GFP expression should be solely
under the control of the tested promoter, meaning that the T5 promoter in pBAV1K-
T5-gfp should be removed.
To fulfil these requirements, the T5-gfp cassette was replaced with a promoterless gfp
gene from plasmid pMW82 (Lawler et al., 2013), as described in section 2.9.1. The
replacement gfp gene encodes an unstable version of GFP, and includes a 5’ EcoRI-XbaI
cloning site into which test promoters can be inserted. The new vector was named
pBAV1K-gfp82.
To confirm that GFP was not expressed from pBAV1K-gfp82 in the absence of a cloned
test promoter, for example due to read-through from the kanamycin resistance gene
into the gfp gene, cultures of R6 and R6 containing pBAV1K-gfp82 were grown and
fluorescence of a cell sample was measured at early and late logarithmic phase and at
stationary phase. No significant differences in fluorescence were observed between R6
with and without pBAV1K-gfp82 at any stage of growth.
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5.7 Measuring GFP expression from patA promoter
regions containing mutated and complemented
transcriptional attenuators
To test whether mutations in the terminator region found upstream of patA lead to
increased gene expression, the patA promoter and attenuator sequences were cloned into
pBAV1K-gfp82 and the effect of the terminator mutations found in R6M101, R6M87 and
R6M168 on GFP expression was measured. To do this, seven variant DNA oligonucleotides
were synthesised by GeneArt that corresponded to a 134 bp region of the upstream
sequence of patA, excluding the Shine-Dalgarno sequence (positions -6 to -11 from
the patA start codon), with added restriction sites (5’ EcoRI site and 3’ XbaI site) for
cloning. The first synthesised oligonucleotide corresponded to the sequence of this region
in R6 and the vector containing this sequence was named pBAV1K-gfp82wt throughout
the following experiments. The remaining six oligonucleotides were mutated as follows
(depicted in Figure 5.6A). Oligonucleotides v101, v87 and v168 contained mutations
corresponding to the mutations identified in the terminator structure in R6M101, R6M87
and R6M168, respectively. Oligonucleotides v101c, v87c and v168c were constructed by
mutating the base that is predicted to pair with the mutated base in each strain, as
determined by the RNAfold model, to the appropriate base such that base pairing in the
stem-loop should be restored. Predicted energies of the RNA structures with restored
base pairing are shown in Figure 5.6B.
The resulting pBAV1K-gfp82 constructs were transformed into R6 cells. A preliminary
attempt was made to measure fluorescence from one ml samples of logarithmic phase
cells resuspended in 200 µl PBS, as described for ppatA and tRNA-ppatA constructs in
section 4.9.3. To assess the degree of variation in replicate fluorescence measurements
in the FluoStar Optima plate reader, resuspended cells for three biological replicates
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of each culture were added to a microtitre tray, and fluorescence was measured from
the same samples three times in quick succession, with five seconds of shaking between
each reading. Considerable variation was observed between replicate measurements of
the same sample (Figure 5.7). This implied that there was background variation in
the fluorescence measurements made by the FluoStar Optima that was large enough to
obscure putative differences in fluorescence between samples. To allow smoothing of
fluorescence measurements to distinguish genuine signal from background noise, it was
decided to measure fluorescence continuously throughout growth of strains containing
each construct. This also allowed investigation of differences in relative expression of GFP
from the patA promoter in different phases of growth. To do this, cultures containing
pBAV1K-gfp82wt, v101, v101c, v87, v87c, v168 or v168c were grown in triplicate in BHI
broth in a microtitre tray and simultaneous fluorescence and absorbance measurements
were taken using a Fluostar Optima plate reader. No significant differences in growth
kinetics were identified between any of the strains (Figures 5.8, 5.9 and 5.10, dashed
lines).
Cells containing the pBAV1K-gfp82v101 construct showed a consistently higher level
of fluorescence than that of the pBAV1K-gfp82wt construct from two hours of growth
(mid-logarithmic phase) onwards (Figure 5.8). From the pBAV1K-gfp82v101c con-
struct, where the corresponding base in the terminator structure had been mutated
to restore base pairing, fluorescence was consistently lower than that of the wild type
construct (Figure 5.8). Cells containing the R6M87 and R6M168 promoter constructs
also showed higher levels of fluorescence than wild type from two hours onwards (Fig-
ures 5.9 and 5.10). However, for these attenuator variants, mutation of the opposing
base in the predicted terminator structure did not result in reduced fluorescence. In
fact, the pBAV1K-gfp82v87c and pBAV1K-gfp82v168c constructs produced consistently
higher levels of fluorescence than pBAV1K-gfp82v87 and pBAV1K-gfp82v168, respec-
tively (Figures 5.9 and 5.10).
196
Figure 5.7. Variation in endpoint fluorecence measurements from 1 ml R6 cells
containing pBAV1K-gfp2-ppatA constructs resuspended in 200 µl PBS. Coloured
points represent independent biological replicate measurements for each construct. Error
bars represent the standard deviation of three technical replicate measurements.
197
F
ig
ur
e
5.
8.
F
lu
or
es
ce
nc
e
fr
om
pB
AV
1K
-g
fp
-v
10
1
an
d
pB
AV
1K
-g
fp
-v
10
1c
tr
an
sc
ri
pt
io
na
l
fu
si
on
s
du
ri
ng
gr
ow
th
in
B
H
I
br
ot
h.
Fl
uo
re
sc
en
ce
(s
ol
id
lin
es
)
an
d
ab
so
rb
an
ce
at
60
0
nm
(d
as
he
d
lin
es
)
w
er
e
m
ea
su
re
d
si
m
ul
ta
ne
ou
sl
y
fr
om
gr
ow
in
g
cu
ltu
re
s
of
R
6
co
nt
ai
ni
ng
em
pt
y
pB
AV
1K
-g
fp
82
ve
ct
or
,
or
th
e
[p
at
A
pr
om
ot
er
co
ns
tr
uc
ts
w
t
,
v1
01
or
v1
01
c
.
Po
in
ts
an
d
er
ro
r
ba
rs
re
pr
es
en
t
av
er
ag
e
an
d
st
an
da
rd
de
vi
at
io
n
of
flu
or
es
ce
nc
e
fr
om
th
re
e
bi
ol
og
ic
al
re
pl
ic
at
es
.
So
lid
lin
es
re
pr
es
en
t
a
sm
oo
th
ed
av
er
ag
e
of
flu
or
es
ce
nc
e
re
ad
in
gs
ov
er
a
15
m
in
ut
e
w
in
do
w
.
198
F
ig
ur
e
5.
9.
F
lu
or
es
ce
nc
e
fr
om
pB
AV
1K
-g
fp
-v
87
an
d
pB
AV
1K
-g
fp
-v
87
c
tr
an
sc
ri
pt
io
na
l
fu
si
on
s
du
ri
ng
gr
ow
th
in
B
H
I
br
ot
h.
Fl
uo
re
sc
en
ce
(s
ol
id
lin
es
)
an
d
ab
so
rb
an
ce
at
60
0
nm
(d
as
he
d
lin
es
)
w
er
e
m
ea
su
re
d
si
m
ul
ta
ne
ou
sl
y
fr
om
gr
ow
in
g
cu
ltu
re
s
of
R
6
co
nt
ai
ni
ng
em
pt
y
pB
AV
1K
-g
fp
82
ve
ct
or
,
or
th
e
[p
at
A
pr
om
ot
er
co
ns
tr
uc
ts
w
t
,
v8
7
or
v8
7c
.
Po
in
ts
an
d
er
ro
r
ba
rs
re
pr
es
en
t
av
er
ag
e
an
d
st
an
da
rd
de
vi
at
io
n
of
flu
or
es
ce
nc
e
fr
om
th
re
e
bi
ol
og
ic
al
re
pl
ic
at
es
.
So
lid
lin
es
re
pr
es
en
t
a
sm
oo
th
ed
av
er
ag
e
of
flu
or
es
ce
nc
e
re
ad
in
gs
ov
er
a
15
m
in
ut
e
w
in
do
w
.
199
F
ig
ur
e
5.
10
.
F
lu
or
es
ce
nc
e
fr
om
pB
AV
1K
-g
fp
-v
16
8
an
d
pB
AV
1K
-g
fp
-v
16
8c
tr
an
sc
ri
pt
io
na
l
fu
si
on
s
du
ri
ng
gr
ow
th
in
B
H
I
br
ot
h.
Fl
uo
re
sc
en
ce
(s
ol
id
lin
es
)
an
d
ab
so
rb
an
ce
at
60
0
nm
(d
as
he
d
lin
es
)
w
er
e
m
ea
su
re
d
si
m
ul
ta
ne
ou
sl
y
fr
om
gr
ow
in
g
cu
ltu
re
s
of
R
6
co
nt
ai
ni
ng
em
pt
y
pB
AV
1K
-g
fp
82
ve
ct
or
,
or
th
e
[p
at
A
pr
om
ot
er
co
ns
tr
uc
ts
w
t
,
v1
68
or
v1
68
c
.
Po
in
ts
an
d
er
ro
r
ba
rs
re
pr
es
en
t
av
er
ag
e
an
d
st
an
da
rd
de
vi
at
io
n
of
flu
or
es
ce
nc
e
fr
om
th
re
e
bi
ol
og
ic
al
re
pl
ic
at
es
.
So
lid
lin
es
re
pr
es
en
t
a
sm
oo
th
ed
av
er
ag
e
of
flu
or
es
ce
nc
e
re
ad
in
gs
ov
er
a
15
m
in
ut
e
w
in
do
w
.
200
To determine whether relative expression of GFP per cell differed at different stages of
growth, values of fluorescence divided by optical density were averaged over 20 minute
windows centered on two hours (mid-logarithmic phase), three hours (late-logarithmic
phase) and five hours (stationary phase) (Figure 5.11). The fluorescence of each strain
relative to its optical density was consistent across these different stages of growth.
This suggests that GFP production from these constructs occurs at a consistent rate
and is not up- or downregulated in particular growth phases, meaning that fluorescence
is proportional to the cell density. This analysis also showed that fluorescence from
construct pBAV1K-gfp82v101 was significantly higher than that of wild type construct
in late-logarithmic, stationary and late-stationary phases of growth (p<0.05, one-tailed
Student’s t-test with Bonferroni correction for multiple testing). The v168 and v168c
constructs both produced higher levels of fluorescence than wild type in all the tested
growth phases (p<0.05). The v101c constructed fluoresced at a significantly lower level
than R6 in all tested growth phases (p<0.05).
5.8 Discussion
Genetic changes causing over-expression of patA and patB in three clinical isolates and
the laboratory mutant M168 were successfully transferred into the R6 genetic background
by whole genome transformation. In all four of the tested transformants a recombination
had occurred that affected the genomic region encompassing patA and patB. In three
of the transformants the mutation causing patAB over-expression was localised to a
Rho-independent terminator sequence directly upstream of patA. Different mutations
affecting this structure have been previously observed in other isolates over-expressing
patAB (Billal et al., 2011; Croucher et al., 2013)
In the four isolates investigated here, mutations causing upregulation of patAB were
identified by sequencing R6 transformed with genomic DNA from the isolates, rather
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than sequencing the isolates directly. The main advantage of this approach was that all
the transformants could be compared to a common reference genome and regions where
recombination had occurred could be readily identified due to the presence of clusters of
SNPs (Croucher et al., 2012). For the three clinical isolates, isogenic drug susceptible
parental strains were not available for comparison. Unless the isolates were very closely
related to a previously sequenced genome, sequencing directly could have resulted in
identifying large of polymorphisms, which would have obscured SNPs related to the in-
vestigated phenotype. Identifying recombinant regions in R6 transformants significantly
narrowed down mutations causing the phenotype to a smaller area of the genome. Al-
though the eventual conclusion of this analysis was that the causative mutations were
associated with the patAB locus itself, if this had not been the case, the method used
here could have identified recombinant DNA segments anywhere in the genome.
The patAB over-expression phenotype was transferred from all four isolates into R6 by
a single round of transformation. However, variation was observed in the phenotypes
of the selected ethidium bromide resistant transformants. Several transformants did
not accumulate significantly lower levels of ethidium bromide than R6, although their
ethidium bromide MICs were elevated. Also, the MIC of norfloxacin for the R6M74 that
was picked as M507 was two dilutions higher than for the other two tested transformants.
Transformation with DNA of foreign origin may result in a higher frequency of selection
of spontaneous ethidium bromide resistant mutants than transformation with R6 DNA,
due to secondary recombinations elsewhere in the genome. This could have been tested
by using M4 DNA as the negative control for transformation experiments instead of R6
DNA. The frequency of occurence of secondary recombinations could also be reduced
by transforming with a lower concentration of DNA (Croucher et al., 2012).
Over-expression of patAB was confirmed in three of the four transformants. The R6M74
transformant M507 did not significantly over-express patA and patB, but transcription
of guaA was significantly increased. The reasons for this are unclear. However, the MICs
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of norfloxacin and ciprofloxacin were unusually high for M507 compared to all the other
tested transformants (Table 5.1). It is therefore possible that this particular transformant
has acquired a secondary mutation in addition to the during the transformation process
that modulates patAB expression and increases norfloxacin resistance. Alternatively, it
may be a spurious multidrug resistant mutant selected by exposure to ethidium bromide.
In the other three tested transformants, patA and patB were expressed at levels three-
to eight-fold higher than in R6. This over-expression is much lower than that observed
in R6M184 transformants (section 4.9.1).
Three out of four of the transformants contained more than one recombinant region.
Four recombinations were observed in R6M74, 14 in R6M101 and 24 in R6M87. This
observation is consistent with previous work by Croucher et al (2012), which showed
that several recombination events can occur simultaneously in the same cell. In the
R6M168 transformant, the single observed recombination affected a genomic region from
approximately 1856000 to 1868000, which includes the patAB genes. The remaining
three transformants all contained a recombination that overlapped with this region,
which suggested that this was the primary recombination causing the ethidium bromide
resistance phenotype in all four transformants. This was confirmed by the ability of
PCR amplimers from this region to confer ethidium bromide when transformed into R6.
Interestingly, transformation of R6 with patA amplimers from M507 (R6M74 produced
ethidium bromide resistant transformants, despite qRT-PCR results that suggested that
M507 did not over-express patA and patB. This could indicate that a secondary mutation
has occurred in M507 that modulates patAB expression, but the original mutation still
exists and can cause patAB upregulation when transferred to another strain.
The mutations causing patAB over-expression in R6M168, R6M101 and R6M87 were lo-
calised to a putative Rho-independent terminator upstream of patA by transformation
of R6 with PCR amplimers progressively decreasing in size. Rho independent transcrip-
tional terminators consist of an RNA stem-loop structure that arrests the transcription
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complex, followed by a uracil-rich tail that promotes dissociation of the polymerase from
the DNA (Gusarov and Nudler, 1999). Rho-independent termination is predominant over
Rho-dependent termination in Gram-positive bacteria (Washburn et al., 2001). This is
particularly true in S. pneumoniae, which does not contain a homologue of the Rho
protein (Opperman and Richardson, 1994). The terminator directly upstream of patA
may act to prevent transcriptional read-through into patA from the upstream hexA gene.
Alternatively, it could form part of a regulated transcriptional attenuator structure.
The effect of terminator mutation on downstream gene expression were investigated by
transcriptional fusion of the predicted patA promoter, combined with wild-type or mu-
tated terminator sequences, with GFP in the pBAV1K-gfp82 plasmid. All three mutant
terminators allowed higher levels of expression of GFP than the wild type terminator
during all phases of growth. However, when the predicted base pairing of the terminator
was restored by mutation of the opposing base in the stem-loop, GFP expression was not
reduced from two of the three constructs (v168c and v87c). In contrast, GFP expression
from the v101c construct was significantly lower in all growth phases than from the wild
type construct, suggesting that repression was restored to a greater extent than in the
wild type attenuator. These observations could be explained by the difference in strength
between AT and GC base pairs. In the complemented R6M101 attenuator, the original AT
base pairing interaction was replaced with a stronger CG base pair, which could result
in higher stability. In contrast, in the complemented R6M87 and R6M168 attenuators,
strong CG base pairs were replaced by weaker TA base pairs, which may not have been
sufficient to restore the terminator structure. Also, the mutated base pair in the v168
and v168c terminators was located adjacent to an unpaired base, whereas the mutated
base pair in v101 and v101c was in the centre of a helix. The presence of unpaired bases
next to the mutated bases in v168c could mean that the base pairing interactions formed
are different from those naively predicted from the wild type terminator structure.
The GFP fusion vector used to monitor expression from the patA promoter in combina-
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tion was the same as that used to measure read-through from tRNAGlu into patA in M184
(section 4.9.3). As discussed in Chapter 4, there are some limitations to this approach.
The main limitation is that the GFP allele from pMW82 has not been validated for
use in S. pneumoniae. The maximum fluorescence observed from the constructs in this
study was approximately 4,500 fluorescence units (measured from broth without blank
correction), whereas fluorescence values up to ten-fold higher have been observed using
the same reporter gene in S. Typhimurium in the same laboratory (Lawler et al., 2013).
This suggests that this GFP may not function optimally in S. pneumoniae, limiting the
sensitivity of the assay.
Fluorescence from the terminator constructs was measured during growth in BHI broth
over several hours, instead of taking single endpoint fluorescence measurements as was
done for the ppatA and tRNA-pppatA constructs in the previous chapter (section 4.9.3).
This approach was taken as a preliminary experiment suggested that there was consid-
erable variation in three fluorescence readings taken in quick succession from the same
sample of cells (Figure 5.7). The differences in fluorescence between wild-type and mu-
tant terminator constructs were less pronounced than between ppatA and tRNA-ppatA
(section 4.9.3), which meant that the large signal to noise ratio had a greater effect on
comparisons between constructs. Measuring fluorescence at regular intervals over the
whole growth cycle allowed smoothing of the data, allowing trends representing genuine
differences in fluorescence between constructs to be distinguished from the background
variation. No differences in growth were observed between strains carrying any of the
tested constructs, suggesting that the levels of GFP produced by these constructs were
not toxic.
The Rho-independent terminator upstream of patA was predicted by RibEx (Abreu-
Goodger and Merino, 2005) to form part of a transcriptional attenuator. Transcriptional
attenuation, defined as the premature termination of the elongation phase of transcrip-
tion, is an important regulatory strategy in bacteria. Attenuators are conserved RNA
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structures in the leader sequence of regulated genes that can fold into at least two differ-
ent confirmations, one of which is a Rho-independent terminator (Henkin and Yanofsky,
2002). The simplest, and most common, attenuator structure is an RNA sequence that
can fold into two mutually exclusive stem-loops, one of which is a terminator. The alter-
native stem-loop of which is an anti-terminator that permits passage of RNA polymerase
and prevents formation of the terminator structure (Henkin and Yanofsky, 2002). The
attenuator structure predicted upstream of patA consisted of this basic structure, with
the addition of a third, anti-anti-terminator stem-loop.
Transcriptional attenuation is conserved throughout all bacteria, but is particularly com-
mon in the Firmicutes, where 2.6% of genes are controlled by transcriptional attenuation,
compared to 1.6% bacteria in general (Naville and Gautheret, 2010a). Expression of a
gene downstream of a transcriptional attenuator is regulated by cellular signals that se-
lectively stabilise or destabilise one of the conformations of the attenuator (Henkin and
Yanofsky, 2002). A variety of different sensory mechanisms have been identified. For
example, riboswitches sense small metabolites using a conserved sensory domain that
folds into a complex secondary structure (Coppins et al., 2007; Dambach and Winkler,
2009; Vitreschak et al., 2004). A variety of metabolites can be sensed by riboswitches,
including purines, glycine, flavin mononucleotide and S-adenosyl methionine (Epshtein
et al., 2003; Mandal and Breaker, 2004; Mandal et al., 2004; McDaniel et al., 2003;
Mironov et al., 2002; Winkler et al., 2002, 2003). Similarly, T-boxes encode structured
RNA leader sequences, and these fold into a secondary structure that responds to un-
charged tRNAs (Grundy and Henkin, 1993; Grundy et al., 2002). Some attenuators are
regulated in trans by an anti-termination protein, which either stabilises an antitermi-
nator structure or prevents its formation (Amster-Choder, 2005; Bonner et al., 2001).
Transcriptional attenuation can also be mediated by a ribosome-dependent mechanism,
where a ribosome will stall at a leader sequence enriched in codons for a particular
amino acid, when levels of that amino acid are low, and prevent terminator formation
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(Vitreschak et al., 2004).
In the last decade there have been several studies that have attempted to computationally
detect the full complement of genes controlled by transcriptional attenuation in order to
identify regulatory signals. The two most comprehensive were performed by Merino and
Yanofsky (2005) and Naville and Gautheret (2010b). Merino and Yanofsky searched 180
completed bacterial genomes for sequences containing mutually exclusive RNA stem-
loop structures, and grouped the downstream genes based on their classification in the
clusters of orthologous genes (COG) database. In the COG1132 family of ABC-type
multidrug transport systems, putative transcriptional attenuators were found upstream
of 153 of 302 members, including patA in S. pneumoniae R6. The predicted attenuator
sequence was identical to that predicted in this study, although this is unsurprising as
the algorithm used to detect transcriptional attenuators is identical to that implemented
in the RibEx webserver (Abreu-Goodger and Merino, 2005; Merino and Yanofsky, 2005).
However, no predictions were made by Merino and Yanofsky as to what might regulate
the attenuator. In a similar study by Naville and Gautheret the patA transcriptional
attenuator was not identified. A different algorithm was used to detect attenuators
in this study, which was based on sequence similarity to a pre-computed profile of a
Rho-independent terminator, instead of prediction of RNA secondary structure.
Riboswitches and T-boxes have conserved structures due to structural constraints re-
quired to bind metabolites and tRNAs (Vitreschak et al., 2003, 2008). They are also
relatively large (100-200 nt for riboswitches and 300 nt for T-boxes), so are usually char-
acterised by long 5’ untranslated regions upstream of genes (Barrick et al., 2004; Grundy
and Henkin, 1993). The upstream sequence of patA did not match any known RNA
structures in the Rfam database (Griffiths-Jones et al., 2005), and the intergenic region
between hexA and patA is only 147 nt. Taken together, these observations suggest that
this transcriptional attenuator is not a riboswitch or T-box. If the putative attenuator
controls patAB expression, it could be regulated in trans by a protein factor that binds
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to the anti-anti-terminator. This has been observed previously for the pyr operon in B.
subtilis, which encodes genes involved in uracil uptake and biosynthesis (Bonner et al.,
2001). When cellular levels of UMP are high, the PyrR anti-termination factor represses
the operon by binding to the anti-anti-terminator loops of three attenuators distributed
throughout the operon. PyrR binding is reduced when UMP levels decrease, promot-
ing formation of the anti-terminator, which is thermodynamically more stable than the
terminator loop.
However, the hypothesis that expression of patA is regulated by a transcriptional attenu-
ator is not supported by the predicted position of the patA promoter, which is postulated
to be located within the predicted attenuator overlapping the anti-anti-terminator and
anti-terminator loops. Transcription from this promoter precludes the attenuator from
regulating transcription as the anti-anti-terminator and anti-terminator loops will not be
transcribed.
There are several possible explanations for this observation:
1. The patA promoter prediction may be inaccurate. However, the prediction made
by PPP (section 4.9.3) is supported by predictions from two other bacterial pro-
moter prediction webservers, BPROM (Softberry Inc., NY, USA) and PePPER
(de Jong et al., 2012). This gives weight to the hypothesis that it is the most
likely promoter sequence and not a spurious prediction from a single piece of soft-
ware. Furthermore, there must be a valid promoter in the DNA regions cloned
into pBAV1K-gfp82, otherwise GFP expression would not have been observed,
regardless of the structure of the transcriptional terminator.
2. Alternatively, the attenuator prediction may be a false positive. The presence of
the Rho-independent terminator was detected by RibEx and TransTermHP, which
use the same underlying algorithm for prediction (Abreu-Goodger and Merino,
2005). However, the attenuator was not predicted by the method used in the
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genome-wide study be Naville and Gautheret which uses the algorithms from the
attenuator prediction program ARNold (Naville et al., 2011).
3. Another possibility is that there might be a second patA promoter further up-
stream of the patA gene. The promoter located close to the patA start codon
may control basal expression, while expression from the hypothetical alternative
promoter could be inducible via the transcriptional attenuator. The nearest pro-
moter detected in the PPP analysis was 3.2 kb upstream of patA. However, Merino
and Yanofsky predicted a possible promoter sequence 232 bp upstream of patA,
within the hexA gene (Merino and Yanofsky, 2005, supplementary data). Presum-
ably, this prediction was made for the DNA sequence within a certain distance
of the predicted attenuator, with the attenuator structure itself being excluded.
However, the authors do not provide details of the promoter prediction algorithm
used. This predicted promoter had a -35 box sequence of TTGATA and a -10
box sequence of TATCCT, separated by 18 bp. Inducible transcription from an
alternative promoter located within an upstream gene was recently observed for
the cbpA gene in E. coli (Chintakayala et al., 2013). In this case, expression of
cbpA was repressed during exponential phase growth by binding of the nucleoid
protein Fis, which blocked transcription from the upstream promoter. Expression
of cbpA was then increased in stationary phase, due to reduction in concentration
of Fis. It is possible that a similar mechanism may operate to control expression
of patA, mediated by attenuation of transcription from the predicted alternative
promoter within hexA.
4. Alternatively, the attenuator may regulate read-through into the patA gene from
the hexA gene. If this were true, basal transcription of patA could be mediated
transcription from the predicted patA promoter and inducible expression could
be mediated by repression of termination between hexA and patA mediated by
the transcriptional attenuator. This hypothesis may also explain why the mutation
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found in R6M74, a synonymous SNP towards the 3’ end of hexA, potentially affects
expression of patA, if it alters transcription from the end of the hexA gene.
5. Finally, the predicted attenuator may be real, but could be a non-functional evo-
lutionary relic. The genomic context of the patA gene is not conserved in other
Streptococci (Escudero et al., 2011; Garvey and Piddock, 2008), and the presence
of the spr1886 degenerate transposase gene suggests that a genomic rearrange-
ment has occurred in this region. It is possible that the attenuator conferred
inducible expression of a downstream gene in a previous context, but is now non-
functional due to loss of an upstream promoter. Evidence of acquisition, loss and
switching of attenuators upstream of some families of genes throughout evolution
was reported in both previously discussed genome-wide studies of transcriptional
attenuation (Merino and Yanofsky, 2005; Naville and Gautheret, 2010b).
However, to distinguish between these possibilities, further work will be required to
accurately map patA transcriptional start sites.
5.9 Further Work
The sensitivity of the GFP assay used in this work was limited by the low fluorescence
in S. pneumoniae of the version of GFP used. Better differentiation between levels of
reporter expression from the contructs tested here could be achieved by optimisation of
this assay. This could provide a high-throughput method to measure inducible expression
of patA, as has been done for ramA expression using the pMW82 reporter in Salmonella
(Lawler et al., 2013). Optimisation of gfp fluorescence in S. pneumoniae could be
achieved by using an alternative GFP allele, which may produce higher fluorescence,
such as the GFP variant used by Ruiz-Cruz et al (Ruiz-Cruz et al., 2010) in a different
S. pneumoniae reporter plasmid. Alternatively, the gfp gene could be replaced with a
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luciferase operon, for example from pBAV1K-T5-lux (Bryksin and Matsumura, 2010).
BHI broth emits a high level of background fluorescence at the wavelengths used to
detect GFP fluorescence, but does not auto-luminesce. Using luciferase as a reporter
instead of GFP would therefore be an advantage for assays involving growth of strains
in broth, as it would reduce background fluorescence.
A putative transcriptional attenuator was detected upstream of patA but it has not
been shown whether this can control inducible expression of patA in response to fluoro-
quinolones. This could be tested by cloning larger fragments of the upstream sequence
of patA into an improved version of the reporter plasmid, and measuring changes in
GFP/luciferase production in response to sub-MIC concentrations of fluoroquinolones.
Cloned fragments should include either the putative alternative patA promoter located
within the hexA gene, or the whole hexA gene sequence, to determine whether regulated
expression of patA is mediated by increased read-through from hexA or by expression
from an alternative promoter.
To further investigate inducible expression of patA potentially mediated by the tran-
scriptional attenuator, the exact location of transcription start sites for patA need to
be experimentally verified. Transcription start sites could be determined using RNAseq.
The advantages of RNAseq are that multiple transcription start sites can be visualised,
transcription from each DNA strand can be investigated separately, and data relating
to the rest of the transcriptome collected during the experiment can be used to answer
other biological questions. Alternatively, patA transcription start sites could be investi-
gated in isolation by carrying out 5’ rapid amplification of cDNA ends, mRNA primer
extension assays (Lloyd et al., 2008) or DNA footprinting of RNA polymerase binding
sites (Singh and Grainger, 2013).
The origins of the putative transcriptional attenuator upstream of patA could also be
further investigated by determining the phylogeny of the patA and patB genes, as it has
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been previously observed that the genomic context of these genes is different in other
streptococci (Escudero et al., 2011; Garvey and Piddock, 2008).
Finally, it was observed that, when R6 was transformed with DNA from clinical isolates
that over-expressed patAB, not all of the selected ethidium bromide resistant transfor-
mants showed a phenotype typical of patAB over-expression. It would be interesting
to determine the genome sequences of these transformants to find the cause of their
ethidium bromide resistance.
5.10 Key Findings
• Over-expression of patAB could be transferred to R6 by transformation with whole
genomic DNA from three clinical isolates and a laboratory mutant from a non-R6
genetic background
• Expression of patAB in the transformants was up to eight-fold higher than R6,
which was much lower than that observed in M184
• Regions where recombination had occurred between recipient and donor DNA in
the transformants could be readily identified from Illumina sequencing data by
defining clusters of SNPs
• In all four investigated transformants a primary recombination had occurred in the
patAB region of the genome
• In three of the transformants, other, secondary recombination events had occurred
throughout the genome
• Mutations in a Rho-independent transcriptional terminator upstream of patA caused
over-expression of patA and patB in three out of four transformants
• This terminator structure may be part of a transcriptional attenuator that could
213
explain inducible expression of patAB
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6 Overall Discussion
The two main aims of this study were to establish the role of over-expression of patAB
in fluoroquinolone resistance in clinical isolates, and to identify how expression of patA
and patB is controlled.
The first of these aims was accomplished, with a strong association shown between over-
expression of patAB and cross-resistance to both fluoroquinolones and dyes in clinical
isolates (Chapter 3). Similar results have been observed in fluoroquinolone resistant
clinical isolates investigated in other studies, two by El Garch et al (2010) and one by
Lupien et al (2013). However, to date, patAB over-expression has not been investigated
in any larger screening studies. Some isolates in the set investigated had phenotypes that
did not fit the general pattern. In particular, one isolate was observed which expressed
low levels of patAB, yet was resistant to fluoroquinolones and dyes and accumulated low
levels of Hoechst 33342. As discussed previously (section 3.4), this could be explained
by expression of a different eﬄux pump in this isolate, such as PmrA or DinF (Gill et al.,
1999; Tocci et al., 2013).
The second aim of this study was to identify how transcription of patAB is controlled.
It was postulated that there is a transcriptional regulator of patAB expression because
induction of transcription of patAB had been observed following exposure to fluoro-
quinolone antibiotics and mitomycin C (El Garch et al., 2010; Marrer et al., 2006a).
This led to the hypothesis that patAB is upregulated as part of a response to DNA
damage (El Garch et al., 2010); subsequent studies have also implicated PatAB in tol-
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erance of high pH (van Opijnen and Camilli, 2012), meningitis (Croucher et al., 2013)
and alleviating the fitness cost of linezolid resistance (Billal et al., 2011). It has been
well established that multidrug eﬄux pumps in other bacteria have diverse functions
beyond antibiotic transport (Piddock, 2006b), and for several, particularly in E. coli and
Salmonella spp., complex regulatory networks controlling eﬄux pump expression have
been elucidated (Nishino et al., 2009). Knowledge of the regulatory network control-
ling an eﬄux pump can provide insight into its physiological role. For instance, the
MacAB ABC transporter in Salmonella is co-regulated with many other genes involved
in virulence under the control of the master regulator PhoPQ (Zwir et al., 2005). How-
ever, no direct regulators of patAB expression had been identified prior to this study.
Several global regulators have been identifed in S. pneumoniae such as StkP (Saskova
et al., 2007), CiaR (Halfmann et al., 2007) and CodY (Hendriksen et al., 2008). The
effects of inactivation of these regulators on the pneumococcal transcriptome have been
investigated, but patAB was not represented in any of the indentified putative regulons.
In this study, the approach used to identify putative regulators of patAB was to sequence
the genomes of strains with constitutive over-expression of patAB and identify causative
mutations. Constitutive over-expression of eﬄux pumps is commonly associated with
mutations in their regulators. There are many examples of this in both laboratory
selected mutants and clinical isolates. For example, loss of function mutations in AcrR
and RamR, and gain of function mutations in RamA have been observed which lead
to over-expression of AcrAB-TolC in Salmonella enterica (Abouzeed et al., 2008; Chiu
et al., 2005; Zheng et al., 2009), and mutations in the AdeRS two-component system
were recently associated with over-expression of the AdeABC RND pump in clinical
isolates of Acinetobacter baumanii (Yoon et al., 2013).
The results obtained in this study were therefore surprising, given previous successes at
finding mutated regulators in mutants with constitutive upregulation of eﬄux pumps.
Two mechanisms were found causing constitutive expression of patAB, (1) duplication
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of a genomic region containing patAB, and (2) mutation of a transcriptional attenuator
upstream of patA. However, neither of these allowed regulatory pathways controlling
inducible expression to be deduced. A third mechanism involving a synonymous mutation
in hexA was tentatively identified in one strain, but was not investigated further.
The first mechanism, found in the laboratory mutant M184, involved duplication of a
chromosomal region containing patA and patB and subsequent "capture" of the second
copy of patAB by a highly active tRNA promoter. This resulted in a very high level of
over-expression of patAB. This is the first report of a gene duplication causing antibiotic
resistance in S. pneumoniae, and is also the first report of a gene duplication causing
antibiotic resistance by expression of a resistance determinant from an alternative pro-
moter. Although several examples of antibiotic resistance caused by gene duplication
and amplification have been reported previously (reviewed by Sandegren and Andersson,
2009), the level of antibiotic resistance observed was directly related to the copy number
of the amplified gene, rather than major changes in its transcription. The duplication
observed in M184 was not found in any of the other mutants or clinical isolates used
in this study. However, a previous study of gene amplification in Acinetobacter species
found that identical duplications were observed independently multiple times when a
selective pressure was applied (Reams and Neidle, 2004). Gene duplications are difficult
to observe as they are often unstable, and the nucleotide sequences of duplicated copies
are identical (Andersson and Hughes, 2009). Therefore, it is unclear whether the dupli-
cation found in M184 has not been observed previously because it is rare or unique, or
because gene duplications have not been investigated. It would be interesting to carry
out a larger screening study to specifically look for duplications of the patAB locus in
fluoroquinolone resistant pneumococci to ascertain the prevalence of this phenomenon.
Interestingly, a recent study by Lupien et al (2013) described a laboratory mutant with
high expression of patAB, with no identified cause. It would be interesting to examine
this mutant for the presence of a patAB duplicate.
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Although induction of patAB expression in response to DNA damage has been hypoth-
esised to be mediated by a classical regulatory interaction, this has not definitively been
shown in this study or by others. Presence of the gene duplication in M184 and its
derivatives was associated with very high over-expression of patAB. In previous studies,
induction of patAB expression in response to DNA damaging agents was measured us-
ing qRT-PCR and microarrays (El Garch et al., 2010; Marrer et al., 2006a); however,
neither of these techniques can differentiate between a regulatory interaction affecting
patAB expression in the whole population, or very high expression of patAB from a
small subpopulation. Therefore, the possibility that patAB induction in these studies
was caused by transient gene duplication and subsequent high patAB expression in a
small proportion of the population cannot be ruled out. Illegitimate joining of DNA
ends by DNA gyrase has been suggested as a possible mechanism for formation of gene
duplications without homology at the duplication junction, as was observed in M184
(Seoane et al., 2003). This process could be promoted by the sub-inihbitory concen-
trations of DNA damaging agents used in the induction assays, either by increasing the
amount of DNA gyrase bound to DNA or, in the case of fluoroquinolones, reducing the
accuracy of double-stranded DNA break religation. However, there are problems with
this hypothesis. Firstly, the kinetics of induction observed by El Garch et al (2010)
suggested that patAB expression dropped to wild-type levels within two hours when
selection was removed, whereas the half-life of the duplication measured in this study
was much longer. Furthermore, if the duplication observed in M184 could form with a
high enough frequency for patAB over-expression to be observed within the timescale of
an induction experiment, it would not explain why R6 cultures are antibiotic susceptible
since a subpopulation of cells would be expected to develop patAB-mediated fluoro-
quinolone resistance rapidly following fluoroquinolone exposure. Further work is needed
to establish whether duplication of patA and patB can be induced by fluoroquinolone
exposure and, if so, to determine the frequency and kinetics of this.
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The second mechanism of constitutive over-expression of patAB identified in this project
was mutation of a predicted Rho-independent transcriptional terminator directly up-
stream of patA. Mutations affecting this structure have also been shown to cause patAB
over-expression in linezolid resistant laboratory-selected mutants (Billal et al., 2011) and
in a clinical isolate isolated from a meningitis patient (Croucher et al., 2013). This ter-
minator forms part of a putative transcriptional attenuator, consisting of a terminator,
anti-terminator and anti-anti-terminator. Transcriptional attenuators control expression
of downstream genes by forming mutually exclusive RNA secondary structures that af-
fect transcription elongation (Henkin and Yanofsky, 2002). Folding of attenuators, and
therefore gene transcription, can be controlled by multiple factors, including tRNA levels,
small metabolites and anti-terminator proteins (Green et al., 2010; Henkin, 2008; Turner
et al., 1994). Examples are common throughout bacteria, but particularly in the Firmi-
cutes (Naville and Gautheret, 2010a). It is therefore possible that inducible expression of
patAB could be mediated via this transcriptional attenuator, in conjunction with a yet to
be identified regulatory factor. Inducible attenuation of expression was not investigated
in this study, however the placement of the predicted patA promoter does not support
this hypothesis. An alternative hypothesis is that the predicted attenuator is simply just
a terminator for the upstream hexA gene that has somehow been co-opted for regulation
of patA. To determine the role of this attenuator in inducible patAB expression further
work will be required to properly define the transcription start site of patA.
A more detailed study of the phylogeny of patAB could provide some insight. In S. suis,
satA and satB, which are homologues of patA and patB, are located directly adjacent to
each other, transcribed as an operon and regulated by a local regulator SatR, encoded
directly upstream of satA (Escudero et al., 2011, 2013). A similar gene organisation is
also observed for lmrCD in L. lactis, which are also patAB homologues, although the local
regulator belongs to a different gene family (Lubelski et al., 2006). The genes directly
surrounding patAB homologues also differ between species. In S. pneumoniae, patA is
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preceded by hexA, which encodes a component of the Hex mismatch repair system, and
patB is followed by the glutamine amidotransferase gene guaA which, based on qRT-PCR
results obtained here, may be co-transcribed with patB. In S. suis, the satRAB operon is
flanked on the 5’ side by a gene encoding a NAD(P)H-dependent glycerol-3-phosphate
dehydrogenase, and on the 3’ side by genes encoding a dUTPase enzyme and fructose-
2,6-bisphosphatase (Zhang et al., 2011). In L. lactis the gene organisation is different
again, with the lmrRCD operon flanked by genes encoding a cation transporter and UDP-
N-acetylglucosamine 1-carboxyvinyltransferase (Makarova et al., 2006). Examination of
the genomic contexts of patAB homologues in published genome sequences of other
Streptococci suggests that at least three other gene organisations exist (Figure 6.1).
This, combined with the presence of a degenerate transposase gene between patA and
patB in S. pneumoniae, implies that several genomic rearrangements have occurred
in the evolutionary history of the Streptococci that have altered the location of the
patAB genes. Mapping these events may provide insight into the origin and function of
the putative transcriptional attenuator in S. pneumoniae, and could distinguish between
alternative evolutionary scenarios. For example, the attenuator may be linked to patA
and co-locate with patA homologues in other Streptococci, or it could have regulated
a different gene that was once located downstream of hexA and which has since been
replaced by patA. It has been previously shown that acquisition, loss and switching
of attenuators upstream of several gene families has occurred frequently throughout
bacterial evolution (Naville and Gautheret, 2010b).
The two mechanisms found in this study differ in the level of patAB expression pro-
duced. The gene duplication in M184 and its derivatives resulted in patAB expression
that was several hundred-fold higher than in R6, while mutation of the upstream termi-
nator increased expression by only two- to ten-fold. This led to phenotypic differences
between strains with the duplication and strains with the terminator mutation, although
these were not as large as might be expected from the magnitude of the difference in
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Figure 6.1. Gene organisation surrounding patAB homologues in several Strepto-
coccus species and Lactococcus lactis.. Homologues of patA and patB are indicated
in red throughout. Regions represented with identical colouring between species are
homologous, and homology is also indicated by dotted lines. HP, hypothetical pro-
tein; TP, degerate transposase; R, regulator; guaA, glutamine amidotransferase; gpsA,
NAD(P)H-dependent glycerol-3-phosphate dehydrogenase; galU, glucose-1-phosphate-
uridylyltransferase; dut, dUTPase; gshAB, bifunctional glutathione biosynthesis pro-
tein; murA, UDP-N-acetylglucosamine 1-carboxyvinyltransferase; czcD, cation trans-
porter
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patAB transcription. Strains carrying the duplication accumulated approximately half
the amount of ethidium bromide accumulated by strains with the terminator mutation.
However, there was little to no difference in the increase in ciprofloxacin, norfloxacin
and ethidium bromide MICs compared to R6 for strains with either mechanism. In
this study, only the transcription of patAB was measured, and not the production of
functional PatAB transporter proteins. The discrepancy between transcription level and
observed phenotype may be explained by incomplete conversion of the over-produced
patAB transcript to functional protein in strains with the duplication, either due to
mRNA degradation or incomplete translation, or by degradation of excess protein. Ad-
ditionally, MICs are an insensitive measure of the efficiency of eﬄux of a compound
(Lim and Nikaido, 2010), which may explain why the difference in ethidium bromide
accumulation did not result in a larger difference in MICs of ethidium bromide conferred
by the two mechanisms.
Neither mechanism of patAB over-expression had an impact on the growth of R6. The
only mutant with a reduced growth rate compared to R6 was M184, but since none
of the R6M184 transformants had similar alterations in growth, it seems likely that the
growth defect was caused by one or more of the 27 point mutations carried by this
mutant, instead of the presence of the duplication. This has implications for stability
of resistance caused by each mechanism. The duplication was lost from cells over time
at a measurable rate and, since the duplication has no effect on growth, this is due
to recombination between duplication copies instead of competition between variants
with and without the duplication. The stability of the mutations in the transcriptional
terminator was not measured, but the persistence of point mutations in a population of
cells tends to depend on the degree to which a strain carrying a mutation is outcompeted
by a strain lacking the mutation, since true reversion of a specific mutated base is rare.
The two mechanisms therefore differ in that the duplication transiently produces very
high levels of patAB expression, while mutation of the transcriptional terminator results
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in lower levels of patAB production which are likely to persist for a longer period of time.
In conclusion, two mechanisms conferring constitutive over-expression of patA and patB
have been identified from four genetic backgrounds. One of these, the duplication
of a genomic region containing patAB, is novel as antibiotic resistance conferred by
this mechanism has not been previously observed in S. pneumoniae. Eﬄux-mediated
fluoroquinolone resistance has been observed in many laboratory mutants and clinical
isolates in previous studies, and the results presented here suggest simple, PCR-based
assays that could be carried out to determine the cause of patAB expression in these
isolates, and therefore estimate the prevalence of each mechanism in the clinical setting.
However, the diversity of the physiological roles postulated for PatAB suggests that
further layers of regulation remain to be identified.
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